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ABSTRACT 
The detoxification function of glutathione S-transferase π (GST-P) was 
associated with drug resistance in many cancers and become a major reason of 
chemotherapy failure and disease recurrence. Thus, inhibitors of GST-P were targeted 
in order to counteract the phenomenon of multidrug resistance. Ethanolic extracts of 43 
local plant samples were screened for their inhibitory effect on GST-P activity. Among 
these, 30 ethanolic extracts displayed inhibition activity on GST-P and 13 out of the 30 
ethanolic extracts have inhibition effects higher than 50%. Furthermore, Garcinia 
atroviridis (branch) and Leptospermum flavescens (leaf) ethanolic extracts have the 
highest inhibitory effect with a 100% inhibition on GST-P activity. These 13 ethanolic 
extracts were then subjected for IC50 determination, kinetic studies and cytotoxicity 
assays. Based on the IC50 value, the most active sample was Cinnamomum zeylanicum 
(branch) ethanolic extract with lowest IC50 value of 0.07 mg/mL, followed by 
Leptospermum flavescens (leaf) and Hibiscus tiliaceus (leaf) ethanolic extracts with IC50 
values of 0.09 and 0.10 mg/mL respectively. 10 of the selected ethanolic extracts shown 
mixed mode inhibition on GST-P while the other 3 shown uncompetitive inhibitions. 
All of the 13 ethanolic extracts were not cytotoxic to both HT-29 and MRC-5 cell lines 
when tested alone, with IC50 value >100 μg/mL. Combination studies indicated that 
GST-P inhibition able to potentiate the cytotoxicity of doxorubicin hydrochloride on 
HT-29 cells, but not for cisplatin. Combination of doxorubicin hydrochloride-
Cinnamomum zeylanicum (branch) ethanolic extract has the lowest IC50 value with 
IC50= 0.22 μg/mL. Nevertheless, Andrographis paniculata (leaf) and Lawsonia inermis 
(branch) ethanolic extracts incredibly increased the cytotoxicity of cisplatin on HT-29 
cells with IC50 values of 4.70 and 5.46 μg/mL respectively. Bioassay-guided 
fractionation of Leptospermum flavescens (leaf) ethanolic extract on polyamide column 
resulted in a fraction with 95% inhibition on GST-P activity (50% methanol 2% acetic 
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acid eluate). The fraction inhibited GST-P in mixed mode with IC50 value of 0.19 
mg/mL. This fraction was not toxic to either HT-29 or MRC-5 cells. Combination of 
doxorubicin hydrochloride with the 50% methanol 2% acetic acid fraction of L. 
flavescens (leaf) ethanolic extract enhanced doxorubicin hydrochloride cytotoxicity on 
HT-29 cells with IC50= 0.26 μg/mL whereas combination of cisplatin-50% methanol 2% 
acetic acid fraction of L. flavescens (leaf) ethanolic extract gave an IC50 value of 8.38 
μg/mL on cytotoxicity of HT-29 cells. Our results revealed that local plants can be 
source of GST-P inhibitors to enhance cytotoxicity of anticancer drugs. 
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ABSTRAK 
Fungsi detoksifikasi glutathione S-transferase π (GST-P) sering dikaitkan 
dengan rintangan kanser terhadap dadah dan ini menjadi punca utama kegagalan dalam 
rawatan kemoterapi dan pengulangan penyakit. Oleh itu, perencat kepada GST-P telah 
dijadikan sebagai sasaran untuk mengatasi fenomena rintangan terhadap pelbagai dadah. 
Kesan perencatan kepada aktiviti GST-P yang disebabkan oleh ekstrak etanolik 
daripada 43 sampel tumbuhan tempatan telah diuji. Di antaranya, 30 ekstrak etanolik 
telah menunjukkan perencatan terhadap GST-P dan 13 daripada 30 ekstrak etanolik itu 
mempunyai kesan perencatan lebih daripada 50%. Lagipun extrak etanolik Garcinia 
atroviridis (batang) dan Leptospermum flavescens (daun) mempunyai 100% perencatan 
terhadap aktiviti GST-P. 13 ekstrak etanolik ini telah dipilih untuk penentuan IC50, 
kajian kinetic dan ujian-ujian kesitotoksikan. Berdasarkan kepada nilai-nilai IC50 yang 
didapati, sampel yang paling aktif adalah ekstrak etanolik Cinnamomum zeylanicum 
(batang) dengan nilai IC50 yang paling rendah sekali iaitu 0.07 mg/mL, diikuti dengan 
ekstrak etanolik daripada Leptospermum flavescens (daun) and Hibiscus tiliaceus (daun) 
yang mempunyai nilai IC50 sebanyak 0.09 and 0.10 mg/mL. 10 daripada ekstrak-ekstrak 
etanolik yang terpilih itu telah menunjukkan perencatan GST-P secara mod campuran 
manakala 3 yang lain itu menunjukkan perencatan secara tak-kompetitif. Semua ekstrak 
etanolik yang terpilih adalah tidak toksik kepada sel-sel HT-29 dan MRC-5 apabila diuji 
secara individu dengan nilai IC50 >100 μg/mL. Kajian-kajian gabungan menunjukkan 
bahawa perencatan GST-P mampu mempertingkatkan kesitotoksikan doxorubicin 
hidroklorida kepada sel-sel HT-29, tetapi tidak untuk cisplatin. Gabungan doxorubicin 
hidroklorida dengan ekstrak etanolik Cinnamomum zeylanicum (batang) mempunyai 
nilai IC50 yang paling rendah  iaitu IC50= 0.22 μg/mL. Walaubagaimanapun, ekstrak 
etanolik daripada Andrographis paniculata (daun) and Lawsonia inermis (batang) telah 
mempertingkatkan lagi kesitotoksikan cisplatin kepada sel-sel HT-29 dengan nilai IC50 
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sebanyak 4.70 and 5.46 μg/mL. Fraksinasi berdasarkan bioassay ekstrak etanolik 
Leptospermum flavescens (daun) menggunakan kolum polyamida telah menunjukkan 
keputusan pecahan dengan 95% perencatan terhadap aktiviti GST-P (eluat 50% metanol 
2% asid asetik). Pecahan ini telah merencatkan GST-P secara mod campuran dengan 
nilai IC50 sebanyak 0.19 mg/mL. Pecahan ini didapati tidak toksik kepada sel-sel HT-29 
ataupun MRC-5. Gabungan doxorubicin hidroklorida dengan pecahan 50% metanol 2% 
asid asetik dari ekstrak etanolik L. flavescens (daun) memperkuatkan kesitotoksikan 
doxorubicin hidroklorida kepada sel-sel HT-29 dengan IC50= 0.26 μg/mL, manakala 
gabungan cisplatin dengan pecahan 50% metanol 2% asid asetik dari ekstrak etanolik L. 
flavescens (daun) memberikan nilai IC50 sebanyak 8.38 μg/mL atas kesitotoksikan 
terhadap sel-sel HT-29. Keputusan kajian kami menunjukkan bahawa tunbuhan 
tempatan boleh dijadikan sumber perencat GST-P untuk memperkuatkan kesitotoksikan 
dadah antikanser. 
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1.0 INTRODUCTION 
Cytosolic Glutathione S-Transferases (GSTs; EC 2.5.1.18) constitute a family of 
multifunctional enzymes which catalyse the conjugation of glutathione (GSH) with a 
wide variety of xenobiotics (Mannervik et al., 1985). Among all of the GST classes that 
have been characterized, Glutathione S-Transferase π (GST-P) has significance in 
cancer diagnosis as it was expressed ubiquitously and abundantly in maglinant cells. 
Elevated GST-P expression is associated with multidrug resistance which contributes to 
chemoresistance in many cancers and become a major reason of chemotherapy failure 
and disease recurrence (Huang et al., 2007). In order to counteract the phenomenon of 
multidrug resistance which partly caused by the GST-P, specific inhibitors for this 
enzyme has been found and designed to sensitize those tumor cells to anticancer drugs. 
Since HT-29 cell line was reported to have high expression of GST-P, this cell line was 
selected for cytotoxicity assays and extraction of GST-P enzyme. Studies on natural 
products reported significant biological effects against different types of cancer. Plant 
polypeptide which has been extensively studied in recent decades has been targeted in 
this study as a potential inhibitor of GST-P. 
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2.0 LITERATURE REVIEW 
2.1 GLUTATHIONE S-TRANSFERASES 
The discovery of Glutathione S-Transferases (GST) is back to the year of 1960, 
where Booth et al. (1960; 1961) shown that there was an enzyme exist in rat liver which 
catalyzed the conjugation of glutathione with epoxides. The enzyme catalyzed the 
reaction was then partially purified and characterized as glutathione S-aryltransferase 
(which currently known as Glutathione S-transferase) by Grover and Sims (1964). 
GSTs (EC 2.5.1.18) constitute a family of multifunctional and multigene enzymes 
which catalyzes the conjugation of glutathione (GSH) with a wide variety of 
xenobiotics and endogenous compounds. The conjugations of glutathione with 
xenobiotics like carcinogens and exogenous drugs often produce more water soluble 
conjugates that usually less toxic and readily to be excreted (Mannervik et al., 1985; 
Zhang and Fang, 1999). GSTs are involves in the metabolism of xenobiotics in the 
phase II detoxification process (illustrated in Figure 2.1). Besides of detoxification, the 
enzymes also involve in other intracellular processes such as the removal of reactive 
oxygen species and thiol protein regeneration (during oxidative stress). Selenium-
independent glutathione peroxidase (GPx) activity of GSTs towards organic 
hydroperoxides prevents engagement of organic hydroperoxides of fatty acids, 
phospholipids and DNA in free radical propagation reactions eventually leads to 
destruction of macromolecules (Hayes and Strange, 1995). Furthermore, GSTs also 
involve in the production of leukotriene and prostaglandin, catalysis of the binding of 
endogenous ligands, catalysis of reactions in non-detoxification metabolic pathways and 
bind non-catalytically to exogenous and endogenous compounds (Dragani et al., 1998; 
Sheehan et al., 2001; Kitteringham et al., 2007; Tew et al., 1988).  
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Figure 2.1 : Illustration of the possible fate of carcinogenic xenobiotic, benzo(a)pyrene, 
once it enter cell. Cytochrome P450 and epoxide hydratase responsible for 
the phase I detoxification system while GSTs are the phase II enzyme 
which catalyze conjugation of GSH with xenobiotic. GSH-xenobiotic 
conjugate is hydrophilic. Thus, it will be pumped out from the cell and 
eventually excreted out as mercapturic acids. (Adapted from Sheehan et al., 
2001) 
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2.1.1 CLASSIFICATION OF GLUTATHIONE S-TRANSFERASES 
GSTs are superfamily enzymes that have been found in most of the life form 
such as animals, plants, insects, helminthes, fungi and bacteria (Grover and Sims, 1964; 
Yu et al., 2003; Fakae et al., 2000; Enayati et al., 2005; Sato et al., 2009; Piccolomini et 
al., 1989). Candidates representing non-mammalian GSTs are such as the fungal-
specific GST, GstB, which was identified and characterized by Sato et al. (2009); the 
basic GST form B which shown no homology to mammalian GST, and the GST form 
AI which exhibit mammalian alpha-family-like biochemical properties, were found in 
nematode cytosol (Papadopoulos et al., 1989); PfGST, which is the only isoform 
present in malarial parasite, shown significantly different structure of binding site 
compared to human isozymes (Hiller et al., 2006); the rho-class GST which specific for 
teleost fish with no homologues in mammals (Liang et al., 2007); the four major classes 
of plant GSTs which is theta, zeta, phi and tau. The theta and zeta classes have related to 
mammalian GST while the phi and tau classes are unique for plant GST (Wagner et al., 
2002); and the insect GSTs which has been grouped into three classes, that is, I, II and 
III. Class I GSTs are insect-specific delta class and class II GSTs are members of sigma 
class (Agianian et al., 2003). 
Mammalian GSTs are consists of three distinct family, that is, the cytosolic, 
mitochondrial and membrane-bound microsomal GSTs family (McIlwain et al., 2006). 
The dimeric cytosolic GSTs has been classified into at least eight major classes, that is, 
Alpha, Mu, Pi, Sigma, Theta, Kappa, Omega and Zeta based on the combination of 
physical, chemical, immunological, structural and catalytic properties (Mannervik et al., 
1985; Pemble et al., 1996; Sheehan et al., 2001; Kitteringham et al., 2007). Meanwhile, 
the homotrimeric mirosomal GSTs has been classified as membrane-associated proteins 
in eicosanoid and glutathione metabolism (MAPEG) (Sun and Morgenstern, 1997; 
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Sheehan et al., 2001). Table 2.1 shows some examples of classification criteria for 
GSTs, and Figure 2.2 demonstrating the subunit structures of different GST class. 
 
Table 2.1 : Classification criteria for GSTs 
Criteria Example of GST 
Primary structure 
comparison 
Alpha, Mu, Pi, Theta, Kappa, Zeta, Omega classes 
Immunoblotting Alpha, Mu, MIF (migration-inhibitory-factor-like) 
classes, Insect classes I and II, Faciola hepatica GSTs 
Kinetic properties: 
Substrate specificity/affinity 
 
Inhibitor sensitivity 
 
Alpha, Mu, Pi, Theta classes 
 
Alpha, Mu,  Pi classes 
Tertiary structure: active site Alpha, Mu, Pi, Theta, Omega, Beta, Sigma classes 
Quarternary structure: 
Ability to hybridize into 
dimers 
 
Inter-subunit interface 
 
Mu, Alpha classes 
 
Hydrophobic lock and key in Alpha, Mu, Pi, Theta 
classes, Polar interface in Beta class 
(Adapted from Sheehan et al., 2001) 
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Figure 2.2 : Ribbon representations of the structures of different classes GST subunits. 
(Adapted from Dixon et al., 2002; Thom et al., 2002) 
 
 
 
 
 
 
 
 
Mammalian 
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2.1.2 GLUTATHIONE 
Glutathione (GSH) is a tripeptide of γ-glutamyl-cysteinyl-glycine, which 
involved in cellular defense mechanism of living organism against reactive oxygen 
species (ROS) and xenobiotics. GSH present freely or bound to proteins in cells. 
Synthesis and degradation of GSH are regulated by the reactions in γ-glutamyl cycle 
(Pastore et al., 2001). The reversible oxidation of the thiol/thiolate group of cysteine 
residue generates oxidized glutathione (GSSG) and acts as a major cellular redox buffer. 
GSH provides electron to glutathione peroxide which reduces hydrogen peroxide to 
water and thus contributed to ROS degradation. Oxidized GSH is then re-reduced by 
glutathione reductase using NADPH as an electron donor (Sato et al., 2009). 
Measurement of the ratio of reduced glutathione to oxidized glutathione in the cells 
used as an indicator of cellular toxicity. 
Another role of GSH in cellular detoxification mechanism is regulated by GSTs. 
GSTs catalyzed the nucleophilic attack of glutathione sulphur atom on the electrophilic 
region of various xenobiotics and endogenous ROS compounds, resulting in the 
production of hydrophilic conjugates which are further metabolized to mercapturic acid 
and then excreted out of the cell (Zhang and Fang, 1999). For example, human GSTA1-
1 and GSTA2-2 attenuates lipid peroxidation by catalyzing GSH-dependent reduction 
of phospholipid hydroperoxides and thus protect the cells from hydrogen peroxide-
induced apoptosis (Yang et al., 2001).  
Besides, GSH also involves in other cellular mechanism such as inhibition of 
melanin synthesis and agglutination by interrupting the function of L-DOPA (Matsuki 
et al., 2008); involvement in iron metabolism by its requirement, together with 
mitochondrial inner-membrane ATP binding cassette (ABC) transporter Atm1 and 
intermembrane Erv1 thiol oxidase in iron-sulphur cluster (ISC) assembly, and served as 
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a backup of thioredoxin in cytosolic thiol-redox control (Kumar et al., 2011); synthesis 
of phytochelatins (PC) which catalyzed by PC synthase in the presence of heavy metals 
(Ha et al., 1999); enhancement of humoral immune response as glutathione is an 
essential element for lymphocyte proliferation (Bounous et al., 1989); Protect DNA 
through donation of hydrogen atom to highly reactive hydroxyl radicals during exposure 
to radiation, and chemical repairment (Bounous and Gold, 1991); regulation of cell 
cycle, in which de novo synthesis of GSH is required for cell proliferation and proper 
transition of S and G2 phase (Poot et al., 1995); Post-translation modification of 
intracellular proteins by glutathionylation which changed the protein folding into 
different conformation (Townsend et al., 2003).  
GSH has been reported as a critical factor in protecting living organism from 
diseases. Deficiency of GSH leads to neurological disorders such as impairment of 
mitochondria and ischemia in brain, Parkinson’s disease, Alzheimer’s disease, 
Huntington disease and Schizophrenia (Dringen, 2000). 
 
Figure 2.3 : Illustration of the conjugation of glutathione (GSH) to xenobiotic by 
glutathione S-transferase (GST). (Adapted from Townsend and Tew, 2003) 
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2.2 GLUTATHIONE S-TRANSFERASE π 
Glutathione S-Transferase π (GST-P) is one of the classes of GST encoded by 
seven exons of polymorphic GSTP1 gene localized in chromosome 11. The GSTP1 
gene has a series of single nucleotide polymorphisms (SNPs) that yield polymorphism 
in the amino acid sequence of encoded protein. There are 4 functionally active 
polymorphisms of GSTP1 have been identified (McIlwain et al., 2006). GST-P has a 
molecular weight of 24 kDa and a pI value of 7.1 (Aliya et al., 2003; Kitteringham et al., 
2007). GST-P expression is inducible by cytotoxic drugs and it was found to be 
different from the ordinary GST subunits.  
Table 2.2 : Genetic variation of GST-P 
Allele Nucleotide variability 
GSTP1*A Ile 105; Ala 114 
GSTP1*B Val 105; Ala114 
GSTP1*C Val 105; Val 114 
GSTP1*D Ile 105; Val 114 
(Adapted from McIlwain et al., 2006) 
 
GST-P was initially identified as an anionic protein in human placenta, but later 
on it was found and characterized for most human cancer cells, such as human M-7609, 
Caco-2 and HT-29 colorectal cancer cells (Niitsu et al., 1998; Peters and Roelofs, 1989; 
Tashiro et al., 2001), diffuse large B-cell lymphomas (Ribrag et al., 2003), malignant 
ovarian tumor cells (Satoh et al., 2001), renal UOK 130 cancer cells (Wang et al., 2007), 
Adr
R
 MCF-7 breast cancer cells (Batist et al., 1986), HOS osteosarcoma cell line 
(Huang et al., 2007), cutaneous squamous cell carcinomas and normal skin cell 
(Shimazu et al., 1995), stomach, gastric and lung carcinomas (Tsutsumi et al., 1987; 
Qin et al., 2002; Eimoto et al., 1988). Among all of the GST classes that have been 
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characterized, GST-P has significance in cancer diagnosis as it was expressed 
ubiquitously and abundantly in maglinant cells (Aliya et al., 2003). 
Elevated GST-P expression is associated with multidrug resistance, malignant 
transformation and decreased number of estrogen receptors in breast cancer (Moscow et 
al., 1989). GST contributes to chemoresistance in many cancers and become a major 
reason of chemotherapy failure and disease recurrence (Huang et al., 2007). Maglinant 
transformation associated with GST-P expression has been demonstrated in eusophagus 
cancer as the GST-P has been prominently expressed in esophageal squamous mucosa 
and adenocarcinoma (Chandra et al., 2002).  
In addition, GST-P also regulates activities of several cellular proteins such as c-
Jun N-terminal kinases (JNK), p38 mitogen-activated protein kinases (p38 MAPK), 
Extracellular signal-regulated kinase (ERK) and TNF receptor-associated factor 2 
(TRAF2) by protein-protein interactions (Adler et al., 1999; Adler and Pincus, 2004; Lu 
et al., 2004; Wu et al., 2006). Under stressed condition, the JNK inhibitor, GST-P, 
undergoes oligomerization and dissociated from JNK which eventually lead to the 
activation of JNK pathway (Adler et al., 1999). Lu et al. (2004) reported dual effects of 
GST-P when prostate cancer cells exposed to arsenic trioxide, As2O3. At low 
concentration of As2O3, GST-P enhanced cell growth inhibition by apoptosis-
independent pathway, which is restricted the cell growth at G2/M phase. Conversely, 
GST-P inhibited As2O3-induced apoptosis by inhibiting the activation of JNK and p38 
kinase, at high concentration of As2O3.  
GST-P also potentiate S-glutathionylation, an alternative to nitration and 
nitrosylation on nitric oxide (NO), by induces nitrosative stress which results in elicits 
toxicity in vitro and in vivo (Townsend et al., 2006). 
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Expression of GST-P in normal cells may play a protective role in preventing 
chemical carcinogenesis as almost 80% of human cancer cases reported were related to 
environmental chemical carcinogens (Zhang and Fang, 1999). Shimazu et al. (1995) has 
reported that GST-P distributed mainly in the upper layers cell of normal epidermis and 
GST-P is involved in carcinogenesis process. Furthermore, down-regulation of GST-P 
expression has been shown to increase the risk of developing prostate and colon cancer 
(Okino et al., 2007; Ritchie et al., 2009). Zhang and Fang (1999) showed that GST-P 
transfected NIH3T3 cells expressed exogenous GST-P which protects the cells from 
carcinogen, glycidyl methacrylate, thus provides the contribution of GST-P in 
preventing chemical carcinogenesis.  
 
 
Figure 2.4 : Ribbon representation of the human GST-P dimer complexes with S-hexyl 
GSH. (Adapted from Oakley et al., 1997) 
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2.2.1 MULTIDRUG RESISTANCE 
Acquired or intrinsic multidrug resistance is one of the mechanisms contributing 
to the failure of lasting chemotherapy treatment in cancer patients. Multidrug resistance 
during cancer therapy has been related to the high expression of GST-P. Niitsu et al. 
(1998) proved the involvement of GST-P in drug resistance by transfer of antisense 
gene into colon cancer cells which had high expression of GST-P and the result shows 
that transfectants have higher sensitivity towards alkylating agents compared to the 
parental cells. Moscow et al. (1989) shown that GST-P expression vector transfected 
drug-sensitive MCF-7 human breast cancer cells have elevated GST-P level and the 
transfectants were more resistant to cytotoxic agents. In addition, GST-P was worked as 
the determinant of drug resistance in GST-P transfectant cell line, pT22-3, whereby the 
increase in resistant toward cytotoxic agents, ethacrynic acid and adriamycin 
(Nakagawa et al., 1990). Tashiro et al. (2001) reported that the expression of GST-P 
reduced the cytotoxicity of potent cytocidal, glutathione-doxorubicin conjugate (GSH-
DXR) against tumor cells and decreased GSH-DXR-induced activation of apoptotic 
marker, caspase-3. An earlier study also shows that GST-P gene transduced human stem 
cells, CD34+ cells, were resistant to alkylating agents, cyclophosphamide and 
adriamycin (Kuga et al., 1997). 
Even though resistance of cancer cell GST-P towards alkylating agents in 
chemotherapy is affecting the results of the therapy, the strategy of utilizing GST-P 
gene for chemoprotection of bone marrow from subsequent high dose chemotherapy is 
promising for cancer gene therapy (Niitsu et al., 1998). This is further supported by 
Matsunaga et al. (2000) whereby the transplantation of GST-P transduced bone marrow 
cells into mice conferred resistance to bone marrow of recipient mice against 
cyclophosphamide in high dose chemotherapy.  
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Besides of GST-P, there are other parameters which are implicated in multidrug 
resistance, such as rapid drug efflux by upregulation of ATP binding cassette (ABC) 
transporters expression (Mann et al., 1990, Sarkadi et al., 2006), elevated levels of 
detoxifying protein molecules like GSH and metallothioneins (Friesen et al., 2004; 
Kelley et al., 1988), overexpression of glycoprotein and enhanced DNA repair (Johnson 
et al., 1993). Figure 2.5 demonstrated different ways of drug resistance in cell when it 
exposed to cytotoxic drugs. 
 
 
Figure 2.5 : A summary of the mechanisms of cytotoxic drugs resistance in cultured 
cancer cells. (Adapted from Gottesman, 2002) 
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2.3 GLUTATHIONE S-TRANSFERASE INHIBITORS 
Several researches have been done to identify the inhibitors of GST. The 
importance of GST is not only concerned for cancer therapy, but also highlighted in the 
establishment of chronic parasite infections. Noticeable GST activity has been detected 
in human, rodent and simian malarial parasites. Antimalarials such as hemin, 
chloroquine, artemisinin and primaquine were inhibited the GST activity in a 
concentration-dependent manner (Srivastava et al., 1999). Malarial parasite PfGST 
which has the highest sequence similarities with GST-P was reported to be inhibited by 
cibacron blue, S-hexylglutathione, hemin, protoporphyrin IX and ferriprotoporphyrin IX 
(Harwaldt, et al., 2002; Tripathi et al., 2007). When Ahmad and Srivastava (2007) 
treated hemin on purified GST of rodent malarial parasite, Plasmodium yoelii, 
noncompetitive inhibition kinetic was observed. Hemin is also a known inhibitor of 
human GST. On the other hand, Triclabendazole (C14H9Cl3N2OS) was reported to have 
inhibitory effect on nematodirus, Fasciola spp. and sheep liver tissue GST (Farahnak et 
al., 2006; 2007; Seyyedi et al., 2005). Hexachlorophene (C13H6Cl6O2) was also found to 
be the inhibitor of helminth and sheep liver tissue GST but with higher affinity toward 
helminth GST (Farahnak and Brophy, 2004). There are also several traditional Nigerian 
medicinal plants found to have inhibition activity on nematode GST and thus the 
pharmacological basis of these plants used traditionally to treat gastrointestinal helminth 
infection is revealed (Fakae et al., 2000). In addition, Brophy et al. (2000) synthesized a 
series of β-carbonyl substituted glutathione conjugates to inhibit OvGST which 
topological structure closely related to mammalian GST-P in the form of wide 
hydrophobic binding cleft. Selectivity of the glutathione conjugates for OvGST over 
human GST-P is reported to be higher than 10-fold. Od-GST of porcine nodule 
nematode, Oesophagostomum dentatum, was found to be functionally similar to 
prostaglandin D synthase and reversibly inhibited by sulphobromophthalein, 
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indomethacin and ethacrynic acid. Sulphobromophthalein is known to be a specific 
inhibitor of alpha and pi-classes of GST (Joachim et al., 2011). 
Other than helminth GST inhibitors, Bromosulphophtalein, cibacron blue, 
indomethacin, S-hexylglutathione, tributyltin acetate and rose bengal have been 
characterized as the inhibitors of rat liver microsomal glutathione S-transferase 
(Mosialou and Morgenstern, 1990; Ji et al., 1996), while bile acids, propylthiouracil, S-
oxides of propylthiouracil, acetonitrile and haloacetonitriles have been demonstrated to 
have inhibition activity on rat liver cytosolic GSTs (Vessey and Zakim, 1981; Kariya et 
al., 1986; Ahmed et al., 1989). Wu and Mathews (1983) work on Indomethacin (1-(p-
chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid) inhibition of rat liver GSTs 
indicates that the compound noncompetitively inhibited GST conjugation with 3,4-
dichloronitrobenzene (DCNB) but uncompetitively inhibited the conjugation with 
glutathione. On the other hand, meclofenamic acid was found to be a competitive 
inhibitor of GSTs. Danielson and Mannervik (1988) further reported rat liver mu-class 
GST (GST-M) was competitively inhibited by micromolar concentration of 
indomethacin in a condition of high CDNB concentration. Interestingly, the inhibition 
pattern of indomethacin on GST-M seems to be paradoxical when CDNB used as a 
substrate. Early on, Mitra et al. (1991) shown that polyunsaturated fatty acids 
(particularly arachidonic acid), and saturated fatty acid esters (such as ascorbate) caused 
remarkable inhibition activity on rat and mouse liver GST. After that, they noticed that 
saturated fatty acids and ascorbate esters of saturated fatty acids also caused significant 
inhibition on human placental and liver GST, especially for the GST-P. Reversible 
competitive inhibition of ascorbyl stearate on placental GST was suggested based on the 
evidence found (Mitra et al., 1992). Acetylenic fatty acids such as 5,8,11-eicosatriynoic 
acid (ETI) and 5,8,11,14-eicosatetraynoic acid (ETYI), were also reported to cause 
inhibition of  human and rat hepatic GST with substrate CDNB. Kinetic study revealed 
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noncompetitive inhibition of ETI on human hepatic GST (Datta and Kulkarni, 1994). 
Dicumarol, an anticoagulant analogue of vitamin K obtained from sweet clover, was 
demonstrated to cause inhibition of several classes of mouse GST. It inhibited mouse 
hepatic GST-M to conjugate with CDNB. With substrate 4-nitroquinoline 1-oxide (4-
NQO), mu and pi classes of GST were inhibited, whereas with cumene hydroperoxide 
(CHP), GSTA is the one been inhibited. Besides of GST, Dicumarol used to be a 
specific inhibitor of DT-diaphorase (NAD(P)H: quinine oxidoreductase) (Mays and 
Benson, 1992). In addition, reversible and irreversible inhibition of rat GSTs by caffeic 
acid and its 2-S-glutathionyl conjugate were demonstrated by Ploemen et al. (1993c). 
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Table 2.3 : GST inhibitors 
Type of GST Inhibitor Ki IC50 value Reference 
Plasmodium yoelii GST Hemin 4 µM 4 µM Ahmad and Srivastava, 2007 
Plasmodium yoelii GST Protoporphyrin IX 
Cibacron blue 
Menadione 
13 µM 
0.4 µM 
80 µM 
12.5   µM 
56.3   µM 
> 200 µM 
Ahmad and Srivastava, 2008a 
Plasmodium falciparum PfGST Cibacron blue 
S-hexylglutathione 
Protoporphyrin IX 
Hemin 
Chloroquine 
0.5 µM 
35 µM 
10 µM 
6.5 µM 
- 
- 
- 
- 
- 
> 200 µM 
Harwaldt et al., 2002 
Plasmodium falciparum PfGST Ferriprotoporphyrin IX 1.4 µM 1 µM Liebau et al., 2002 
Fasciola hepatica GST 
Sheep liver GST 
Hexachlorophene 
Hexachlorophene 
- 
- 
0.25 µM 
1       µM 
Farahnak and Brophy, 2004 
Ascaris suum GST 
 
 
Onchocerca volvulus GST 
P. thonningii extract 
O. gratissimum extract 
N. latifolia extract 
P. thonningii extract 
O. gratissimum extract 
N. latifolia extract 
- 
- 
- 
- 
- 
- 
2   mg/L 
10 mg/L 
15 mg/L 
4   mg/L 
8   mg/L 
28 mg/L 
Fakae et al., 2000 
Oesophagostomum dentatum Od-GST 
 
 
 
Caenorhabditis elegans GST 
Schistosoma mansoni Sm28 GST 
Schistosoma japonicumi GST 
Setaria digitata GST 
Sulphobromophthalein 
Indomethacin 
Ethacrynic acid 
HQL-79 
Sulphobromophthalein 
Sulphobromophthalein 
Sulphobromophthalein 
Ethacrynic acid 
- 
- 
- 
- 
- 
- 
- 
- 
150 µM 
56-280 µM 
0.05-5 µM 
330 µM 
17 µM 
0.09 µM 
36.4 µM 
19.42 µM 
Joachim et al., 2011 
Setaria cervi GST Hemin 
Ethacrynic acid 
S-hexylglutathione 
Quercetin 
Cibacron blue 
Lithocholate sulfate 
Ellagic acid 
4 µM 
22 µM 
0.04 mM 
5 µM 
0.02 µM 
0.1 mM 
0.27 µM 
25 µM 
15 µM 
0.1 mM 
25 µM 
0.025 µM 
0.3 mM 
0.8 µM 
Ahmad and Srivastava, 2008b 
Rat liver GST Indomethacin 
Indomethacin 
4-Chlorobenzoic acid 
5-methoxy-2-methylindole-3-acetic acid 
53 µM, with DCNB 
40 µM, with GSH 
470 µM, with DCNB 
330 µM, with DCNB 
- 
- 
- 
- 
Wu and Mathews, 1983 
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Table 2.3, continued 
Type of GST Inhibitor Ki IC50 value Reference 
Rat liver GST Meclofenamic acid 300 µM, with DCNB - Wu and Mathews, 1983 
Rat liver cytosolic GST Acetonitrile 
Monofluoroacetonitrile 
Monochloroacetonitrile 
Monobromoacetonitrile 
Dichloroacetonitrile 
Trichloroacetonitrile 
Dibromoacetonitrile 
Monoiodoacetonitrile 
- 
- 
- 
- 
- 
- 
- 
- 
> 10 mM 
> 10 mM 
> 10 mM 
> 10 mM 
2.49 mM 
0.34 mM 
0.82 mM 
4.44 mM 
Ahmed et al., 1989 
Rat liver microsomal GST Indomethacin - 800 µM Ji et al., 1996 
Human placental GST 
 
 
 
Human fetal liver GST 
 
 
 
Rat liver GST 
Ascorbyl stearate 
Ascorbyl palmitate 
Palmitic acid 
Stearic acid 
Ascorbyl stearate 
Ascorbyl palmitate 
Palmitic acid 
Stearic acid 
Ascorbyl stearate 
Ascorbyl palmitate 
Palmitic acid 
Stearic acid 
3.1 µM 
10.0 µM 
13.5 µM 
18.5 µM 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
15   µM 
45   µM 
83   µM 
78   µM 
21   µM 
6     µM 
88   µM 
117 µM 
Mitra et al., 1992 
HT-29 GST 
 
BE GST 
Ethacrynic acid 
Piriprost 
Ethacrynic acid 
Piriprost 
- 
- 
- 
- 
30   µM 
22   µM 
30   µM 
170 µM 
Tew et al., 1988 
Rat GST-M Indomethacin - 1 µM Danielson and Mannervik, 1988 
Rat GSTA 1-1 
 
Rat GSTA 2-2 
 
Rat GST-M 3-3 
 
Rat GST-M 4-4 
 
Rat GST-P 7-7 
 
Caffeic acid 
2-S-glutathionylcaffeic acid 
Caffeic acid 
2-S-glutathionylcaffeic acid 
Caffeic acid 
2-S-glutathionylcaffeic acid 
Caffeic acid 
2-S-glutathionylcaffeic acid 
Caffeic acid 
2-S-glutathionylcaffeic acid 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
> 640 µM 
13      µM 
> 640 µM 
> 125 µM 
360    µM 
7.1     µM 
58      µM 
26      µM 
470    µM 
36      µM 
Ploemen et al., 1993c 
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Table 2.3, continued 
Type of GST Inhibitor Ki IC50 value Reference 
Mouse GST-M 
 
Mouse GST-P 
Mouse GSTA 
Dicumarol 
Dicumarol 
Dicumarol 
Dicumarol 
- 
- 
- 
- 
11 µM, with CDNB 
14 µM, with 4-NQO 
9 µM, with 4-NQO 
14 µM, with CHP 
Mays and Benson, 1992 
Rat and human GST-M 
Rat and human GST-P 
Dibromodihydroethacrynic acid 
Dibromodihydroethacrynic acid 
- 
- 
0.4-0.6 µM 
4.6-10 µM 
Ploemen et al., 1993a 
Rat and human GSTA 
 
Rat and human GST-M 
 
Rat and human GST-P 
 
Ethacrynic acid 
Glutathione-Ethacrynic acid conjugate 
Ethacrynic acid 
Glutathione-Ethacrynic acid conjugate 
Ethacrynic acid 
Glutathione-Ethacrynic acid conjugate 
- 
- 
- 
- 
- 
- 
4.6-6.0 µM 
0.8-2.8 µM 
0.3-1.9 µM 
< 0.1-1.2 µM 
3.3-4.8 µM 
11 µM 
Ploemen et al., 1993b 
RPMI 8322 GSTA 
RPMI 8322 GST-M 
RPMI 8322 GST-P 
Ethacrynic acid 
Ethacrynic acid 
Ethacrynic acid 
- 
- 
- 
10 µM 
1 µM 
15 µM 
Hansson et al., 1991 
Human GST-P 
 
 
 
 
Human GSTA 
 
 
 
 
Human GST-M 1a-1a 
 
 
 
 
Human GST-M 2-2 
TER 117 
TER 135 
TER 211 
TER 143 
Ethacrynic acid 
TER 117 
TER 135 
TER 211 
TER 143 
Ethacrynic acid 
TER 117 
TER 135 
TER 211 
TER 143 
Ethacrynic acid 
TER 117 
TER 135 
TER 211 
0.4 µM 
0.85 µM 
1.2 µM 
1.9 µM 
4.0 µM 
20 µM 
5.8 µM 
4.2 µM 
0.27 µM 
2.0 µM 
25 µM 
41 µM 
0.01 µM 
1.2 µM 
3.0 µM 
31 µM 
97 µM 
1.5 µM 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Morgan et al., 1996 
Human GST-P Hypochlorous acid 0.55 µM 0.6 µM van Haaften et al., 2001 
Human GST-P Auranofin - 32.9 µM De Luca et al., 2012 
Human GST-P Ethacrynic acid 
Ethacrynic acid oxadiazole analogs 
- 
- 
3.4 µM 
0.6-5.4 µM 
Yang et al., 2010 
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2.3.1 GST-P INHIBITOR 
To counteract the phenomenon of multidrug resistance which partly caused by 
the GST-P, potential inhibitors for this enzyme has been found and designed to sensitize 
those tumor cells to antineoplastic drugs. Ethacrynic acid (EA), which originally found 
as plant phenolic acid, is reported to be preferentially conjugated by alpha, mu and pi-
class GSTs (Ploemen et al., 1993b; Liebau et al., 2002). Reversible inhibition of GSH-
EA conjugates on alpha and mu-classes of GST is reported to be more potent than EA 
itself, but not for GST-P (Ploemen et al., 1993b). However, dibromo dihydro derivative 
of EA exhibit strong inhibitory capacity on both human and rat GST-P (Ploemen et al., 
1993a). EA has been used to increase the sensitivity of tumor cells towards alkylating 
cytostatic agents used in chemotherapy. EA enhanced the cytotoxic effects of 
chlorambucil in patients with chronic leukemia and also in human colon carcinoma cell 
line in in vitro assays. Besides, EA has been found to potentiate the effect of melphalan 
in human colon tumor xenografts of SCID mice (Townsend and Tew, 2003). According 
to Tew et al. (1988), EA and piriprost (6,9-deepoxy-6,9-(phenylimino)-∆6,8-
prostaglandin I1) have the ability to enhance cytotoxic activity of chlorambucil on rat 
and human tumor cells by interfering thiol metabolism and GST functions. Both of 
them have shown significant inhibitory activity on intracellular GST which result in the 
reversion of drug-resistant cells to the drug-sensitive cells. Even though EA is a potent 
GST-P inhibitor, EA is also both inhibitor and inducer of GST which found to increases 
the expression of GST-P and also half-life of the protein (Shen et al., 1995). Non-
specific inhibition of EA on GST isozyme and also side effects limited its clinical 
application as the possible deleterious effects on normal cell’s defense system should 
also take into consideration (Wang et al., 2008). 
A potent and specific inhibitor of GST-P has been developed by Schultz et al. 
(1997), which is the glutathione analog Terrapin 199 (TER 199). Later on, TER 117 has 
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been developed for efficient inhibition of the most abundant form of GST-P/Ile 105. It 
was found that the inhibitory effect of TER 117 on both GST-P and glyoxalase I may 
act synergically and thus improve the effectiveness of chemotherapy. TER 117 is a 
GSH analog designed to block the active site of GST-P (Johansson et al., 2000).  
The inhibition of GST-P by TLK 199 results in the activation of c-Jun NH2-
terminal kinases (JNK) thus induced cell apoptosis. TLK 199 is a rationally designed 
GSH-based-peptidomimetic inhibitor of GST-P (Townsend and Tew, 2003). It has been 
reported as an inhibitor of the multidrug resistance-associated protein-1 (MRP-1) which 
reversed the resistance to various types of chemotherapeutic agents in NIH3T3 cells 
which transfected with MRP-1 (O’Brien et al., 1999). 
A GST-P specific inactivator, haloenol lactone (HEL) derivative, was designed 
by Zheng et al. (1996). HEL is a site-directed inhibitor targeted on the nucleophile near 
the active site of GST. Binding of HEL to the nucleophile leads to opening of lactone 
ring, results in the formation of α-bromoketone intermediate which permanently 
modified the protein. HEL enhanced cytotoxicity of alkylating agents by GST inhibition 
and GSH depletion (Wang et al., 2008). 
Another potent, non-competitive GST-P inhibitor, hypochlorous acid (HOCl), 
was introduced by van Haaften et al. (2001). HOCl was generated by neutrophils 
through the conversion of H2O2 by myeloperoxide. HOCl inhibited GST-P with an IC50 
value thousand times lower than IC50 value reported for H2O2 previously. H2O2 is ROS 
that specifically inhibited GST-P but has no inhibition effect on other GST subclass, 
such as Mu-class GST. Even though GSTs were known to be the class of enzyme to 
combat ROS during oxidative stress, GST-P was an exception. The powerful oxidant 
HOCl not only capable of inhibiting GST-P but also induced apoptosis through the 
activation of caspase 3 (Vissers et al., 1999). However, uncontrolled and/or excessive 
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production of HOCl may leads to oxidative stress and harmful effects to surrounding 
cells (Li et al., 2004). 
Anticancer metallodrugs act on cytosolic GSTs were reported to cause potent 
and selective inhibition of GST-P. EA conjugated ruthenium-arene complexes are 
reported as one of the most effective rutherium complexes-based GST-P inhibitor (Ang 
et al., 2007). Gold compound, auranofin, exhibit strong anticancer effects and also 
causes inhibition of pi-class GST. Auranofin inhibited GST-P in a way different from 
other reported inhibitor, where cysteine residues are not essential for enzyme 
inactivation (De Luca et al., 2012). Moreover, pharmacological mode of action of gold 
compounds is targeted on essential enzymes rather than DNA. For example, Gold (I) 
carbene complexes reported to have cytotoxic effects on cancer cell lines by causing 
thioredoxin 1 and thioredoxin 2 oxidation (Schuh et al., 2012) and recombinant human 
serum albumin conjugated organoruthenium complexes are shown to enhance 
cytotoxicity with known cyclin-dependent kinase (Cdk) inhibition activity (Stepanenko 
et al., 2011). 
Structures of the GST inhibitors are shown in Figure 2.6. 
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Figure 2.6 : Structures of GST inhibitors. (Adapted from O’Brien et al., 1999; Tew et al, 
1988; Schultz et al., 1997; Townsend and Tew, 2003) 
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2.4 COLORECTAL CANCER 
Colorectal cancer, or commonly known as colon cancer or bowel cancer, is 
cancer initially develop in glands in the lining of colon (large intestine) or rectum (end 
of colon) (Medical Encyclopedia, 2012). The colorectal cancers are adenocarcinomas 
which progress from normal to dysplastic epithelium to carcinoma. It involves alteration 
of selected gene that eventually results in abnormal rates of apoptosis and proliferation 
(Evans et al., 2006). Most of the colorectal cancer developed through the formation 
benign polyp on the inner lining (mucosa) of the colon or rectum (Lanza et al., 2011). 
In order to choose an appropriate treatment for the disease, determination of the 
colon cancer stage becomes a very important part of diagnosis. Basically, colon cancer 
can be divided into 5 different stages. 
Stage 0: Also known as carcinoma in situ, where the cancerous cells are limited at the 
inner lining (mucosa layer) of colon. 
Stage 1: Cancer is formed in the mucosa layer and spread out to the submucosa and 
muscle layers of colon. 
Stage 2: Cancer has spread through the muscle layer to the outermost layer (serosa layer) 
of colon. The cancer will then spread through the serosa layer followed by 
spreading to nearby organs. 
Stage 3: Cancer probably spread through mucosa, submucosa and muscle layers of 
colon, and reach either 1-3 nearby lymph nodes or tissues surrounding the 
lymph nodes or just 4-6 nearby lymph nodes or more than 7 nearby nodes. The 
cancer is then metastasis to nearby organs. 
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Stage 4: At this stage, the cancer has spread through the colon wall and one or more 
organs at other parts of the body, such as liver, lung and ovary. The cancer 
metastasized through blood and lymph nodes. (National Cancer Institute, 2012) 
 
 
Figure 2.7 : (a) Illustration of the cross section of normal intestinal tract. (Adapted from 
American Cancer Society, 2012) (b) Scheme of the initiation and 
progression of colon cancer. (Adapted from Marks, 2012) 
 
(a) 
(b) 
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Colorectal cancer is one of the leading causes of death by cancer worldwide. 
According to the World Health Organization (WHO), there were 639,000 deaths 
worldwide attributed to colorectal cancer and it is the second leading cause of cancer-
related death in Western country (World Health Organization, 2009). Colon cancer is 
reported as the second most frequent cancer in Malaysia (MAKNA, 2006). Besides, 
colorectal cancer is also reported as the third most diagnosed cancer in male and second 
most diagnosed cancer in female of England in the year 2009 (Cancer Research UK, 
2012). Risk factors for development of colon cancer include gender, age, genetics, race, 
diet, obesity, cigarette smoking, environmental carcinogens, Lynch syndrome and 
polyps (Salmon and Sartorelli, 1998; Giovannucci, 2002; Pande et al., 2010; Lanza et 
al., 2011). 
Until now, surgical resection still considered as the only curative treatment for 
colorectal cancer and the chances of cure is higher for earlier pathological stage (Jänne 
& Mayer, 2000). Since only around 50% of these cancers can be cured by either surgery 
or other mode of treatments, there is considerable need for further study on this kind of 
disease (Pfragner and Freshney, 2004). Colon cancer is relatively resistant to most of 
the chemotherapeutic treatments. Success of cancer chemotherapy primarily limits by 
cytostatic resistance (Hengstler et al., 1998). High level of GST-P found to be expressed 
in human colon cancer cell line and it is believed that GST-P indeed one of the 
multidrug resistance factors. 
For in vitro studies to be relevant clinically, cell lines that are representative to a 
disease are important. A numbers of the colon carcinoma cell lines have been 
established and deposited at the American Type Culture Collection (ATCC) and 
European Collection of Cell Cultures (ECACC) cell banks. Examples of established 
human colorectal adenocarcinoma cell lines are such as WiDr (Noguchi et al., 1979), 
COLO 320DM (Quinn et al., 1979), HCT 116 (Brattain et al., 1981), LoVo (Drewinko 
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et al., 1976), Caco-2 (Jumarie and Malo, 1991), HT-29 (Chen et al., 1987), LS 123 
(Rutzky et al., 1983) and BE (Tew et al., 1988) cell lines. 
In my research, HT-29 cell line is selected for the cytotoxicity assays and 
extraction of GST-P enzymes as the cell line expresses high level of GST-P. In fact, 
HT-29 cell line was reported to be more resistant to cytotoxic agent compared to other 
cell lines. High GST-P-expressing HT-29 cell line has an IC50 value 3 times higher than 
the IC50 value of low GST-P-expressing HepG2 cells in response to doxorubicin. 
Toxicity of GSH-conjugated doxorubicin is higher compared to doxorubicin, where IC50 
values for HT-29 and HepG2 are 28 and 0.15 nM, respectively (Tashiro et al., 2001).  
Felth et al. (2009) reported that HT-29 cells were significantly more resistant to 
cytotoxic cardiac glycosides and standard chemotherapeutic drugs, compared to HCT 
116 and CC 20 cell lines. Monomethyltriazene is also demonstrated to be more toxic to 
BE cell line compared to drug-resistant HT-29 cell line (Gibson et al., 1986). 
Furthermore, HT-29 cell line is one of the best described cell line among several 
adenocarcinoma cell lines and has been extensively used in the study of colorectal 
cancer (Lu et al., 1992). For example, HT-29 cell line was shown to become more 
resistant to methotrexate in an increasing concentration manner by growth adaptation 
associated cell differentiation. The morphological and functional characteristics of the 
differentiated phenotypes are examples of tumor heterogeneity and probably responsible 
for poor prognosis of colon cancers (Lesuffleur et al., 1990). 
 
 2.5 ANTICANCER DRUGS 
Generally, chemotherapy referred as the treatment of cancers with one or in 
combination of several anticancer drugs, depending on the treatment regimen. Although 
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there are several other cancer treatments like radiation therapy and surgery, 
chemotherapy still remain as the most common used treatment for solid tumors.  
There are different types of anticancer drugs available nowadays, such as 
alkylating agents, antimetabolites, topoisomerase inhibitors, cytotoxic antibiotics, 
hormonal agents, plant alkaloids and miscellaneous antineoplatics. They are grouped 
based on factors such as mode of action, chemical structure and interaction with other 
drugs. Generally, the mechanisms of action of different anticancer drugs are such as 
following: 
Alkylating agent: Prevent cell proliferation by directly damage intracellular DNA, RNA 
and proteins with the formation of covalent bonds. Not cell-cycle-
phase-specific.  
Antimetabolites: Kill cells by either interfering catalytic or regulatory activities of 
intracellular enzymes, or competing with metabolites to incorporate into 
DNA and RNA. More effective on S phase cells compared to G0 phase 
cells. 
Topoisomerase inhibitor: Prevent DNA synthesis by interfere with DNA topoisomerase, 
which functions to unwind double-stranded DNA during 
transcription or replication. Cell cycle is trapped at G1 phase. 
Cytotoxic antibiotic: Prevent DNA replication by intercalation of DNA and inhibition of 
topoisomerases. Not cell-cycle-phase-specific. 
Hormonal agent: Block the supply or production of hormones needed for cancer cell 
growth.  
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Plant alkaloid: Antimitosis by inhibition of enzymes regulating cell proliferation. Most 
active on cell of M phase but can also act on cells in all phases. (Page and 
Takimoto, 2004) 
Many more new drugs have been developed and tested in the attempt to achieve 
long lasting effect (Salmon and Sartorelli, 1998).  
 
 
Table 2.4 : Different types of anticancer drugs used in cancer therapy 
Types of Anticancer Drugs Examples 
Alkylating agents Nitrogen mustards (Chlorambucil, Melphalan, 
Mechlorethamine, Ifosfamide, Cyclophosphamide), 
Ethylenimines (Thiotepa, Hexamethylmelamine), 
Alkylsulfonates (Busulfan), Hydrazines and Triazines 
(Altretamine, Procarbazine, Dacarbazine, 
Temozolomide), Nitrosureas (Carmustine, Lomustine, 
Streptozocin) and Metal salts (Cisplatin, Carboplatin, 
Oxaliplatin). 
Antimetabolites Folic acid antagonists (Methotrexate, Pemetrexed), 
Adenosine deaminase inhibitors (Cladribine, 
Fludarabine, Pentostatin), Purine antagonists (6-
Mercaptopurine, 6-Thioguanine, Clofarabine) and 
Pyrimidine antagonists (5-Fluorouracil, Capecitabine, 
Cytarabine, Gemcitabine). 
Topoisomerase inhibitors Topoisomerase I inhibitors (Irinotecan, Topotecan) 
and Topoisomerase II inhibitors (Amsacrine, 
Etoposide, Mitoxantrone, Teniposide). 
Antibiotics Anthracyclines (Doxorubicin, Daunorubicin, 
Epirubicin, Idarubicin, Mitoxantrone), Chromomycins 
(Actinomycin-D, Plicamycin) and Miscellaneous 
(Mitomycin-C, Bleomycin). 
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Table 2.4, continued 
Types of Anticancer Drugs Examples 
Hormones Corticosteroids (Dexamethasone, Methylprednisolone, 
Prednisone), Antiestrogens (Fulvestrant, Tamoxifen, 
Toremifene), Aromatase inhibitors (Anastrozole, 
Letrozole, Exemestane), Estrogens, Progestins 
(Megestrol acetate), Antiandrogens (Bicalutamide, 
Flutamide, Nilutamide) and Gonadotropin-releasing 
hormones (Leuprolide, Goserelin). 
Plant alkaloids Vinca alkaloids (Vincristine, Vinblastine, 
Vinorelbine), Taxanes (Docetaxel, Paclitaxel), 
Podophyllotoxins (Etoposide, Tenisopide) and 
Camptothecan analogs (Irinotecan, Topotecan). 
Immunomodulators Monoclonal antibody (Rituximab, Alemtuzumab), 
Cytokines (Interferon-alfa, Interleukin-2), Vaccines 
(BCG, Sipuleucel-T, Oncophage) and 
Immunomodulating drugs (Thalidomide, 
Lenalidomide). 
Miscellaneous antineoplastics Adrenocortical steroid inhibitors (Mitotane), 
Antimicrotubule agents (Estramustine), Enzymes (L-
asparaginase, Pegaspargase), Proteasome inhibitors 
(Bortezomid, Disulfiram, Carfilzomid), 
Ribonucleotide reductase inhibitors (Hydroxyurea),  
Retinoids (Bexarotene, Arsenic trioxide, Tretinoin) 
and Tyrosine kinase inhibitors (Imatinib, Gefitinib, 
Sunitinib) 
(Adapted from American Cancer Society, 2011) 
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Cisplatin 
 
Figure 2.8 : Structure of cisplatin. (Adapted from Trzaska, 2005) 
 
Cisplatin or cis-diamminedichloroplatinum(II) is one of the most potent 
platinum-based chemotherapy drug clinically used to treat a wide variety of tumors. It is 
also known as “penicillin of cancer drugs” because of its wide prescription as well as 
the first effective treatment for cancers (Trzaska, 2005). Cisplatin has major 
antineoplastic activities on sarcoma, testicular, ovarian, bladder, uterine, cervical, non-
small cell and small cell lung cancer, head and neck cancer, and germ cell tumor (Page 
and Takimoto, 2004). 
The DNA damaging effect of cisplatin is mediated by its interaction with DNA 
that forms intra- and inter-strand DNA adducts, which in turn activates several apoptotic 
pathways lead to cell apoptosis (Siddik, 2003). Cisplatin induced activation of MAPK 
apoptotic pathways of ERK, JNK and p38 in human ovarian carcinoma cells. ERK 
pathway is responsible for the cell protection against apoptosis and regulation of cell 
proliferation and differentiation, while JNK and p38 pathways play important roles in 
stress and inflammatory responses. Sustained activation of JNK and p38 pathways by 
cisplatin were shown to trigger up-regulation of Fas ligand expression, which 
accompanied by caspase induction and apoptosis (Mansouri et al., 2003). Besides, 
Pruefer et al. (2008) shown that cisplatin induced apoptosis in colon cancer cells by the 
intrinsic pathway involving Omi Htra2 serine protease. Omni Htra2 serine protease is 
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one of the mitochondrial releasing apoptotic proteins which inactivate inhibitors of 
apoptosis proteins (IAPs).  
Even though cisplatin was extensively used in the treatment of solid tumor, its 
effectiveness is limited by the development of multidrug resistance (Parker et al., 2011). 
Most of the cisplatin-resistant cell lines showed overexpression of GST-P isozymes and 
reversal of drug resistance is demonstrated with the inhibition of GST-P (Pasello et al., 
2008; Nakajima et al., 2003; Huang et al., 2007). According to Huang et al. (2007), 
GST-P expression is up-regulated when osteosarcoma cells exposed to cisplatin and this 
caused the cells to be more resistant to cisplatin. Both of the mRNA and protein levels 
of GST-P are increased in SAOS-2 cells treated with cisplatin. In contrast, GST-P 
suppression by gene silencing resulted in 2.5-fold increase in cell growth inhibition 
when treated with cisplatin. GST-P suppression increased apoptosis and DNA 
destruction in response to cytotoxic drugs exposure, and this also decreased the 
cisplatin-induced signal activation of kinase1/2 thus enhanced chemosensitivity. 
The use of cisplatin is also limited by its side effects, such as nephrotoxicity, 
neurotoxicity, ototoxicity, myelosuppression, radiosensitizer, electrolyte imbalance, 
nausea, and vomiting (Page and Takimoto, 2004). However, the major dose-limiting 
toxicity of cisplatin is nephrotoxicity, which indicated by damage of renal tubule due to 
the elevation of serum creatinine or blood urea nitrogen (BUN) (Barakat et al., 2009). 
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Figure 2.9 : Illustration of cellular uptake of cisplatin and its possible intracellular 
targets. (Adapted from Pil and Lippard, 1997) 
 
 
Doxorubicin 
 
Figure 2.10 : Chemical structure of doxorubicin. (Retrieved from Inspiralis, 2006) 
 
The anthracycline drug, Doxorubicin (or adriamycin), was first introduced by 
Arcamone et al. (1969) in the 1970’s.  Doxorubicin is the 14-hydroxy derivative of 
daunomycin extracted from Streptomyces peucetius var. caesius. It is commonly used in 
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the treatment of broad range of tumors, including breast, ovarian, bladder, gastric, 
thyroid cancer, srcoma, Wilms’ tumorand neuroblastoma (Page and Takimoto, 2004). 
There are different mechanisms have been proposed for the cytostatic and 
cytotoxic actions of doxorubicin. These include interference with macromolecular 
biosynthesis through DNA intercalation, free radicals generation, lipid peroxidation, 
formation of DNA adduct and DNA cross-linking, interference with DNA unwinding 
and DNA helicase action, direct membrane interaction, induction of DNA damage 
through inhibition of topoisomerase II and direct induction of apoptosis. However, the 
induction of DNA strand breaks by inhibition of nuclear enzyme topoisomerase II is 
suggested to be the primary mechanism of doxorubicin action (Gewirtz, 1999).  
Chemoresistance was developed in bone cancer cells due to the overexpression 
of GST-P when the cells are exposed to doxorubicin. GST-P was claimed as the main 
cause of drug resistance due the suppression of GST-P in HOS cells was shown to 
increase apoptosis of the cells in response to doxorubicin. Indeed, GST-P-mediated 
activation of ERK 1/2 may be the mechanism of the development of drug resistance 
(Huang et al., 2007). Besides, Awasthi et al. (1996) able to enhance cytotoxicity of 
doxorubicin on human lung cancer cell line by enthacrynic acid inhibition on GSTs. 
Other than GST-P, Nielsen et al. (1996) proposed several other mechanisms of 
resistance developed in cell in response to anthracycline exposure. This includes P-
glycoprotein-mediated multidrug resistance, Non P-glycoprotein-mediated multidrug 
resistance, vesicular drug compartmentalization, altered topoisomerase II activities and 
enhanced DNA repair. 
The major limitation of clinical utilization of doxorubicin is cardiotoxicity in the 
aspect of cumulative dosage of the drug. Besides, the side effects of doxorubicin include 
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myelotoxicity, stomatitis, alopecia, diarrhea, dermatitis, red urine, anaphylactoid 
reaction, nausea and vomiting (Page and Takimoto, 2004).  
 
 
 
Figure 2.11 : Representation of the mechanisms involve in the action of doxorubicin 
(DOX) in cancer cell. Mechanisms described in the diagram include DNA 
intercalation, inhibition of topoisomerase II (TOP2A), generation of 
reactive oxygen species (ROS) which in turn lead to DNA damage, lipid 
peroxidation and membrane disruption, pharmacokinetics (PK) pathway 
and transporters associated with drug resistance. (Adapted from Thorn et 
al., 2011) 
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2.6 NATURAL PRODUCTS 
Studies on natural products not only revealed new insight into fundamental 
biological mechanisms but also discovered new pharmaceutical or biotechnological 
possibilities of immediate use. Secondary metabolites which produced by different 
enzymatic pathways in plants to gain evolutionary advantages, has been reported to 
have a wide range of bioactivities. Besides, plant based biologically active cyclotides 
which have a unique protein folding, has been provides a framework in protein 
engineering and drug design applications (Bohlin et al., 2010).  
There are numerous reports on natural products which have been proven to have 
significant biological effects against different types of cancer. Plant containing cardiac 
glycosides such as convallatoxin, olenandrin, proscillaridin A, digitoxin and digoxin, 
were identified to exhibit cytotoxic activity against colorectal cancer cell lines (HT-29, 
HCT-116 and CC20) with IC50 values ranging from 0.007-4.1µM (Felth et al., 2009). 
Curcumin, a yellow pigment derived from Curcuma longa Linn, was reported to induce 
apoptosis of HT-29 colorectal cells by inducing the p53 which involved in apoptosis 
signalling pathway and regulating the expression of apoptosis related proteins. Besides, 
it also suppressed carcinogenesis of skin, breast, stomach and liver (Song et al., 2005). 
Naphthoquinones and their respective analogs isolated from Avicennia plants, 
phenylpropanoids and phytoquinoids isolated from Illicium plants, and phenylpropanoid 
of sucrose, vanicoside B and lapathoside A from Polygonum lapathifolium, have 
displayed remarkable anti-tumor-promoting activities against Eptein-Barr virus early 
antigen (EBV-EA) activation which induced by 12-O-tetradecanoylphorbol-13-acetate 
(TPA) in Raji cell line (Itoigawa et al., 2001; 2004; Takasaki et al., 2001). Finally, plant 
stress hormone, methyl jasmonate, exert selective cytotoxicity towards tumor cells by 
the induction of severe intracellular ATP depletion, induction of cellular re-
differentation via mitogen-activated protein kinase (MAPK) pathway and induction of 
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apoptosis via hydrogen peroxide generation and Bcl-2 proapoptotic proteins (Cohen and 
Flescher, 2009). 
 
2.7 PLANT POLYPEPTIDES 
In recent decades, plant polypeptides have been extensively studied due to the 
presence of unique pharmacologically active polypeptides in several plant species 
(Gerlach et al., 2010; Witherup et al., 1994; Bokesch et al., 2001), similarity with 
endogenous signaling compounds in animals which make use of peptides (Saether et al., 
1995), and the presence of transgenic plants that produced valuable recombinant 
polypeptides (Claeson et al., 1998; Yu et al., 2003).  
Examples of established biologically active plant polypeptides are, the HIV-
inhibitory macrocyclic polypeptides, palicourein from Palicourea condensata (Bokesch 
et al., 2001), circulins A-F from Chassalia parvifolia (Gustafson et al., 1994; 2000); 
cyclopsychotride A from Psychotria longipes, which inhibits binding of neurotensin to 
HT-29 cell membranes and also elevated intracellular Ca
2+
 concentration in cell lines 
without neurotensin receptors (Witherup et al., 1994); kalata B1 peptide from 
Oldenlandia affinis, which has uterotonic activity (Saether et al., 1995); finotin from 
Clitoria ternatea that possess antimicrobial and antifungal activities (Kelemu et al., 
2004); kalata B1 and B6 of Oldenlandia affinis and cycloviolacin O14 of Viola odorata 
that proved to have antihelmintic activity (Colgrave et al., 2009); psyles A, C and E of 
Psychotria leptothyrsa which showed to have cytotoxic effect on lymphoma cell line 
U937-GTB (Gerlach et al., 2010); and the varv A and varv F of Viola arvensis and 
cycloviolacin O2 of Viola odorata which exhibited high cytotoxic activities on several 
cancer cell lines (Lindholm et al., 2002). In addition, the four macrocycliccystine-knot 
peptides, kalata, circulin A and B, and cyclopsychotride, have been shown to have 
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antimicrobial, antifungal and haemolytic properties (Tam et al., 1999). Occurrence of 
highly stable small cyclic peptides in plants is common especially for those worked as 
antibiotics of microbial origin. Immunosuppressant, cyclosporine, is the best example to 
exemplified the pharmaceutical uses of these type of cyclic peptides (Craik et al., 1999).  
According to Craik et al. (2001), cystine knot motif has been found in wide 
variety of peptides and proteins. Presence of cystine knot engendered a particularly high 
degree of chemical and biological stability to the protein molecule itself. So, the ability 
to synthesize and figure out the structures of the cystine knot containing peptides 
somehow offered a valuable framework in protein engineering (Gran et al., 2000). 
Thus, wide range of bioactivities, high stability of cytine knot motif and 
distinctive structure scaffold of peptide toxins like cyclotides (Gerlach et al., 2010), can 
be harnessed for drugs design applications. 
 
2.8 RESEARCH STATEMENT 
Since GST-P has significance in cancer diagnosis and its over-expression 
contributes to chemoresistance in many cancers and become a major reason of 
chemotherapy failure and disease recurrence, finding of agents that can inhibit GST-P 
can be consider as an adjuvant in cancer treatment. 
There was a number of potential inhibitors of GST-P has been found and 
designed. Some of the inhibitors were reported to have the ability to enhance 
cytotoxicity effects of clinically used anti-cancer drugs. However, some of the GST-P 
inhibitors are found have side effects and thus limited its clinical application. 
In my research, HT-29 cell line is selected for the cytotoxicity assays and 
extraction of GST-P enzymes as the cell line expresses high level of GST-P. In fact, 
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HT-29 cell line was reported to be more resistant to cytotoxic agent compared to other 
cell lines. 
Besides, plant-based GST-P inhibitor is targeted in my research as there are 
numerous reports on natural products which have been proven to have significant 
biological effects against different types of cancer. 
The significance of this research would be the finding of GST-P inhibitors in 
local plant that can be used as a medication drug to overcome anti-cancer drug 
resistance during cancer treatment. 
 
2.9 OBJECTIVES 
The objectives of this study are listed out as below: 
 To screen plant extracts with inhibitory activity toward GST-P. 
 To evaluate the behavior of inhibitors toward GST-P. 
 To evaluate the ability of inhibitors to potentiate cytotoxicity of selected 
drugs on HT-29 cell line. 
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3.0 MATERIALS & METHODS 
3.1 MATERIALS 
3.1.1 PLANT MATERIALS 
31 local plants (43 samples) selected in this study were collected and prepared 
by Mr. Ghazali and Mr. Izuwan from University of Malaya. Plant samples were 
authenticated by plant taxonomist, Prof. Dr. Ong Hean Chooi. All of the samples were 
given in dried form and readily separated into different plant parts. The plant parts 
consist of leaf, fruit, flower, branches and also the whole plant. Plant samples used in 
this study included Anacardium occidentale (branch, fruit & flower), Andrographis 
paniculata (branch, leaf), Artocarpus heterophyllus (leaf), Averrhoa bilimbi (branch, 
leaf), Cinnamomum zeylanicum (branch), Commelina nudiflora (whole plant), Euodia 
redlevi (flower & fruit), Eupatorium odoratum (branch), Fagraea fragrans (leaf & 
branch, fruit & flower), Ficus auriculata (leaf), Garcinia atroviridis (branch), Garcinia 
mangostana (branch, leaf), Hibiscus tiliaceus (leaf), Ipomoea aquatica (leaf), Justicia 
gendarussa (branch), Lagerstroemia speciosa (fruit, leaf), Lawsonia inermis (branch), 
Leptospermum flavescens (leaf, branch), Macaranga conifera (branch), Melaleuca 
cajuputi (fruit & flower), Moringa oleifera (branch), Orthosiphon stamineus (leaf), 
Oxalis barrelieri (root), Peltophorum pterocarpum (fruit, leaf), Pereskia bleo (fruit), 
Piper nigrum (leaf, branch, fruit), Scoparia dulcis (root), Strobilanthes crispa (branch), 
Tetracera indica (fruit), Vitex sp. (branch, leaf) and Vitex trifolia ‘purpurea’ (branch, 
leaf). Table 7.1 in Appendix I indicates the details of origin and references of plant parts. 
 
3.1.2 CELL MATERIALS 
The human colon adenocarcinoma HT-29 cell line and fetal lung fibroblast 
MRC-5 cell line were purchased from American Type Culture Collection (ATCC, 
USA).  
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3.1.3 CHEMICAL REAGENTS AND DRUGS 
All of the chemical reagents used in this study were of analytical grade unless 
stated. The chemicals and drugs used included: 
0.5M Tris-HCl buffer, pH 6.8 (Bio-Rad), 1.5M Tris-HCl buffer, pH 8.8 (Bio-Rad), 1-
chloro-2,4-dinitrobenzene (CDNB) (Sigma-aldrich), 2-Mercaptoethanol (Merck), 3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-aldrich), 30% 
Acrylamide/Bis solution, 37.5:1 (2.6% C) (Bio-Rad), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) (Fluka), Accutase® solution (Sigma-aldrich), 
Acetonitrile (ACN) (J. T. Baker), Ammonium bicarbonate ((NH4)HCO3) (Sigma-
aldrich), Ammonium persulfate (APS) (Bio-Rad), Ammonium sulfate ((NH4)2SO4) 
(Systerm®), Amphotericin B (PAA), Brilliant blue G-250 (Sigma-aldrich), 
Bromophenol blue (Sigma-aldrich), CelLytic™ M (Mammalian cell lysis/extraction 
reagent) (Sigma-aldrich), cis-Diamineplatinum(II) dichloride (Cisplatin) (Sigma-
aldrich), Dichloromethane (DCM) (Systerm®), Dimethyl sulfoxide (DMSO) (Sigma-
aldrich), Doxorubicin hydrochloride (Sigma-aldrich), Eagle Minimum Essential 
Medium, with L-glutamine, powder (EMEM) (Sigma-aldrich), Ethacrynic acid (Sigma-
aldrich), Ethanol (Systerm®), Foetal bovine serum (FBS) (PAA), Formaldehyde 
(Systerm®), Glacial acetic acid (Systerm®), Glycerol (Systerm®), Glycine (Systerm®), 
Hydrochloric acid (HCl) (Systerm®), IEF anode buffer (50X) (Invitrogen), IEF cathode 
buffer, pH 3-10 (10X) (Invitrogen), IEF sample buffer, pH 3-10 (2X) (Invitrogen), L-
Glutathione reduced (GSH) (Sigma-aldrich), Mark 12™ unstained standard (Invitrogen), 
Mass standards kit for the 4700 proteomics analyzer (includes calibration mixture 1, 
4700 proteomic analyzer calibration mixture, digested β-galactosidase, α-cyano-4-
hydroxycinnamic acid (CHCA) ) (Applied Biosystems), Methanol (Systerm®), 
N,N,N’,N’- Tetramethylethylenediamine (TEMED) (Bio-Rad), Ortho-phosphoric acid 
(H3PO4) (Systerm®), Penicillin/Streptomycin (PAA), Phosphate buffered saline powder, 
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pH 7.4 (PBS) (Sigma-aldrich), Protease inhibitor cocktail (Sigma-aldrich), RPMI-1640 
Medium (with L-glutamine, without sodium bicarbonate, powder) (Sigma-aldrich), 
SERVA IEF protein markers 3-10 (Invitrogen), Silver nitrate (AgNO3) (Systerm®), 
Sodium bicarbonate (NaHCO3) (BDH), Sodium carbonate (Na2CO3) (R&M Chemicals), 
Sodium dihydrogen phosphate (NaH2PO4) (Systerm®), Sodium dodecyl sulfate (SDS) 
(Sigma-aldrich), Sodium hydroxide (NaOH) (Systerm®), Sodium pyruvate (Sigma-
aldrich), Sodium thiosulfate (Na2S2O3) (Systerm®), Trichloroacetic acid (TCA) (R&M 
Chemicals), Trifluoroacetic acid (TFA) (Fisher Scientific), Tris base (Promega), Trypan 
blue (Sigma-aldrich), Trypsin (Sigma-aldrich), Trypsin-EDTA (PAA). 
 
3.1.4 EQUIPMENTS 
 -20°C refrigerator 
 4°C refrigerator 
 -80°C refrigerator 
 ÄKTA Prime Plus 
 ÄKTA Purifier FPLC 
 Autoclave machine 
 Centrifuge machine (refrigerated and non-refrigerated) 
 CO2 incubator 
 Cold room 
 Freeze-dryer 
 Fraction collector 
 Fume hood 
 GSTrap HP column, 1 mL 
 Haemocytometer 
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 Hot plate and magnetic stirrer 
 Hot water incubator 
 Ice maker 
 Image scanner 
 Lamina hood 
 Liquid nitrogen tank 
 MALDI TOF mass spectrometer 
 Microplate mixer 
 Microplate reader 
 Microscope 
 Microsep™ centrifugal concentrator 
 Mini-PROTEAN® tetra cell 
 Orbital shaker 
 Oven 
 pH meter 
 PowerPac Basic™ power supply 
 Rotary evaporator 
 SpeedVac concentrator 
 Ultrapure water system 
 Ultrasonic cleaner 
 UV-Vis spectrophotometer 
 Vortex mixer 
 Water distiller 
 Weighing machine 
 XCell SureLock® Mini-Cell 
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Figure 3.1 : Overview of methodology. 
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3.2 METHODS 
3.2.1 PLANT EXTRACT PREPARATION 
The plant samples (a total of 43 samples) supplied were readily ground into 
small pieces. The extraction was done according to Claeson et al. (1998), with some 
modification. In brief, 20 g of each plant sample was weighed and soaked in 200 mL of 
Dichloromethane (DCM). The mixture was shaken overnight at 100 rpm on orbital 
shaker in cold room. Then, the mixture was filtered with filter paper and the plant 
residue was then dried in fume hood. After that, dried residue was soaked in ethanol: 
water at a ratio of 1:1 (100 mL ethanol: 100 mL water). The mixture was then shaken 
overnight at 100 rpm on orbital shaker in cold room. Then, the mixture was filtered and 
the filtrate was collected. Filtrate was washed with DCM using separating funnel and 
then sent for rotary evaporation at 36-38°C. The concentrated extract will be denoted as 
ethanolic extract and it was transferred into a universal bottle and frozen at -80°C before 
subjected to freeze-drying. Freeze-dried ethanolic extract is then stored at -20°C prior to 
use.  
 
3.2.2 HT-29 CELL CULTURE AND LYSIS 
3.2.2.1 PREPARATION OF MEDIA AND SOLUTIONS 
The media and solutions used in this experiment were prepared as stated in 
Appendix II. 
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3.2.2.2 CELL REVIVAL 
A vial of HT-29 cell line was removed from liquid nitrogen and quick thawed in 
a water bath at 37°C. The cells were then transferred into a centrifuge tube containing 1 
mL of 20% supplemented RPMI 1640 medium. The cells were spun at 1000 rpm for 5 
minutes. Then, the supernatant was discarded and 1 mL of 20% supplemented RPMI 
1640 medium was added and mixed. The cells were then transferred into a 25 cm
2
 
culture flask (Nunc, Denmark) which contained 4 mL of 20% supplemented RPMI 1640 
medium. The cells were cultured in humidified 5% CO2 incubator at 37°C. 
 
3.2.2.3 CELL MAINTENANCE 
After the HT-29 cells adherent and started to grow, the medium was discarded. 
The cells were rinsed with PBS and 5 mL of 10% supplemented RPMI 1640 medium 
was then added to maintain the growth of the cells. Medium was changed regularly until 
the cells confluent. 
 
3.2.2.4 CELL SUBCULTURATION 
When the monolayer HT-29 cells were confluent, the cells were then trypsinized 
with trypsin-EDTA and PBS at the ratio of 1: 3 (1 mL of trypsin-EDTA: 3 mL of PBS). 
The medium was removed and the monolayer cells were rinsed with PBS prior to 
trypsinization. In the process of trypsinization, the cells were incubated in 5% CO2 
incubator at 37°C for 5-10 minutes, until the cells started to detach (this was assisted by 
tapping the sides of the flask for a few times). The cells were then transferred into a 
centrifuge tube which contained 1 mL of 10% supplemented RPMI 1640 medium, and 
then spun at 1000 rpm for 5 minutes. After that, the supernatant was discarded and the 
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cell pellet was re-suspended in 3 mL of 10% supplemented RPMI 1640 medium. 1 mL 
of cell suspension was transferred into each culture flask (a total of 3 flasks) and 
maintained with 4 mL of 10% supplemented RPMI 1640 medium. 
 
3.2.2.5 CELL CRYOPRESERVATION 
In order to maintain the availability of cell line, cell line stocks were preserved 
and stored in liquid nitrogen. Confluent monolayer HT-29 cells were trypsinized with 
trypsin-EDTA and PBS at the ratio of 1: 3 (1 mL of trypsin: 3 mL of PBS) in 5% CO2 
incubator at 37°C for 5-10 minutes, after removed the medium and rinsed the 
monolayer with PBS. The cell suspension was then transferred into a centrifuge tube 
with 1 mL of 10% supplemented RPMI 1640 medium. The cells were spun at 1000 rpm 
for 5 minutes. Supernatant was then removed and the cells were re-suspended in 
freezing medium and transferred into cryopreservation vials. The vials were placed in 
vapour phase of liquid nitrogen for 3-4 h before transferred to cryocane in liquid 
nitrogen (-196°C) for long term storage. The liquid nitrogen tank was stored in cold 
room at 4°C. 
 
3.2.2.6 CELL LYSIS 
Medium of a flask of confluent monolayer HT-29 cells was removed and the 
cells were rinsed with PBS and then trypsinized with trypsin-EDTA and PBS at a ratio 
of 1: 3 (1 mL of trypsin EDTA: 3 mL of PBS) in 5% CO2 incubator at 37°C for 5-10 
minutes. Cells suspension was then transferred into a centrifuge tubes which contained 
1 mL of PBS. The cells were then spun at 1000 rpm for 5 minutes. After that, the 
supernatant was discarded and the cells were re-suspended in 1 mL of PBS. In order to 
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determine the number of cells in the cell suspension, cell counting was done with 
haemocytometer. 100 µL of cells were mixed with 900 µL of 0.4% trypan blue (0.2 g of 
trypan blue dissolved in 50 mL of distilled water) and 20 µL was pipette and loaded 
onto loading port of the haemocytometer. The haemocytometer was then observed 
under the microscope for cell counting. There were nine 1 mm x 1 mm boxes observed 
on the counting area. Only cells scattered in the four cornered boxes and the center box 
were counted. Number of cells counted was used to determine the amount of CelLytic™ 
M to be added in for cell lysis. The cell concentration per ml was calculated using the 
following formula: 
 
C1 = N x D x 1/5 x10
4
 
Where, 
C1 = initial cell concentration per ml 
N = total cell count for the 5 boxes 
D = correction for the tryphan blue dilution 
1/5 = correction to give mean cells per box 
10
4
 = conversion factor for counting chamber 
 
The remaining cells were then spun at 500 xg for 5 minutes. Supernatant was 
then discarded and cells were re-suspended in 250-350 µL of CelLytic™ M (depends on 
the number of cells counted) with protease inhibitor cocktail at the ratio of 10: 1. The 
mixture was shook for 15 minutes and then spun at 15,000 xg for another 15 minutes at 
4°C. The clear supernatant (lysate) was collected and stored at -80°C for further use. 
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3.2.3 GLUTATHIONE S-TRANSFERASE π PURIFICATION 
3.2.3.1 PREPARATION OF BUFFERS AND SOLUTIONS 
The buffers and solutions used in this experiment were prepared as stated in 
Appendix II. 
 
3.2.3.2 AFFINITY CHROMATOGRAPHY 
GSTrap HP affinity column (1 mL) was used to purify glutathione S-transferase 
π from the lysate of HT-29 cell line. The GSTrap HP column was pre-packed with 
GSH-Agarose matrix for one-step purification of glutathione S-transferase (GST) 
tagged protein. The GSTrap HP column was connected to ÄKTA Prime Plus which 
used to monitor the purification process. Flow rate was set at 0.3 mL/min. The system 
was first equilibrated with 25 mM sodium phosphate buffer. After that, 1 mL of lysate 
was loaded into the system. The lysate was eluted through the column with 25 mM 
sodium phosphate buffer, pH 7.4. All the unbound proteins were eluted out from the 
column once it entered the column. To elute the bound GST protein, eluting buffer was 
changed to 10 mM reduced glutathione in 25 mM sodium phosphate buffer, pH 7.4. 
Fractions were collected once the peak observed and it was then subjected to GST 
activity assay. Fractions (GST eluent) with high activities were pooled together and 
concentrated with 1K Microsep™ centrifugal concentrator, spun at 6000 xg for 90 
minutes at 4°C. Concentrated GST was subjected to SDS-PAGE analysis and IEF 
electrophoresis, the remaining kept at -80°C before subjected to freeze-drying. 
Lyophilized GST was kept at -20°C for further use. 
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3.2.4 GLUTATHIONE S-TRANSFERASE π IDENTIFICATION 
3.2.4.1 GLUTATHIONE S-TRANSFERASE (GST) ACTIVITY 
DETERMINATION 
3.2.4.1.1 PREPARATION OF BUFFERS AND SOLUTIONS 
The buffers and solutions used in this experiment were prepared as stated in 
Appendix II. 
 
3.2.4.1.2 GLUTATHIONE S-TRANSFERASE (GST) ACTIVITY ASSAY 
The activity of the glutathione S-transferase was determined according to the 
spectrophotometric enzyme assay described by Habig et al. (1974). The condition of the 
GST activity assay as below: 
Blank: 3.00 mL of buffer A 
Control: 2.90 mL of buffer A + 0.05 mL of 60 mM reduced glutathione + 0.05 
mL of 60 mM CDNB 
Sample: 2.85 mL of buffer A + 0.05 mL of 60 mM reduced glutathione + 0.05 
mL of GST solution + 0.05 mL of 60 mM CDNB 
Changes of absorbance at the wavelength of 340 nm were recorded for 10 
minutes at 25°C, using Jasco V630 UV-Vis spectrophotometer. The enzyme activity 
and specific activity of GST were then determined by using the formula below. The 
molar extinction coefficient of CDNB is 9600 M
-1
cm
-1
. 
Enzyme activity, μmol/min/mL =    
∆A
t
 x 
1
𝑘𝑙
 x 
𝑉𝑡
𝑉𝑠
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Where,  
∆A = absorbance changes 
t = time (min) 
k = molar extinction coefficient (M
-1
cm
-1
) 
l = diameter of cuvette (cm) 
Vt = total volume of assay (mL) 
Vs = volume of sample (mL) 
 
Specific activity, μmol/min/mg protein =    
𝑡𝑜𝑡𝑎𝑙  𝑒𝑛𝑧𝑦𝑚𝑒  𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦  (𝜇𝑚𝑜𝑙 /𝑚𝑖𝑛 )
𝑡𝑜𝑡𝑎𝑙  𝑝𝑟𝑜𝑡𝑒𝑖𝑛  𝑐𝑜𝑛𝑡𝑒𝑛𝑡  (𝑚𝑔 )
 
 
 
3.2.4.2 SODIUM DODECYL SULFATE POLYACRYLAMIDE GEL 
ELECTROPHORESIS (SDS-PAGE) 
The concentrated GST eluent obtained from affinity chromatography (Section 
3.2.3.2) was subjected to SDS-PAGE analysis by using a 4% stacking: 12% resolving 
gel. This was carried out according to Laemmli (1970), using Mini-PROTEAN® Tetra 
Cell (Bio-rad). 
 
3.2.4.2.1 PREPARATION OF BUFFERS AND SOLUTIONS 
The buffers and solutions used in this experiment were prepared as stated in 
Appendix II. 
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3.2.4.2.2 GEL PREPARATION 
4% stacking: 12% resolving gel monomer solutions were prepared as shown in 
Appendix II. The monomer solutions were prepared by mixing all reagents except for 
TEMED and 10% APS. The solutions were then degassed for 15 minutes. After that, 
TEMED and 10% APS were added and the mixtures were swirled gently to initiate 
polymerization prior to be loaded into the casting cassette. The solutions were then load 
into the casting cassette in the order of resolving monomer solution first, followed by 
stacking monomer solution after the resolving gel completely polymerized. Distilled 
water was used to overlay the resolving monomer solution. A comb was inserted into 
the stacking monomer solution to form well. The 4% stacking: 12% resolving gel was 
leave overnight in order to achieve complete polymerization before sample loading. 
 
3.2.4.2.3 SAMPLE LOADING 
Before loading the sample (concentrated GST eluent), sample was mixed with 
SDS sample buffer at the ratio of 1: 2 (10 µL of sample: 20 µL of SDS sample buffer). 
50 µL of 2-mercaptoethanol was added to 950 µL of SDS sample buffer prior to use. 
Sample buffer mixed sample was then heated at 95°C for 4 minutes to denature the 
protein sample. Then, 10 µL of sample buffer mixed sample was loaded into one the 
well of the gel. 4 µL of Mark 12™ unstained standard, which used as the protein marker, 
was loaded into another well.  
 
 
 
53 
 
3.2.4.2.4 ELECTROPHORESIS 
Electrophoresis was carried out at 150 V for approximately 1 hour. The process 
was stopped when the tracking dye reached about 1 cm from the bottom of the gel. The 
gel was then removed and subjected to colloidal coomassie blue staining. 
 
 
3.2.4.3 COLLOIDAL COOMASSIE BLUE STAINING 
3.2.4.3.1 PREPARATION OF COLLOIDAL COOMASSIE BLUE SOLUTION 
The colloidal coomassie blue solution was prepared as shown in Appendix II.  
  
3.2.4.3.2 GEL STAINING 
The colloidal coomassie blue staining was done according to Neuhoff et al. 
(1988). Prior to staining, the colloidal coomassie blue solution was mixed with 
methanol at the ratio of 4: 1 (80 mL of colloidal brilliant blue: 20 mL of methanol). The 
gel removed from SDS-PAGE was then stained by immersed the gel in the colloidal 
solution and leave overnight on orbital shaker. After that, the gel was de-stained with 20% 
methanol (20 mL of methanol: 80 mL of distilled water). 
 
3.2.4.4 MOLECULAR WEIGHT DETERMINATION 
Single protein band appeared on the lane of sample (GST eluent) was compared 
with the bands of standard marker. Relative mobility, Rf, of each band was determined 
by dividing the distance migrated by the band with the distance migrated by the tracking 
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dye. A standard curve of log molecular weight against Rf of standard marker was 
constructed. The molecular weight of the single protein band can then be determined 
from the curve. 
 
3.2.4.5 PEPTIDE MASS FINGERPRINT (PMF) ANALYSIS 
After determined the molecular weight of the sample protein band, the protein 
band was then excised for PMF analysis at Medical Biotechnology Lab, Faculty of 
Medicine, University of Malaya, using MALDI-TOF mass spectrometer (ABI 4800 
Plus). 
 
3.2.4.5.1 PREPARATION OF SOLUTIONS 
The solutions used in this experiment were prepared as stated in Appendix II. 
 
3.2.4.5.2 DESTAINING AND TRYPSIN DIGESTION 
This method was done according to Speicher et al. (2000) with some 
modification. After excised the protein band from stained SDS-PAGE gel, the gel slice 
was de-stained with 200 µL of 200 mM (NH4)HCO3 in 50% ACN for 45 minutes at 
37°C. The supernatant was then discarded. Destaining process was repeated until the 
stain no longer visible. Gel slice was then dried using SpeedVac concentrator. Dried gel 
slice was then re-hydrated with 20 µL of trypsin solution for an hour. Then, an 
additional 50 µL of 40 mM (NH4)HCO3 in 10% ACN was added and incubation was 
continued for 16-18 h at 37°C. After the incubation, supernatant was removed into a 
cleaned tube (extract 1). Then, 50 µL of 0.1% TFA was added on the gel and incubated 
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for 45 minutes at 37°C. The supernatant was then removed and pooled into the tube 
with extract 1. 
 
3.2.4.5.3 PMF ANALYSIS 
The extract 1 was mixed with CHCA matrix solution at a ratio of 1: 1 (1 µL of 
extract 1: 1 µL of CHCA matrix solution) before spotted on the sample plate. 0.5 µL of 
diluted CHCA matrix was spotted on one of the spot on the sample plate, followed by 
0.5 µL of CHCA mixed extract 1 on the same spot. Digested β-galactosidase was used 
as the control for PMF analysis. The sample was then allowed to air evaporated before 
subjected to MALDI-TOF (ABI 4800 PLUS) at Medical Biotechnology Lab, Faculty of 
Medicine, University of Malaya. 
 
3.2.4.6 ISOELECTRIC FOCUSING (IEF) ELECTROPHORESIS 
To determine the number of pi isoform of GST exist in the sample, IEF was 
done. IEF electrophoresis separated proteins according to their isoelectric point (pI). 
The electrophoresis was done according to manufacturer’s manual on pre-cast 12-
welled Novex® pH 3-10 IEF mini gel using XCell SureLock® Mini-Cell (Invitrogen).  
 
3.2.4.6.1 BUFFERS PREPARATION 
The buffers used in this experiment were prepared as stated in Appendix II. 
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3.2.4.6.2 SAMPLE AND BUFFER LOADING 
Prior to loading of sample, 5 μL of GST eluent was mixed with 5 μL of 2X IEF 
sample buffer pH 3-10. A total of 10 μL sample was loaded on the gel, with 2 μL of 
SERVA IEF protein markers 3-10 loaded on another lane which to be used as reference. 
The upper buffer chamber of XCell SureLock® Mini-Cell is loaded with 200 mL of IEF 
cathode buffer and the lower buffer chamber is loaded with 600 mL of IEF anode buffer. 
 
3.2.4.6.3 ELECTROPHORESIS RUNNING CONDITION 
The electrophoresis was started with 100 V at 7 mA and kept constant for 1 hour, 
followed by 200 V for another 1 hour. Lastly ran at 500 V for 30 minutes. The final 
current reading is expected to be 5 mA. 
 
3.2.4.7 VORUM SILVER STAINING 
Other than Coomassie blue and fluorescent dyes, silver staining is also one of 
the common methods available to visualize proteins separated by gel electrophoresis. 
The Vorum silver staining procedures adopted from Mortz et al. (2001) are compatible 
with mass spectrometry. 
 
3.2.4.7.1 PREPARATION OF SOLUTIONS 
The buffers used in this experiment were prepared as stated in Appendix II. 
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3.2.4.7.2 STAINING PROCEDURES 
After the electrophoresis, gel was removed from the cassette and placed into a 
tray containing 12% trichloroacetic acid and soaked for 30 minutes. After that, the 
solution was discarded and gel was soaked in fixing solution for approximately 2 h. 
After discard the fixing solution, the gel was washed 3 times with washing solution, 
each time took 20 minutes. After the washing step, the gel was sensitized with 
sensitizing solution for 2 minutes. Then, sensitizing solution was discarded and the gel 
was washed thrice, one minutes each, with de-ionized water. It is then followed by 
addition of silver staining solution and incubated for 20 minutes. After completed the 
staining step, staining solution was poured off and the gel was rinsed twice, each time 
10 seconds, with de-ionized water. Protein image of the gel was developed by 
incubating gel in developing solution for 3-5 minutes. The reaction was stopped as soon 
as the desired intensity of protein bands observed. The reduction reaction was stopped 
by the addition of terminating solution and incubated of 5 minutes. The whole staining 
process was carried out with gentle rotation. The gel is then preserved in preservation 
solution. Image of the gel was scanned with ImageScanner III (GE Healthcare). 
 
3.2.5 PRELIMINARY GST-P INHIBITION ASSAY 
Ethanolic extracts of the 43 plant samples were tested in this experiment. 10 
mg/mL of GST-P solution was prepared by dissolving 10 mg of freeze-dried GST-P in 
1 mL of buffer A and 10 mg/mL of the ethanolic extract was prepared by dissolving 10 
mg of freeze-dried ethanolic extract in 1 mL of buffer A. Condition of the GST-P 
inhibition assay as below: 
Blank: 3.00 mL of buffer A 
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Control: 2.90 mL of buffer A + 0.05 mL of 60 mM reduced glutathione + 0.05 
mL of 60 mM CDNB 
GST-P only: 2.85 mL of buffer A + 0.05 mL of 60 mM reduced glutathione + 
0.05 mL of 10 mg/mL of GST-P solution + 0.05 mL of 60 mM 
CDNB 
GST-P with ethanolic extract: 2.85 mL of buffer A + 0.05 mL of 60 mM reduced 
glutathione +   0.05 mL of 10 mg/mL of GST-P 
solution + 0.05 mL of 10 mg/mL of ethanolic extract + 
0.05 mL of 60 mM CDNB 
 
Changes of absorbance at the wavelength of 340 nm were recorded for 10 
minutes at 25°C, using Jasco V630 UV-Vis spectrophotometer. The specific activity of 
GST-P (SAGST-P) was then calculated (formula used same as the formula stated in 
Section 3.2.4.1.2) and the relative change in SAGST-P was then determined as below. The 
molar extinction coefficient of CDNB is 9600 M
-1
cm
-1
. 
SAGST-P - SAGST-P with ethanolic extract 
Relative reduction in SAGST-P  =                                                        X  100% 
  SAGST-P 
 
3.2.6 BIOASSAY-GUIDED FRACTIONATION 
3.2.6.1 PREPARATION OF SOLUTIONS 
The solutions used in this experiment were prepared as stated in Appendix II. 
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3.2.6.2 POLYAMIDE FILTRATION AND FRACTIONATION 
Based on the results of previous experiment (Section 3.2.5), selected ethanolic 
extracts with 100% inhibition activity on GST-P were further fractionated with 
polyamide column chromatography. The lyophilized ethanolic extract was re-dissolved 
in 2% acetic acid and filtered. Polyamide resin (Fluka, Germany) was pre-swollen in 2% 
acetic acid and packed in a 25 mL glass column. Initially, Polyamide column was 
equilibrated with 50% methanol 2% acetic acid and 2% acetic acid before application of 
ethanolic extract onto the column. After the injection of ethanolic extract into the 
system, the unbound sample was eluted with 2% acetic acid, followed by 50% methanol 
2% acetic acid for the compounds slightly bound to the resin. Eluates were then rotary 
evaporated and freeze-dried prior to further uses. The chromatography was monitored 
with ÄKTA Purifier FPLC (GE Healthcare, UK) equipped with fraction collector. 
Fractions were then subjected for GST-P inhibition assay (refer to Section 3.2.5). 
 
3.2.7 IC50 VALUE DETERMINATION WITH GST ACTIVITY ASSAYS 
Plant ethanolic extracts and fraction with GST-P inhibition activity higher than 
50% (refer to Section 4.4) were selected for this experiment. 
Basically, the GST-P inhibition assays were done on 96-well microplate (Nunc, 
Denmark). Plant samples (ethanolic extract/fraction) prepared at different 
concentrations were mixed with reaction mixture containing 0.2 mg/mL of GST-P and 1 
mM of reduced glutathione (GSH) in buffer A. Reactions were initiated with the 
addition of 1 mM of CDNB and changes in absorbance were recorded at the wavelength 
of 400 nm (with reference wavelength at 500 nm) for 10 minutes at 25°C, using 
Sunrise™ Absorbance Reader (Tecan). The assay condition includes: 
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Blank: 250 μL of buffer A 
Control 1: 230 μL of buffer A + 10 μL of 25 mM GSH + 10 μL of 25 mM 
CDNB 
GST-P only: 220 μL of buffer A + 10 μL of 25 mM GSH + 10 μL of 25 mM 
CDNB + 10 μL of 5 mg/mL GST-P 
GST-P and plant sample: 220 μL of buffer A + 10 μL of 25 mM GSH + 10 μL 
of 25 mM CDNB + 10 μL of 5 mg/mL GST-P + 10 μL 
of plant sample 
Control 2: 240 μL of buffer A + 10 μL of plant sample 
 
The percentage inhibition on GST-P activity (%) by each sample was calculated 
as following: 
Percentage of inhibition, % = {[(AGST-P – Acontrol 1) – (AGST-P and plant sample – Acontrol 
1 – Acontrol 2)] / (AGST-P – Acontrol 1)} x 100% 
 
Where, Acontrol 1, Acontrol 2, AGST-P and AGST-P and plant sample were the absorbance at 
400 nm (with reference wavelength of 500 nm) for Control 1, Control 2, GST-P and 
GST-P and plant sample, respectively. 
The GST-P inhibition ability of plant ethanolic extracts and fraction were 
expressed as IC50 value, which indicates the inhibition concentration at which 50% of 
GST-P activities were inhibited. The IC50 value was determined from the graph of 
percentage of inhibition on GST activity (%) versus concentration of plant sample, 
generated using the software Microsoft Excel.  
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3.2.8 KINETIC STUDIES 
Rate of reaction was measured as described by van Haaften et al. (2003). In 
order to determine the inhibitory mechanism of plant samples (ethanolic extract/fraction) 
on GST-P activity, the substrate (either CDNB or GSH) concentrations were varied. In 
this study, the CDNB concentration was maintained at 1 mM while the concentration of 
GSH varied in the reaction mixture of buffer A. The concentration of plant samples was 
kept constant at the IC50 value which determined from previous experiment (Section 
3.2.7) and the concentration of GST-P maintained at 0.2 mg/mL in 1 mL reaction 
mixture. Changes in GST-P activity were monitored at the wavelength of 340 nm at 
25 °C for 10 minutes using Jasco V630 UV-Vis spectrophotometer. Spontaneous 
reaction between GSH and CDNB in the absence of GST-P was corrected from the 
reading obtained. Vmax and Km values of GST-P with or without addition of plant 
samples were generated using SigmaPlot 12.0 graph and analysis software.  
 
3.2.9 CYTOTOXICITY ASSAY 
3.2.9.1 PREPARATION OF DILUENTS AND SOLUTIONS 
The diluents and solutions used in this experiment were prepared as stated in 
Appendix II. 
 
3.2.9.2 CELL CULTURE 
In order to examine the toxicity effects of selected plant samples (ethanolic 
extract/fraction) against normal human cells, cytotoxicity of the plant samples on fetal 
lung fibroblast MRC-5 cell line were tested.  
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The MRC-5 cells used in this experiment were cultured in 10% supplemented 
EMEM (diluent X). Cell culture was maintained in humidified 5% CO2 incubator at 
37°C. The cells were grown to 90-100% confluence before proceed to seeding. 
 
3.2.9.3 CELL PREPARATION AND SEEDING 
Cytotoxicity effect of plant samples (ethanolic extract/fraction), doxorubicin 
hydrochloride, cisplatin and ethacrynic acid against MRC-5 cells were tested. 
Monolayer MRC-5 cells with 90-100% confluence were detached using accutase 
solution and transferred into a centrifuge tube containing 1 mL of diluent X. The cells 
were spun at 1000 rpm for 5 minutes. Then, the supernatant was discarded. 1 mL of 
diluent X was added and the cells were gently resuspended. 
10 μL of cell suspension was mixed with 90 μL of trypan blue solution in a 
microcentrifuge tube and then 10 μL of the mixture was transferred to a 
haemocytometer for cell counting. Percentage of cell viability was determined and 
viability should be at least 95% in order to proceed with the assay. 
Cells were seeded in flat bottom 96-well microplate (Nunc, Denmark) at a 
concentration of 2 x 10
5
 cells/mL, in 100 μL culture medium per well. Cells were 
allowed to attach for 24 h in humidified 5% CO2 incubator at 37°C. 
 
3.2.9.4 SAMPLE DILUTION PREPARATION 
Sample stock and sub-stock were prepared before conducting serial dilution. 
Sample stock was prepared by dissolving 0.02 g of plant sample (ethanolic 
extract/fraction) in 0.2 mL of 100% DMSO, which final concentration is 100 mg/mL. 
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Meanwhile, to prepare 1 mL of sub-stock at a concentration of 200 μg/mL containing 
0.2% DMSO, 2 μL of stock was added to 998 μL of diluent X. Calculation can be done 
with the formula:  
M1V1 = M2V2 
Where, 
M1 = initial concentration 
V1 = volume of M1 required 
M2 = final concentration 
V2 = final volume 
After preparation of sub-stock, serial dilution was conducted using flat bottom 
96-well microplate and multi-channel pipettor (Eppendorf, Germany). First of all, 150 
μL of diluent Y was added to wells in row B to H (Appendix III, Figure 7.1). Then, 300 
μL of sub-stock was added to wells in row A, at which the concentration of sample was 
200 μg/mL. After that, 150 μL of solution in wells of row A was transferred to wells in 
row B, which create a second concentration at row B, which is 100 μg/mL. The dilution 
was continued until row G and 150 μL of solution in wells of row G was discarded. 
Hence, the volume in each well was 150 μL containing 0.2% DMSO. This is then 
followed by addition of 150 μL of diluent Y into every single well from row A to H. So, 
total volume in each well becomes 300 μL. Final sample concentration for wells in each 
row is such as following: 
A: 100 μg/mL containing 0.2% DMSO 
B: 50 μg/mL containing 0.2% DMSO 
C: 25 μg/mL containing 0.2% DMSO 
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D: 12.5 μg/mL containing 0.2% DMSO 
E: 6.25 μg/mL containing 0.2% DMSO 
F: 3.13 μg/mL containing 0.2% DMSO 
G: 1.56 μg/mL containing 0.2% DMSO 
H: diluent Y  
For ethacrynic acid, the preparation of dilution was done as previously described 
for plant sample. While for the doxorubicin hydrochloride, the stock was prepared at the 
10 mg/mL in 100% DMSO. To prepare 1 mL of doxorubicin hydrochloride sub-stock at 
concentration of 20 μg/mL containing 0.2% DMSO, 2 μL of stock was added to 998 μL 
of diluent X. The serial dilution was done as previously described for plant sample 
preparation. 
For cisplatin, the stock was prepared at 10 mg/mL in PBS. To prepare 1 mL of 
sub-stock at the concentration of 20 μg/mL, 2 μL of stock was added to 998 μL of 
diluent X. Serial dilution was started with the addition of 150 μL of diluent Z to wells in 
row B and addition of 150 μL of diluent Y to wells in row C to H (Appendix III, Figure 
7.1). Then, 300 μL of sub-stock was added to wells in row A, at which the concentration 
of sample was 20 μg/mL. After that, 150 μL of solution in wells of row A was 
transferred to wells in row B, which create a second concentration at row B, which is 10 
μg/mL. The dilution was continued until row G and 150 μL of solution in wells of row 
G was discarded. Hence, the volume in each well was 150 μL containing 0.2% DMSO. 
This is then followed by addition of 150 μL of diluent Y into every single well from 
row A to H. So, total volume in each well becomes 300 μL. Final sample concentration 
for wells in each row is such as following: 
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A: 10 μg/mL containing 0.2% DMSO 
B: 5 μg/mL containing 0.2% DMSO 
C: 2.5 μg/mL containing 0.2% DMSO 
D: 1.25 μg/mL containing 0.2% DMSO 
E: 0.625 μg/mL containing 0.2% DMSO 
F: 0.313 μg/mL containing 0.2% DMSO 
G: 0.156 μg/mL containing 0.2% DMSO 
H: diluent Y  
 
3.2.9.5 CELLS TREATMENT  
After 24 h incubation, utilized media in each well of cell seeding plate was 
discarded with pipettor. Then, the wells in row A to G were replaced with 200 μL of 
sample-containing media prepared by serial dilution. The wells in row H was replaced 
with 200 μL of diluent Y. The final DMSO concentration in each well was 0.2%. Cells 
were then incubated for 72 h in humidified 5% CO2 incubator at 37°C. The actual assay 
condition was illustrated in Appendix III, Figure 7.2 and 7.3. 
Control groups in this assay include blank, cells in media containing 0.2% 
DMSO (negative control) and cells in media containing 0.156-10.0 μg/mL of 
doxorubicin hydrochloride or cisplatin (positive control).  
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3.2.9.6 CELL VIABILITY DETERMINATION 
The cytotoxicity activities of samples were evaluated using MTT assay 
described by Mosmann (1983). After 72 h incubation, old media were discarded and 
100 μL of 10% supplemented EMEM was dispensed into each well of cells. 20 μL of 5 
mg/mL of MTT reagent was then added into each well and incubated for 4 h. 
After 4 h of incubation time, the media were discarded and the formazan product 
of MTT reduction was dissolved in 100 μL of DMSO. The plate shook on a microplate 
mixer for 15 minutes. The optical density at 570 nm (OD570) with reference wavelength 
of 650 nm, was determined using Asys HiTech UVM 340 microplate reader (Biochrom). 
The absorbance of formazan in negative control was taken as 100% viability. 
Cytotoxicity of each sample was expressed as IC50 value, which is the concentration of 
sample required to reduce the viability of cells by 50% compared to control (untreated 
cells). 
 
3.2.10 CELL PROLIFERATION AND VIABILITY ASSAY 
3.2.10.1 PREPARATION OF DILUENTS 
The diluents used in this experiment were prepared as stated in Appendix II. 
 
3.2.10.2 CELL CULTURE 
The human colon adenocarcinoma cell line, HT-29, used in this experiment were 
cultured in 10% supplemented RPMI 1640 medium. Cell culture was maintained in 
humidified 5% CO2 incubator at 37°C. The cells were grown to 90-100% confluence 
before proceed to seeding. 
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3.2.10.3 CELL PREPARATION AND SEEDING 
Cytotoxicity effect of plant samples (ethanolic extract/fraction), doxorubicin 
hydrochloride, cisplatin and ethacrynic acid against HT-29 cells were tested. Monolayer 
HT-29 cells with 90-100% confluence were detached using accutase solution and 
transferred into a centrifuge tube containing 1mL of diluent A. The cells were spun at 
1000 rpm for 5 minutes. Then, the supernatant was discarded. 1 mL of diluent A was 
added and the cells were gently resuspended. 
10 μL of cell suspension was mixed with 90 μL of trypan blue solution in a 
microcentrifuge tube and then 10 μL of the mixture was transferred to a 
haemocytometer for cell counting. Percentage of cell viability was determined and 
viability should be at least 95% in order to proceed with the assay. 
Cells were seeded in flat bottom 96-well microplate (Nunc, Denmark), at a 
concentration of 6 x 10
4
 cells/mL, in 100 μL culture medium per well. Cells were 
allowed to attach for 24 h in humidified 5% CO2 incubator at 37°C. 
 
3.2.10.4 SAMPLE DILUTION PREPARATION 
Sample stock and sub-stock were prepared before conducting serial dilution. 
Sample stock was prepared by dissolving 0.02 g of plant sample (ethanolic 
extract/fraction) in 0.2 mL of 100% DMSO, which final concentration is 100 mg/mL. 
Meanwhile, to prepare 1 ml of sub-stock at a concentration of 200 μg/mL containing 0.2% 
DMSO, 2 μL of stock was added to 998 μL of diluent A.  
After preparation of sub-stock, serial dilution was conducted using flat bottom 
96-well microplate and multi-channel pipettor. First of all, 150 μL of diluent B was 
added to wells in row B to H (Appendix III, Figure 7.1). Then, 300 μL of sub-stock was 
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added to wells in row A, at which the concentration of sample was 200 μg/mL. After 
that, 150 μL of solution in wells of row A was transferred to wells in row B, which 
create a second concentration at row B, which is 100 μg/mL. The dilution was 
continued until row G and 150 μL of solution in wells of row G was discarded. Hence, 
the volume in each well was 150 μL containing 0.2% DMSO. This is then followed by 
addition of 150 μL of diluent B into every single well from row A to H. So, total 
volume in each well becomes 300 μL. Final sample concentration for wells in each row 
is such as following: 
A: 100 μg/mL containing 0.2% DMSO 
B: 50 μg/mL containing 0.2% DMSO 
C: 25 μg/mL containing 0.2% DMSO 
D: 12.5 μg/mL containing 0.2% DMSO 
E: 6.25 μg/mL containing 0.2% DMSO 
F: 3.13 μg/mL containing 0.2% DMSO 
G: 1.56 μg/mL containing 0.2% DMSO 
H: diluent B  
For ethacrynic acid, the preparation of dilution was done as previously described 
for plant sample. While for the doxorubicin hydrochloride, the stock was prepared at the 
10 mg/mL in 100% DMSO. To prepare 1 mL of doxorubicin hydrochloride sub-stock at 
concentration of 20 μg/mL containing 0.2% DMSO, 2 μL of stock was added to 998 μL 
of diluent A. The serial dilution was done as previously described for plant sample 
preparation. 
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For cisplatin, the stock was prepared at 10 mg/mL in PBS. To prepare 1 mL of 
sub-stock at concentration of 20 μg/mL, 2 μL of stock was added to 998 μL of diluent A. 
Serial dilution was started with the addition of 150 μL of diluent C to wells in row B 
and addition of 150 μL of diluent B to wells in row C to H (Appendix III, Figure 7.1). 
Then, 300 μL of sub-stock was added to wells in row A, at which the concentration of 
sample was 20 μg/mL. After that, 150 μL of solution in wells of row A was transferred 
to wells in row B, which create a second concentration at row B, which is 10 μg/mL. 
The dilution was continued until row G and 150 μL of solution in wells of row G was 
discarded. Hence, the volume in each well was 150 μL containing 0.2% DMSO. This is 
then followed by addition of 150 μL of diluent B into every single well from row A to H. 
So, total volume in each well becomes 300 μL. Final sample concentration for wells in 
each row is such as following: 
A: 10 μg/mL containing 0.2% DMSO 
B: 5 μg/mL containing 0.2% DMSO 
C: 2.5 μg/mL containing 0.2% DMSO 
D: 1.25 μg/mL containing 0.2% DMSO 
E: 0.625 μg/mL containing 0.2% DMSO 
F: 0.313 μg/mL containing 0.2% DMSO 
G: 0.156 μg/mL containing 0.2% DMSO 
H: diluent B  
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3.2.10.5 CELLS TREATMENT  
After 24 h incubation, utilized media in each well of cell seeding plate was 
discarded with pipettor. Then, the wells in row A to G were replaced with 200 μL of 
sample-containing media prepared by serial dilution. The wells in row H was replaced 
with 200 μL of diluent B. The final DMSO concentration in each well was 0.2%. Cells 
were then incubated for 72 h in humidified 5% CO2 incubator at 37°C. The actual assay 
condition was illustrated in Appendix III, Figure 7.2 and 7.3. 
Control groups in this assay include blank, cells in media containing 0.2% 
DMSO (negative control) and cells in media containing 0.156-10 μg/mL of doxorubicin 
hydrochloride or cisplatin (positive control).  
 
3.2.10.6 CELL VIABILITY DETERMINATION 
The cytotoxicity activities of samples were evaluated using MTT assay 
described by Mosmann (1983). After 72 h incubation, old media were discarded and 
100 μL of 10% supplemented RPMI 1640 medium was added into each well of cells. 20 
μL of 5 mg/mL of MTT reagent was then added into each well and incubated for 4 h. 
After 4 h of incubation time, the media were discarded and the formazan product 
of MTT reduction was dissolved in 100 μL of DMSO. The plate shook on microplate 
mixer for 15 minutes. The optical density at 570 nm (OD570) with reference wavelength 
of 650 nm, was determined using Asys HiTech UVM 340 microplate reader (Biochrom). 
The absorbance of formazan in negative control was taken as 100% viability. 
Cytotoxicity of each sample was expressed as IC50 value, which is the concentration of 
sample required to reduce the viability of cells by 50% compared to control (untreated 
cells). 
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3.2.11 DOXORUBICIN HYDROCHLORIDE AND PLANT SAMPLE 
COMBINATION CYTOTOXICITY ASSAY 
In order to examine the synergic effect of doxorubicin hydrochloride and plant 
samples (ethanolic extract/fraction) on HT-29 cytotoxicity, doxorubicin hydrochloride 
at different concentrations in combination with fixed concentration of plant sample were 
tested against HT-29 cells.  
Based on the results obtained from previous experiment (Section 3.2.10), plant 
sample concentration was fixed at 50 μg/mL and ethacrynic acid concentration (as a 
reference) was fixed at 10 μg/mL. The concentration fixed was the concentration at 
which viability of HT-29 cells is higher than 90%, when treated with samples. 
 
3.2.11.1 PREPARATION OF DILUENTS 
The diluents used in this experiment were prepared as stated in Appendix II. 
 
3.2.11.2 CELL CULTURE 
The human colon adenocarcinoma cell line, HT-29, used in this experiment were 
cultured in 10% supplemented RPMI 1640 medium. Cell culture was maintained in 
humidified 5% CO2 incubator at 37°C. The cells were grown to 90-100% confluence 
before proceed to seeding. 
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3.2.11.3 CELL PREPARATION AND SEEDING 
Cytotoxicity effect of doxorubicin hydrochloride in combination with ethacrynic 
acid and plant samples (ethanolic extract/fraction) against HT-29 cells were tested. 
Monolayer HT-29 cells with 90-100% confluence were detached using accutase 
solution and transferred into a centrifuge tube containing 1 mL of diluent A. The cells 
were spun at 1000 rpm for 5 minutes. Then, the supernatant was discarded. 1 mL of 
diluent A was added and the cells were gently resuspended. 
10 μL of cell suspension was mixed with 90 μL of trypan blue solution in a 
microcentrifuge tube and then 10 μL of the mixture was transferred to a 
haemocytometer for cell counting. Percentage of cell viability was determined and 
viability should be at least 95% in order to proceed with the assay. 
Cells were seeded in flat bottom 96-well microplate at a concentration of 6 x 10
4
 
cells/mL, in 100 μL culture medium per well. Cells were allowed to attach for 24 h in 
humidified 5% CO2 incubator at 37°C. 
 
3.2.11.4 SAMPLE DILUTION PREPARATION 
Sample stock was prepared by dissolving 0.01 g of plant sample (ethanolic 
extract/fraction) in 0.2 mL of 100% DMSO, which final concentration is 50 mg/mL. 
Meanwhile, to prepare 1 mL of sub-stock at a concentration of 100 μg/mL containing 
0.2% DMSO, 2 μL of stock was added to 998 μL of diluent A.  
Ethacrynic acid stock was prepared at the 10 mg/mL in 100% DMSO. To 
prepare 1 mL of ethacrynic acid sub-stock at concentration of 20 μg/mL containing 0.2% 
DMSO, 2 μL of stock was added to 998 μL of diluent A. 
73 
 
For doxorubicin hydrochloride, the stock was prepared at the 10 mg/mL in 100% 
DMSO. To prepare 1 mL of doxorubicin hydrochloride sub-stock at concentration of 20 
μg/mL containing 0.2% DMSO, 2 μL of stock was added to 998 μL of diluent A. After 
preparation of sub-stock, serial dilution was conducted using flat bottom 96-well 
microplate and multi-channel pipettor. First of all, 150 μL of diluent B was added to 
wells in row B to H (Appendix III, Figure 7.4). Then, 300 μL of sub-stock was added to 
wells in row A, at which the concentration of doxorubicin hydrochloride was 20 μg/mL. 
After that, 150 μL of solution in wells of row A was transferred to wells in row B, 
which create a second concentration at row B, which is 10 μg/mL. The dilution was 
continued until row G and 150 μL of solution in wells of row G was discarded. Hence, 
the volume in each well was 150 μL containing 0.2% DMSO. This is then followed by 
addition of 150 μL of plant sample sub-stock into every single well from row A to G. 
While for wells in row H, 150 μL of diluent B was added. So, total volume in each well 
becomes 300 μL. Final sample concentration for wells in each row is such as following: 
A: 10 μg/mL doxorubicin hydrochloride + 50 μg/mL plant sample containing 
0.2% DMSO 
B: 5 μg/mL doxorubicin hydrochloride + 50 μg/mL plant sample containing 0.2% 
DMSO 
C: 2.5 μg/mL doxorubicin hydrochloride + 50 μg/mL plant sample containing 
0.2% DMSO 
D: 1.25 μg/mL doxorubicin hydrochloride + 50 μg/mL plant sample containing 
0.2% DMSO 
E: 0.625 μg/mL doxorubicin hydrochloride + 50 μg/mL plant sample containing 
0.2% DMSO 
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F: 0.313 μg/mL doxorubicin hydrochloride + 50 μg/mL plant sample containing 
0.2% DMSO 
G: 0.156 μg/mL doxorubicin hydrochloride + 50 μg/mL plant sample containing 
0.2% DMSO 
H: diluent B  
 
With ethacrynic acid used as reference, 150 μL of ethacrynic acid sub-stock was 
added into every single well from row A to G (Appendix III, Figure 7.4) of serially 
diluted doxorubicin hydrochloride. The final concentration of ethacrynic acid in each 
well of dilution was 10 μg/mL, containing 0.2% DMSO. 
 
3.2.11.5 CELLS TREATMENT  
After 24 h incubation, utilized media in each well of cell seeding plate was 
discarded with pipettor. Then, the wells in row A to G were replaced with 200 μL of 
sample-containing media prepared by serial dilution. The wells in row H was replaced 
with 200 μL of diluent B. The final DMSO concentration in each well was 0.2%. Cells 
were then incubated for 72 h in humidified 5% CO2 incubator at 37°C. The actual assay 
condition was illustrated in Appendix III, Figure 7.5. 
Control groups in this assay include blank, cells in media containing 0.2% 
DMSO (negative control) and cells in media containing 0.156-10 μg/mL of doxorubicin 
hydrochloride (positive control).  
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3.2.11.6 CELL VIABILITY DETERMINATION 
The cytotoxicity activities of the combination of doxorubicin hydrochloride and 
plant samples (ethanolic extract/fraction) were evaluated using MTT assay described by 
Mosmann (1983). After 72 h incubation, old media were discarded and 100 μL of 10% 
supplemented RPMI 1640 medium was added into each well of cells. 20 μL of 5 mg/mL 
of MTT reagent was then added into each well and incubated for 4 h. 
After 4 h of incubation time, the media were discarded and the formazan product 
of MTT reduction was dissolved in 100 μL of DMSO. The plate was shook on a 
microplate mixer for 15 minutes. The optical density at 570 nm (OD570) with reference 
wavelength of 650 nm, was determined using Asys HiTech UVM 340 microplate reader 
(Biochrom). The absorbance of formazan in negative control was taken as 100% 
viability. Cytotoxicity of each combination was expressed as IC50 value, which is the 
concentration of doxorubicin hydrochloride required to reduce the viability of cells by 
50% compared to control (untreated cells). 
 
3.2.12 CISPLATIN AND PLANT SAMPLE COMBINATION CYTOTOXICITY 
ASSAY 
In order to examine the synergic effect of cisplatin and plant samples (ethanolic 
extract/fraction) on HT-29 cytotoxicity, cisplatin at different concentrations in 
combination with fixed concentration of plant sample were tested against HT-29 cells.  
Based on the results obtained from previous experiment (Section 3.2.10), plant 
sample concentration was fixed at 50 μg/mL and ethacrynic acid concentration (as a 
reference) was fixed at 10 μg/mL. The concentration fixed was the concentration at 
which viability of HT-29 cells is higher than 90%, when treated with samples. 
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3.2.12.1 PREPARATION OF DILUENTS 
The diluents used in this experiment were prepared as stated in Appendix II. 
 
3.2.12.2 CELL CULTURE 
The human colon adenocarcinoma cell line, HT-29, used in this experiment were 
cultured in 10% supplemented RPMI 1640 medium. Cell culture was maintained in 
humidified 5% CO2 incubator at 37°C. The cells were grown to 90-100% confluence 
before proceed to seeding. 
 
3.2.12.3 CELL PREPARATION AND SEEDING 
Cytotoxicity effect of cisplatin in combination with ethacrynic acid and plant 
samples (ethanolic extract/fraction) against HT-29 cells were tested. Monolayer HT-29 
cells with 90-100% confluence were detached using accutase solution and transferred 
into a centrifuge tube containing 1 mL of diluent A. The cells were spun at 1000 rpm 
for 5 minutes. Then, the supernatant was discarded. 1 mL of diluent A was added and 
the cells were gently resuspended. 
10 μL of cell suspension was mixed with 90 μL of trypan blue solution in a 
microcentrifuge tube and then 10 μL of the mixture was transferred to a 
haemocytometer for cell counting. Percentage of cell viability was determined and 
viability should be at least 95% in order to proceed with the assay. 
Cells were seeded in flat bottom 96-well microplate at a concentration of 6 x 10
4
 
cells/mL, in 100 μL culture medium per well. Cells were allowed to attach for 24 h in 
humidified 5% CO2 incubator at 37°C. 
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3.2.12.4 SAMPLE DILUTION PREPARATION 
Sample stock was prepared by dissolving 0.01 g of plant sample (ethanolic 
extract/fraction) in 0.2 mL of 100% DMSO, which final concentration is 50 mg/mL. 
Meanwhile, to prepare 1 mL of sub-stock at a concentration of 100 μg/mL containing 
0.2% DMSO, 2 μL of stock was added to 998 μL of diluent A. 
Ethacrynic acid stock was prepared at the 10 mg/mL in 100% DMSO. To 
prepare 1 mL of ethacrynic acid sub-stock at concentration of 20 μg/mL containing 0.2% 
DMSO, 2 μL of stock was added to 998 μL of diluent A. 
For cisplatin, the stock was prepared at 10 mg/mL in PBS. To prepare 1 mL of 
sub-stock at concentration of 20 μg/mL, 2 μL of stock was added to 998 μL of diluent A. 
After preparation of sub-stock, serial dilution was conducted using flat bottom 96-well 
microplate and multi-channel pipettor.  Serial dilution was started with the addition of 
150 μL of diluent C to wells in row B and addition of 150 μL of diluent B to wells in 
row C to H (Appendix III, Figure 7.4). Then, 300 μL of sub-stock was added to wells in 
row A, at which the concentration of sample was 20 μg/mL. After that, 150 μL of 
solution in wells of row A was transferred to wells in row B, which create a second 
concentration at row B, which is 10 μg/mL. The dilution was continued until row G and 
150 μL of solution in wells of row G was discarded. Hence, the volume in each well 
was 150 μL containing 0.2% DMSO. This is then followed by addition of 150 μL of 
plant sample sub-stock into every single well from row A to G. While for wells in row 
H, 150 μL of diluent B was added. So, total volume in each well becomes 300 μL. Final 
sample concentration for wells in each row is such as following: 
A: 10 μg/mL cisplatin + 50 μg/mL plant sample containing 0.2% DMSO 
B: 5 μg/mL cisplatin + 50 μg/mL plant sample containing 0.2% DMSO 
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C: 2.5 μg/mL cisplatin + 50 μg/mL plant sample containing 0.2% DMSO 
D: 1.25 μg/mL cisplatin + 50 μg/mL plant sample containing 0.2% DMSO 
E: 0.625 μg/mL cisplatin + 50 μg/mL plant sample containing 0.2% DMSO 
F: 0.313 μg/mL cisplatin + 50 μg/mL plant sample containing 0.2% DMSO 
G: 0.156 μg/mL cisplatin + 50 μg/mL plant sample containing 0.2% DMSO 
H: diluent B  
With ethacrynic acid used as reference, 150 μL of ethacrynic acid sub-stock was 
added into every single well from row A to G (Appendix III, Figure 7.4) of serially 
diluted cisplatin. The final concentration of ethacrynic acid in each well of dilution was 
10 μg/mL, containing 0.2% DMSO. 
 
3.2.12.5 CELLS TREATMENT  
After 24 h incubation, utilized media in each well of cell seeding plate was 
discarded with pipettor. Then, the wells in row A to G were replaced with 200 μL of 
sample-containing media prepared by serial dilution. The wells in row H was replaced 
with 200 μL of diluent B. The final DMSO concentration in each well was 0.2%. Cells 
were then incubated for 72 h in humidified 5% CO2 incubator at 37°C. The actual assay 
condition was illustrated in Appendix III, Figure 7.6. 
Control groups in this assay include blank, cells in media containing 0.2% 
DMSO (negative control) and cells in media containing 0.156-10 μg/mL of cisplatin 
(positive control).  
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3.2.12.6 CELL VIABILITY DETERMINATION 
The cytotoxicity activities of the combination of cisplatin and plant samples 
(ethanolic extract/fraction) were evaluated using MTT assay described by Mosmann 
(1983). After 72 h incubation, old media were discarded and 100 μL of 10% 
supplemented RPMI 1640 medium was added into each well of cells. 20 μL of 5 mg/mL 
of MTT reagent was then added into each well and incubated for 4 h. 
After 4 h of incubation time, the media were discarded and the formazan product 
of MTT reduction was dissolved in 100 μL of DMSO. The plate shook on a microplate 
mixer for 15 minutes. The optical density at 570 nm (OD570) with reference wavelength 
of 650 nm, was determined using Asys HiTech UVM 340 microplate reader (Biochrom). 
The absorbance of formazan in negative control was taken as 100% viability. 
Cytotoxicity of each combination was expressed as IC50 value, which is the 
concentration of cisplatin required to reduce the viability of cells by 50% compared to 
control (untreated cells). 
 
3.2.13 STATISTICAL ANALYSIS 
All experiments were performed in three triplicates (N=3). The data were 
presented as mean ± standard deviation (S.D.) and were statistically analysed with 
SigmaPlot 12.0 graph and analysis software.  
IC50 values of GST-P inhibitory assays and cytotoxicity assays were obtained 
from dose-response graph generated using Microsoft Excel software.  
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4.0 RESULTS 
4.1 HT-29 CELL LINE 
In my study, human HT-29 colon adenocarcinoma cell line is selected for the 
extraction of enzyme Glutathione S-Transferase π (GST-P), which will then react with 
selected plant sample (ethanolic extract/fraction) in GST-P inhibitory assays. HT-29 is 
selected due to its high expression of GST-P (Tashiro et al., 2001). The images of the 
monolayer HT-29 cells cultured in conventional RPMI 1640 medium are shown in 
Figure 4.1-4.3 at the objective power of 5X, 10X and 20X. 
 
 
Figure 4.1 : Monolayer HT-29 cells cultured in 10% supplemented RPMI 1640 medium. 
5X objective. 
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Figure 4.2 : Subconfluent culture of monolayer HT-29 cells. 10X objective. 
 
 
 
   
Figure 4.3 : Morphology of monolayer HT-29 cells. 20X objective. 
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HT-29 cell is a type of adherent cell which will adhere to surface of the culture 
flask once seeded. It is grown as monolayer and it acquired an epithelial-like 
morphology. Under standard culture condition, HT-29 cells grew into compact cell 
clusters with distinct intercellular cysts (Figure 4.1-4.3). When the cell growth reached 
90-100% confluent, the cells were lysed and the lysate was spun at 15,000 xg to remove 
the cell debris. Clear lysate was subjected to affinity chromatography for the extraction 
of GST protein. 
 
 
4.2 AFFINITY CHROMATOGRAPHY 
 
 
Figure 4.4 : Protein elution profile obtained for affinity chromatography on GSTrap™ 
HP column. The insert shows a magnification of the elution peak of 
purified GST-P protein.  
 
GST-P 
↓ 
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Figure 4.4 shows the elution profile of HT-29 cell lysate. The optical density 
(OD) shown by the blue line is the UV absorbance of proteins at the wavelength of 280 
nm. The red line represented the conductivity of the chromatography. The first peak 
indicates the elution of unbound proteins which does not bind to the GST affinity 
column. The unbound protein eluted out with the 25 mM sodium phosphate buffer, pH 
7.4, after the sample injected into the system. There is not GST enzyme detected in the 
unbound fraction as there was no GST activity measured with CDNB (result not shown). 
That means, all of the GST has been bound to column. When the unbound protein has 
been completely eluted, the buffer was then changed to the 10 mM reduced glutathione 
in 25 mM sodium phosphate buffer, pH 7.4, which has high affinity for GST. The 
second peak which has been highlighted in the insert is the peak for GST protein which 
has been eluted out together with the reduced GSH. The GST eluate has shown a high 
GST activity when reacted with CDNB and reduced GSH. The following peak is the 
peak for reduced GSH. From the insert, we can see that the amount of GST obtained is 
very little as there was only 1 mL of lysate has been injected. 
 
 
4.3 GLUTATHIONE S-TRANSFERASE π IDENTIFICATION 
4.3.1 GST ACTIVITY 
The activity of the GST isolated from HT-29 cell line was determined with 
spectrophotometric enzyme assay described by Habig et al. (1974). CDNB and reduced 
GSH were used as substrates. With GST protein of 10 mg (weighed lyophilized GST) in 
1 mL buffer A, the total activity obtained was 0.3228 μmol/min. Thus, the specific 
activity of the GST is 0.03228 μmol/min/mg protein. 
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4.3.2 SODIUM DODECYL SULFATE POLYACRYLAMIDE GEL 
ELECTROPHORESIS (SDS-PAGE) 
SDS-PAGE is one of the molecular biology techniques that frequently used to 
separate protein accordingly by size. It is probably the most powerful technique used for 
resolving protein mixtures. The ionic detergent, sodium dodecylsulfate (SDS), 
denatures the protein and dissociates multimeric proteins into their respective subunits. 
Besides, all of the polypeptide chains are in the conformation with similar charge over 
mass ratio and thus chain length which reflects the mass, is the sole determinant of the 
migration rate. 
 
kDa     Lane 1 Lane 2 
 
Figure 4.5 : SDS-PAGE banding pattern of purified GST-P from HT-29 cells. 
Lane 1: Mark 12 unstained protein standard markers. 
Lane 2: Concentrated eluent of GST obtained from affinity chromatography. 
31.0 
21.5 
 23.8 kDa 
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By referring to Figure 4.5, there was only single protein band observed in lane 2 
which loaded with concentrated GST eluent obtained from affinity chromatography. 
The single band was positioned in between the bands of carbonic anhydrase and trypsin 
inhibitor, which molecular weight are 31.0 and 21.5 kDa respectively. That mean, the 
protein present is the monomers of an isoform of GST which has a range of monomer 
molecular weight in between 25 and 30 kDa. 
To further determine the actual molecular weight of the GST isoform, a standard 
curve of log molecular weight against relative mobility is constructed (Appendix V, 
Figure 7.85). The standard curve is constructed based on the molecular weight of the 
proteins used as standard marker in Mark™ 12 unstained marker and the relative 
mobility, Rf, of each proteins which can be calculated by the division of the distance 
migrated of the protein band over the distance migrated by the solvent front on SDS-
PAGE gel. Then, the molecular weight of the GST was determined from the curve by 
comparing the Rf of the GST band with the curve. The calculated Rf value for the GST 
band was 0.51. Thus, the molecular weight of the GST obtained was 23.8 kDa and this 
is near to the molecular weight of human GST-P as reported by Aliya et al. (2003). To 
further confirm with this, the protein band was then subjected to peptide mass 
fingerprint analysis. 
 
  
4.3.3 PEPTIDE MASS FINGERPRINT (PMF) ANALYSIS 
The need for highly accurate and sensitive methods to analyse biomolecules are 
increasingly important due to the increase in interdisciplinary research. Mass 
spectrometry (MS) has becomes an important tool for the characterization and analysis 
of variant complex biomolecules, especially the matrix assisted laser 
desorption/ionization (MALDI) mass spectrometry which able to analyze biomolecules 
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up to over 300kDa (Karas et al., 1987). Meanwhile, the matrix assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry has improved 
mass resolution obtained by utilization of either single-stage or a dual-stage reflectron 
(RETOF-MS). 
The result obtained from PMF analysis (Appendix IV) indicates that the purified 
GST is belongs to the human GST-P (EC 2.5.1.18). The nominal mass (Mr) is 23341 Da 
and the calculated pI valus is 5.43. The result convinced that HT-29 cell line expressed 
high level of GST-P isoform and this is compatible with data obtained from Schultz et 
al., (1997) that only mRNA of GST-P quantified from HT-29 cell line.  
 
4.3.4 ISOELECTRIC FOCUSING (IEF) ELECTROPHORESIS 
In order to determine the number of pi isoform of GST exist in the purified GST 
sample, IEF was carried out. IEF electrophoresis separated proteins according to their 
isoelectric point (pI) based on the fact that overall charge on the protein molecule is a 
function of its surrounding pH. Figure 4.6 shows the image of protein bands on a pre-
cast IEF mini gel. The image was captured with ImageScanner III (GE Healthcare). 
By referring to Figure 4.6, there was only single protein band observed in lane 2 
and 3 which loaded with concentrated GST eluent obtained from affinity 
chromatography. The single band was positioned in between the bands of β-
lactoglobulin and carbonic anhydrase, which pI values are 5.3 and 6.0 respectively. That 
mean, the protein present is the monomers of single isoform of GST-P and the expected 
pI value is 5.4. So, there is only one isoform of GST-P purified from HT-29 cell line. 
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Figure 4.6 : Analytical isoelectric focusing (IEF) of purified GST-P. IEF gel showing 
the pI value of the replicate of purified GST-P loaded at lane 2 and 3. Lane 
1 is loaded with SERVA IEF markers 3-10.  
 
 
4.4 PRELIMINARY SCREENING ON GST-P INHIBITION 
This preliminary study was done to establish the inhibitory effects of local plants on 
GST-P. 43 plant ethanolic extracts have been screened for possible inhibitor of GST-P. 
However, some of them appeared to be the enhancer of GST-P instead of inhibitor 
based on the results obtained in Table 4.1. The effects of ethanolic extracts on GST-P 
were determined by relative changes in specific activity of GST-P with the addition of 
the ethanolic extracts.  
.  
 pI    Markers     GST-P  GST-P 
 
 
 
 
 
 
 
 
5.3 
6.0 
 5.4 
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Table 4.1 : Relative changes of GST-P specific activity by ethanolic extracts of local 
plants 
Sample Relative changes in specific 
activity of GST-P, 
(%) 
Anacardium occidentale (Gajus)-branch ↓  64 
Anacardium occidentale (Gajus)-fruit & flower ↓    8 
Andrographis paniculata (Hempedu bumi)-branch ↓  36 
Andrographis paniculata (Hempedu bumi)-leaf ↓  61 
Artocarpus heterophyllus (Nangka)-leaf                        ↑    5 
Averrhoa bilimbi (Belimbing buluh)-branch                        ↑  20 
Averrhoa bilimbi (Belimbing buluh)-leaf                        ↓  17 
Cinnamomum zeylanicum (kayu manis)-branch  ↓  78 
Commelina nudiflora (Rumput kupu-kupu)-whole plant  ↑    5 
Euodia redlevi (Tenggek burung)-flower & fruit  ↓  82 
Eupatorium odoratum (Pokok jepun)-branch                        ↑  51 
Fagraea fragrans (Tembusu)- leaf & branch  ↑  18 
Fagraea fragrans (Tembusu)-fruit & flower  ↓  43 
Ficus auriculata (Ara)-leaf  ↓  50 
Garcinia atroviridis (Asam gelugor)-branch                        ↓ 100 
Garcinia mangostana (Manggis)-branch  ↓  72 
Garcinia mangostana (Manggis)-leaf                        ↓  75 
Hibiscus tiliaceus (Bebaru)-leaf  ↓  81 
Ipomoea aquatica (Kangkung)-leaf  ↓  17 
Justicia gendarussa (Gandarusa, hitam)-branch  ↑    9 
Lagerstroemia speciosa (Bungur)-fruit  ↓  50 
Lagerstroemia speciosa (Bungur)-leaf  ↓  44 
Lawsonia inermis (Inai)-branch                        ↓  52 
Leptospermum flavescens (Gelam bukit)-leaf                        ↓ 100  
Leptospermum flavescens (Gelam bukit)-branch  ↓  46 
Macaranga conifera (Mahang)-branch  ↓  31 
Melaleuca cajuputi (Gelam)-fruit & flower  ↓    4 
Moringa oleifera (Kelor)-branch                        ↑  66 
Orthosiphon stamineus (Misai kucing)-leaf                        ↓  15 
Oxalis barrelieri (Belimbing tanah)-root                        ↓  75 
Peltophorum pterocarpum (Batai laut)-fruit  ↓  24 
Peltophorum pterocarpum (Batai laut)-leaf                        ↓  72 
Pereskia bleo (Jarum 7 bilah)-fruit  ↓  10 
Piper nigrum (Lada hitam )- leaf  ↑  27 
Piper nigrum (Lada hitam)-branch                        ↓  21 
Piper nigrum (Lada hitam)-fruit                        ↑  97 
Scoparia dulcis (Rempah padang)-root  ↑  17 
Strobilanthes crispa (Bayam karang)-branch  ↑  14 
Tetracera indica (Mempelas)-fruit  ↓  71 
Vitex sp.-branch                        ↑  87 
Vitex sp.-leaf  ↑  12 
Vitex trifolia ‘purpurea’ (Legundi)-branch                        ↓    6 
Vitex trifolia ‘purpurea’ (Legundi)-leaf  ↓  24 
* ↑ = increase in specific activity of GST-P    ↓= decrease in specific activity of GST-P 
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From Table 4.1, ethanolic extracts of Anacardium occidentale (branch and 
fruit&flower), Andrographis paniculata (branch and leaf), Averrhoa bilimbi (leaf), 
Cinnamomum zeylanicum (branch), Euodia redlevi (fruit&flower), Fagraea fragrans 
(fruit&flower), Ficus auriculata (leaf), Garcinia atroviridis (branch), Garcinia 
mangostana (branch and leaf), Hibiscus tiliaceus (leaf), Ipomoea aquatica (leaf), 
Lagerstroemia speciosa (leaf and fruit), Lawsonia inermis (branch), Leptospermum 
flavescens (branch and leaf), Macaranga conifera (branch), Melaleuca cajuputi 
(fruit&flower), Orthosiphon stamineus (leaf), Oxalis barrelieri (root), Peltophorum 
pterocarpum (leaf and fruit), Pereskia bleo (fruit), Piper nigrum (branch), Tetracera 
indica (fruit), Vitex trifolia ‘purpurea’ (branch and leaf) are those samples shown 
inhibition activity on GST-P by causing a decrease in specific activity of GST-P. 
However, Anacardium occidentale (branch) (64%), Andrographis paniculata (leaf) 
(61%), Cinnamomum zeylanicum (branch) (78%), Euodia redlevi (fruit&flower) (82%), 
Garcinia atroviridis (branch) (100%), Garcinia mangostana (branch and leaf) (72% and 
75%), Hibiscus tiliaceus (leaf) (81%),  Lawsonia inermis (branch) (52%), 
Leptospermum flavescens (leaf) (100%), Oxalis barrelieri (root) (75%), Peltophorum 
pterocarpum (leaf) (72%) and Tetracera indica (fruit) (71%) ethanolic extracts are more 
potent inhibitors as they have a relative reduction of more than 50%. These ethanolic 
extracts were then selected for the subsequent experiments. And, the most potent 
inhibitors which have 100% inhibition on GST-P are found to be the ethanolic extracts 
of Garcinia atroviridis (branch) and Leptospermum flavescens (leaf). Both ethanolic 
extracts were then further fractionated to identify the possible inhibitory peptides 
present in the samples.  
In contrast to the inhibition effect, ethanolic extracts of Artocarpus 
heterophyllus (leaf) (5%), Averrhoa bilimbi (branch) (20%), Commelina nudiflora 
(whole plant) (5%), Eupatorium odoratum (branch) (51%), Fagraea fragrans 
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(branch&leaf) (18%), Justicia gendarussa (branch) (9%), Moringa oleifera (branch) 
(66%), Piper nigrum (leaf and fruit) (27% and 97%), Scoparia dulcis (root) (17%), 
Strobilanthes crispa (branch) (14%) and Vitex sp. (branch and leaf) (87% and 12%) 
increased GST-P activity. Some of them even have activity higher than 50%. However, 
they are not in our research interest which is looking for GST-P inhibitor. Anyway, 
these plants can be use as functional food to boost up body GST activity. 
A comparative GST inhibition study carried out by using polyamide fractionated 
fractions of L. flavescens (leaf) and G. atroviridis (branch) ethanolic extracts with 
purified GST-P (Table 4.2). The results indicated that only 50% MeOH 2% acetic acid 
fractions of L. flavescens (leaf) and G. atroviridis (branch) ethanolic extracts showed 
inhibition on GST-P. The relative reduction percentage of 50% MeOH 2% acetic acid 
fractions of L. flavescens (leaf) and G. atroviridis (branch) ethanolic extract are 95% 
and 11% respectively. However, only 50% MeOH 2% acetic acid fraction of L. 
flavescens (leaf) ethanolic extract selected to continue with subsequent experiment since 
there is only little inhibition activity showed by 50% MeOH 2% acetic acid fraction of 
G. atroviridis (branch) ethanolic extract. The 2% acetic acid fractions for both L. 
flavescens (leaf) and G. atroviridis (branch) ethanolic extracts had no inhibition toward 
GST-P activity. 
  
Table 4.2 : Relative changes of GST-P specific activity with fractions of Leptospermum 
flavescens (leaf) and Garcinia atroviridis (branch) ethanolic extracts 
Fraction Relative reduction in specific activity 
of GST-P, (%) 
L. flavescens (leaf) ethanolic extract 
2% Acetic acid 
50% MeOH 2% Acetic acid 
 
 
0 
95 
G. atroviridis (branch) ethanolic extract 
2% Acetic acid 
50% MeOH 2% Acetic acid 
 
 
0 
11 
* MeOH = methanol 
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4.5 IC50 VALUES OF SAMPLES ON GST-P INHIBITION 
There were 13 ethanolic extracts and 1 fraction of selected plant samples tested 
in this experiment. The concentration of GST-P is fixed at 0.2 mg/mL. GST-P inhibition 
effect at various concentrations of plant samples (ethanolic extract/fraction) was 
determined and the dose-response graph, percentage of inhibition on GST activity (%) 
versus concentration, of each sample was generated using the software Microsoft Excel 
(Appendix IV, Figure 7.7-7.20). ANOVA was done on each sample using the software 
of SigmaPlot 12.0. 
The half maximal inhibitory concentration (IC50) values are the concentration of 
samples where 50% of the GST-P enzyme activity is inhibited compared to controls run 
without addition of samples. The IC50 value of each sample (ethanolic extract/fraction) 
was determined from the dose-response graph. IC50 resulting from the inhibition of 
GST-P by ethanolic extracts and fraction were showed in Figure 4.7 and Table 4.3.  
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Figure 4.7 : IC50 values of selected samples in GST-P inhibitory assays. Each bar represents the mean ± S.D. calculated from three independent 
determinations. Comparison of IC50 values between samples using ANOVA indicates statistically significant difference with P = <0.001.
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Table 4.3 : IC50 values of samples on GST-P 
Plant sample IC50 
(mean ± S.D., mg/mL) 
Significant 
difference, P 
   
Ethanolic extract    
Anacardium occidentale (branch) 0.18 ± 0.006 <0.001 
Andrographis paniculata (leaf) 0.32 ± 0.021 <0.001 
Cinnamomum zeylanicum (branch) 0.07 ± 0.006 <0.001 
Euodia redlevi (fruit&flower) 0.19 ± 0.031 <0.001 
Garcinia atroviridis (branch) 0.16 ± 0.005 <0.001 
Garcinia mangostana (branch) 0.12 ± 0.002 <0.001 
Garcinia mangostana (leaf) 0.11 ± 0.006 <0.001 
Hibiscus tiliaceus (leaf) 0.10 ± 0.000 <0.001 
Lawsonia inermis (branch) 0.46 ± 0.042 <0.001 
Leptospermum flavescens (leaf) 0.09 ± 0.002 <0.001 
Oxalis barrelieri (root) 0.15 ± 0.012 <0.001 
Peltophorum pterocarpum (leaf) 0.25 ± 0.025 <0.001 
Tetracera indica (fruit) 0.12 ± 0.006 <0.001 
   
Fraction   
50% MeOH 2% acetic acid fraction of 
L. flavescens (leaf) ethanolic extract 
0.19 ± 0.004 <0.001 
* MeOH= Methanol. IC50 values indicated are the means (± standard deviation, S.D.) of 
three determinations. 
 
 
 
 
94 
 
In general, IC50 is a quantitative measurement of the effectiveness of a 
compound in inhibiting biological or biochemical function in vitro (FDA, 2000). The 
lower the IC50 value of a sample, the more effective the sample in inhibiting GST-P. 
From Table 4.3, Ethanolic extract of Cinnamomum zeylanicum (branch) has the lowest 
IC50 value, which is 0.07 mg/mL. That means Ethanolic extract of Cinnamomum 
zeylanicum (branch) is the most active sample in inhibiting GST-P activity. This is then 
followed by ethanolic extracts of Leptospermum flavescens (leaf), Hibiscus tiliaceus 
(leaf), Garcinia mangostana (leaf), Garcinia mangostana (branch) Tetracera indica 
(fruit), Oxalis barrelieri (root), Garcinia atroviridis (branch), Anacardium occidentale 
(branch), Euodia redlevi (fruit&flower) and 50% MeOH 2% acetic acid fraction of L. 
flavescens (leaf) ethanolic extract, which has an IC50 value of less than 0.2 mg/mL. 
Peltophorum pterocarpum (leaf), Andrographis paniculata (leaf) and Lawsonia inermis 
(branch) ethanolic extracts has an IC50 value slightly higher than 0.2 mg/mL, which is 
0.25, 0.32 and 0.46 mg/mL respectively. 
 
4.6 KINETIC STUDIES 
In brief, enzyme kinetics in a biological system is always related with Km and 
Vmax values. Km is the concentration of substrate which required to produce an enzyme 
reaction at 1/2 Vmax. While for Vmax, it is the maximum rate that the enzyme reaction 
can proceed at. Theoretically, when there is a competitive inhibition, Km appears to 
increase but Vmax remain the same; non-competitive inhibition, Vmax decrease and Km 
remain the same; uncompetitive inhibition, both Km and Vmax appear to decrease and for 
mixed inhibition, Km increase but Vmax decrease (Segel, 1993). 
The nature of the inhibition of GST-P by selected plant samples (ethanolic 
extract/fraction) was studied. The activities of GST-P were measured with variable 
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concentrations of GSH (0.2-1.0 mM) with the presence of a fixed concentration of plant 
samples (ethanolic extract/fraction). The CDNB was maintained at 1 mM. Vmax and Km 
values of GST-P with and without addition of plant samples (ethanolic extract/fraction) 
were determined from Michaelis-Menten equation and Lineweaver-Burk plot generated 
using SigmaPlot 12.0 software.  Vmax and Km values were shown in Table 4.4. 
By referring to Table 4.4, almost all of plant samples (ethanolic extract/fraction) 
exhibit mixed mode inhibition on GST-P, except for ethanolic extracts of Andrographis 
paniculata (leaf), Garcinia mangostana (leaf) and Lawsonia inermis (branch) which 
shown uncompetitive inhibition, Most of plant samples (ethanolic extract/fraction) 
tested in this experiment displayed mixed mode inhibition because the samples are in 
the form of mixture and thus there were probably more than one type of GST-P 
inhibitor present in one single sample.  
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Table 4.4 : Vmax and Km values of GST-P in the presence of plant samples (ethanolic extract/fraction) 
Sample (Concentration used, mg/mL) Vmax 
(μmol/min) 
Km 
(mM) 
Type of inhibition 
GST-P (0.2) 0.22 0.58 - 
Ethanolic extract     
Anacardium occidentale (branch) (0.2) 0.05 7.47 Mixed 
Andrographis paniculata (leaf) (0.3) 0.06 0.47 Uncompetitive 
Cinnamomum zeylanicum (branch) (0.1) 0.05 0.99 Mixed 
Euodia redlevi (fruit&flower) (0.2) 0.15 3.01 Mixed 
Garcinia atroviridis (branch) (0.2) 0.16 4.51 Mixed 
Garcinia mangostana (branch) (0.1) 0.05 0.89 Mixed 
Garcinia mangostana (leaf) (0.1) 0.03 0.38 Uncompetitive 
Hibiscus tiliaceus (leaf) (0.1) 0.04 0.91 Mixed 
Lawsonia inermis (branch) (0.5) 0.04 0.40 Uncompetitive 
Leptospermum flavescens (leaf) (0.1) 0.02 0.62 Mixed 
Oxalis barrelieri (root) (0.2) 0.04 0.61 Mixed 
Peltophorum pterocarpum (leaf) (0.3) 0.05 13.82 Mixed 
Tetracera indica (fruit) (0.1) 0.06 1.18 Mixed 
Fraction    
50% MeOH 2% acetic acid fraction of L. flavescens (leaf) 
ethanolic extract (0.2) 
0.08 6.29 Mixed 
* MeOH= Methanol. All GST-P activity data were obtained from triplicate determinations. 
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4.7 TOXICITY EFFECTS OF SAMPLES ON MRC-5 CELLS  
In order to examine the toxicity effects of selected plant samples (ethanolic 
extract/fraction) and drugs on normal cells, in vitro cytotoxicity effects of the samples 
against MRC-5 cell line were evaluated using MTT assay. The effect at different 
concentrations of samples was studied after 72 h treatment. The dose-response graph for 
each sample (Appendix IV, Figure 7.21-7.37) was generated using Microsoft Excel 
software. Statistical analysis of data obtained was done by using SigmaPlot 12.0 
analytical software. 
IC50 values of the samples, which obtained from the dose-response curve, were 
shown in Table 4.5. IC50 value is the concentration of sample that reduced the cell 
viability by 50% compared to control, which were treated with 0.2% DMSO. The 
percentage of cell viability at the highest concentration tested (100 μg/mL) for each 
plant sample (ethanolic extract/fraction) was also stated in Table 4.5. 
From Table 4.5, all of the plant samples (ethanolic extract/fraction) show no 
toxicity to MRC-5 cells up to 50 μg/mL. Anacardium occidentale (branch), Euodia 
redlevi (fruit&flower), Garcinia atroviridis (branch), Garcinia mangostana (leaf), 
Hibiscus tiliaceus (leaf) and Leptospermum flavescens (leaf) ethanolic extracts were not 
cytotoxic to MRC-5 cells as they have a 100% cell viability when treated at the highest 
concentration of 100 μg/mL. Meanwhile, Andrographis paniculata (leaf), Cinnamomum 
zeylanicum (branch), Garcinia mangostana (branch), Oxalis barrelieri (root) and 
Peltophorum pterocarpum (leaf) ethanolic extracts and 50% MeOH 2% acetic acid 
fraction of L. flavescens (leaf) ethanolic extract shown less toxicity on MrC-5 cells, with 
cell viability ≥ 80% when treated at 100 μg/mL. Ethanolic extracts of Lawsonia inermis 
(branch) and Tetracera indica (fruit) were slightly toxic to MRC-5 cells with cell 
viability of 75% and 78% respectively, when treated at 100 μg/mL. Doxorubicin 
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hydrochloride is more toxic to MRC-5 cells as compared to cisplatin and ethacrynic 
acid as it has the lowest IC50 values, which is 0.82 ± 0.011 μg/mL. 
Table 4.5 : Cytotoxicity effects of samples on MRC-5 cells 
Sample IC50 
(mean ± S.D., μg/mL) 
Percentage of cell 
viability at 100 μg/mL 
(%) 
Doxorubicin hydrochloride 0.82 ± 0.011 ND 
Cisplatin 4.07 ± 0.04 ND 
Ethacrynic acid 22.71 ± 0.24 1 
Ethanolic extract   
Anacardium occidentale (branch) >100 100 
Andrographis paniculata (leaf) >100 94 
Cinnamomum zeylanicum (branch) >100 97 
Euodia redlevi (fruit&flower) >100 100 
Garcinia atroviridis (branch) >100 100 
Garcinia mangostana (branch) >100 80 
Garcinia mangostana (leaf) >100 100 
Hibiscus tiliaceus (leaf) >100 100 
Lawsonia inermis (branch) >100 75 
Leptospermum flavescens (leaf) >100 100 
Oxalis barrelieri (root) >100 88 
Peltophorum pterocarpum (leaf) >100 99 
Tetracera indica (fruit) >100 78 
Fraction   
50% MeOH 2% acetic acid fraction 
of L. flavescens (leaf) ethanolic 
extract 
>100 97 
* MeOH= Methanol, ND= not determined. IC50 values indicated are the means (± 
standard deviation, S.D.) of three independent experiments.  
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4.8 EFFECTS OF SAMPLES ON HT-29 CELL PROLIFERATION 
In order to examine the effects of selected plant samples (ethanolic 
extract/fraction) and drugs on HT-29 cell viability and proliferation, in vitro 
cytotoxicity effects of the samples against HT-29 cell line were evaluated using MTT 
assay. The effect at different concentrations of samples was studied after 72 h treatment. 
The dose-response graph for each sample (Appendix IV, Figure 7.38-7.54) was 
generated using Microsoft Excel software. Statistical analysis of data obtained was done 
by using SigmaPlot 12.0 analytical software. 
IC50 values of the samples, which obtained from the dose-response curve, were 
shown in Table 4.6. IC50 value is the concentration of sample that reduced the cell 
viability by 50% compared to control, which were treated with 0.2% DMSO. The 
percentage of cell viability at the highest concentration tested (100 μg/mL) for each 
plant sample (ethanolic extract/fraction) was also stated in Table 4.6. 
From Table 4.6, all of the plant samples (ethanolic extract/fraction) were not 
active in killing HT-29 cells as the IC50 values obtained were higher than 100 μg/mL. 
Euodia redlevi (fruit&flower), Garcinia atroviridis (branch), Garcinia mangostana 
(branch), Garcinia mangostana (leaf), Lawsonia inermis (branch), Oxalis barrelieri 
(root) and Tetracera indica (fruit) ethanolic extracts, and 50% MeOH 2% acetic acid 
fraction of L. flavescens (leaf) ethanolic extract were not cytotoxic to HT-29 cells up to 
100 μg/mL because the cell viability was 100% when treated at 100 μg/mL. 
Anacardium occidentale (branch), Cinnamomum zeylanicum (branch), Hibiscus 
tiliaceus (leaf), Leptospermum flavescens (leaf) and Peltophorum pterocarpum (leaf) 
ethanolic extracts were less toxic to HT-29 cells with cell viability ≥80% when treated 
at highest concentration, 100 μg/mL. Ethanolic extract of Andrographis paniculata (leaf) 
was slightly toxic to HT-29 cells with the cell viability of 57% at 100 μg/mL. On the 
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other hand, doxorubicin hydrochloride, cisplatin and ethacrynic acid showed highly 
active cytotoxicity on HT-29 cells. Doxorubicin hydrochloride is the most active 
cytotoxic agent compared to cisplatin and ethacrynic acid, with IC50 value of 0.79 
μg/mL. The IC50 values of cisplatin and ethacrynic acid were 9.49 and 19 μg/mL 
respectively. 
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Table 4.6 : Cytotoxicity effects of samples on HT-29 cell proliferation 
Sample IC50 
(mean ± S.D., μg/mL) 
Percentage of cell 
viability at 100 μg/mL 
(%) 
Doxorubicin hydrochloride 0.79 ± 0.05  ND 
Cisplatin 9.49 ± 0.13 ND 
Ethacrynic acid 19.0 ± 0.26 1 
Ethanolic extract   
Anacardium occidentale (branch) >100 80 
Andrographis paniculata (leaf) >100 57 
Cinnamomum zeylanicum (branch) >100 99 
Euodia redlevi (fruit&flower) >100 100 
Garcinia atroviridis (branch) >100 100 
Garcinia mangostana (branch) >100 100 
Garcinia mangostana (leaf) >100 100 
Hibiscus tiliaceus (leaf) >100 96 
Lawsonia inermis (branch) >100 100 
Leptospermum flavescens (leaf) >100 83 
Oxalis barrelieri (root) >100 100 
Peltophorum pterocarpum (leaf) >100 82 
Tetracera indica (fruit) >100 100 
Fraction   
50% MeOH 2% acetic acid fraction 
of L. flavescens (leaf) ethanolic 
extract 
>100 100 
* MeOH= Methanol, ND= not determined. IC50 values indicated are the means (± 
standard deviation, S.D.) of three independent experiments. 
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4.9 COMBINATION EFFECTS OF PLANT SAMPLES AND DOXORUBICIN 
HYDROCHLORIDE ON CYTOTOXICITY OF HT-29 CELLS 
In order to examine the potentiation effects of plant sample (ethanolic 
extract/fraction) and ethacrynic acid on doxorubicin hydrochloride cytotoxicity of HT-
29, doxorubicin hydrochloride at different concentrations in combination with fixed 
concentration of plant sample(ethanolic extract/fraction) or ethacrynic acid were tested 
against HT-29 cells. in vitro cytotoxicity effects of the combination against HT-29 cell 
line were evaluated using MTT assay. Plant sample (ethanolic extract/fraction) 
concentration was fixed at 50 μg/mL and ethacrynic acid concentration (as a reference) 
was fixed at 10 μg/mL. The concentration fixed was the concentration at which viability 
of HT-29 cells is higher than 95%, when treated alone with plant samples (ethanolic 
extract/fraction) or ethacrynic acid (Appendix IV, Figure 7.40-7.54). 
The dose-response graph for each combination (Appendix IV, Figure 7.55-7.69) 
and Figure 4.8 which showed the comparison of IC50 values between groups of 
combination were generated using Microsoft Excel software. Table 4.7 showed the IC50 
values of doxorubicin hydrochloride, alone or in combination with plant samples 
(ethanolic extract/fraction) or ethacrynic acid. Statistical analysis of data obtained was 
done by using SigmaPlot 12.0 analytical software. 
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Figure 4.8 : Comparison of IC50 values of doxorubicin hydrochloride, alone or in combination, on cytotoxicity of HT-29 cells. Each bar represents the 
mean ± S.D. calculated from three independent determinations. Comparison of IC50 values between groups of combination using ANOVA 
indicates statistically significant difference with P = <0.001. Doxo= Doxorubicin hydrochloride. 
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Based on Figure 4.8, all of the plant samples (ethanolic extract/fraction) 
demonstrated potentiation effect on doxorubicin hydrochloride cytotoxicity of HT-29 
cells. The IC50 value was significantly (P < 0.05) lower for all combinations compared 
with doxorubicin hydrochloride alone. Ethacrynic acid which is well-known as GST-P 
inhibitor was used as a reference in this experiment and the combination of Doxo-
ethacrynic acid had the lowest IC50 value (0.19 ug/mL), followed by Doxo-
Cinnamomum zeylanicum (branch) (0.22 ug/mL), Doxo-Andrographis paniculata (leaf) 
(0.25 ug/mL), Doxo-Lawsonia inermis (branch) (0.26 ug/mL), Doxo-50% MeOH 2% 
acetic acid fraction of L. flavescens (leaf) (0.26 ug/mL), Doxo-Garcinia mangostana 
(leaf) (0.30 ug/mL), Doxo-Tetracera indica (fruit) (0.30 ug/mL), Doxo-Garcinia 
atroviridis (branch) (0.33 ug/mL), Doxo-Hibiscus tiliaceus (leaf) (0.33 ug/mL), Doxo-
Oxalis barrelieri (root) (0.33 ug/mL), Doxo-Garcinia mangostana (branch) (0.39 
ug/mL), Doxo-Leptospermum flavescens (leaf) (0.39 ug/mL), Doxo-Euodia redlevi 
(fruit&flower) (0.41 ug/mL), Doxo-Peltophorum pterocarpum (leaf) (0.48 ug/mL) and 
Doxo-Anacardium occidentale (branch) (0.59 ug/mL) (Table 4.7). When the Doxo-
ethacrynic acid combination was statistically compared (ANOVA) with the remaining 
combinations, the difference was significant (P < 0.05) in all cases. 
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Table 4.7 : Cytotoxicity effects of doxorubicin hydrochloride, alone or in combination, 
on HT-29 cells 
Test sample 
  
IC50 of doxorubucin hydrochloride 
cytotoxicity on HT-29 
(ug/mL) 
Doxorubicin hydrochloride alone 0.79 ± 0.05 
In combination with:  
Ethacrynic acid  0.19 ± 0.01 
Ethanolic extract  
Anacardium occidentale (branch) 0.59 ± 0.03 
Andrographis paniculata (leaf) 0.25 ± 0.01 
Cinnamomum zeylanicum (branch) 0.22 ± 0.00 
Euodia redlevi (fruit&flower) 0.41 ± 0.01 
Garcinia atroviridis (branch) 0.33 ± 0.02 
Garcinia mangostana (branch) 0.39 ± 0.01 
Garcinia mangostana (leaf) 0.30 ± 0.01 
Hibiscus tiliaceus (leaf) 0.33 ± 0.01 
Lawsonia inermis (branch) 0.26 ± 0.02 
Leptospermum flavescens (leaf) 0.39 ± 0.01 
Oxalis barrelieri (root) 0.33 ± 0.01 
Peltophorum pterocarpum (leaf) 0.48 ± 0.02 
Tetracera indica (fruit) 0.30 ± 0.04 
Fraction  
50% MeOH 2% acetic acid fraction of L. 
flavescens (leaf) ethanolic extract 
0.26 ± 0.00 
* MeOH= Methanol. IC50 values indicated are the means (± standard deviation, S.D.) of 
three independent experiments. Multiple comparisons versus control group 
(doxorubicin hydrochloride alone) using Holm-Sidak method indicated an overall 
significance level equal to 0.05. 
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4.10 COMBINATION EFFECTS OF PLANT SAMPLES AND CISPLATIN ON 
CYTOTOXICITY OF HT-29 CELLS 
In order to examine the potentiation effects of plant sample (ethanolic 
extract/fraction) and ethacrynic acid on cisplatin cytotoxicity of HT-29, cisplatin at 
different concentrations in combination with fixed concentration of plant sample 
(ethanolic extract/fraction) or ethacrynic acid were tested against HT-29 cells. in vitro 
cytotoxicity effects of the combination against HT-29 cell line were evaluated using 
MTT assay. Plant sample (ethanolic extract/fraction) concentration was fixed at 50 
μg/mL and ethacrynic acid concentration (as a reference) was fixed at 10 μg/mL. The 
concentration fixed was the concentration at which viability of HT-29 cells is higher 
than 95%, when treated alone with plant samples (ethanolic extract/fraction) or 
ethacrynic acid (Appendix IV, Figure 7.40-7.54). 
The dose-response graph for each combination (Appendix IV, Figure 7.70-7.84) 
and Figure 4.9 which showed the comparison of IC50 values between groups of 
combination were generated using Microsoft Excel software. Table 4.8 showed the IC50 
values of cisplatin, alone or in combination with plant samples (ethanolic 
extract/fraction) or ethacrynic acid. Statistical analysis of data obtained was done by 
using SigmaPlot 12.0 analytical software. 
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Figure 4.9 : Comparison of IC50 values of cisplatin, alone or in combination, on cytotoxicity of HT-29 cells. Each bar represents the mean ± S.D. 
calculated from three independent determinations. Comparison of IC50 values between groups of combination using ANOVA indicates 
statistically significant difference with P = <0.001. 
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Figure 4.9 show that all of the plant samples (ethanolic extract/fraction) 
demonstrated potentiation effect on cisplatin cytotoxicity of HT-29 cells. The IC50 value 
was significantly (P < 0.05) lower for all of the combinations compared with cisplatin 
alone, except for the combinations of Cisplatin-Cinnamomum zeylanicum (branch), 
Cisplatin-Hibiscus tiliaceus (leaf) and Cisplatin-Garcinia mangostana (branch). 
Ethacrynic acid which is well-known as GST-P inhibitor was used as a reference in this 
experiment. However, the combination of Cisplatin-ethacrynic acid does not exhibit 
lowest IC50 value (8.78 ug/mL) compared with the combinations of cisplatin with plant 
samples (ethanolic extract/fraction). Cisplatin-Andrographis paniculata (leaf) was the 
combination which had the lowest IC50 value (4.70 ug/mL), followed by Cisplatin-
Lawsonia inermis (branch) (5.46 ug/mL), Cisplatin- Leptospermum flavescens (leaf) 
(6.33 ug/mL), Cisplatin-Garcinia mangostana (leaf) (6.74 ug/mL), Cisplatin-
Peltophorum pterocarpum (leaf) (7.16 ug/mL), Cisplatin-Garcinia atroviridis (branch) 
(8.30 ug/mL), Cisplatin-Oxalis barrelieri (root) (8.33 ug/mL), Cisplatin-50% MeOH 2% 
acetic acid fraction of L. flavescens (leaf) (8.38 ug/mL), Cisplatin-Tetracera indica 
(fruit) (8.47 ug/mL), Cisplatin-Euodia redlevi (fruit&flower) (8.55 ug/mL), Cisplatin-
Anacardium occidentale (branch) (8.66 ug/mL), Cisplatin-Cinnamomum zeylanicum 
(branch) (9.23 ug/mL), Cisplatin-Garcinia mangostana (branch) (9.24 ug/mL) and 
Cisplatin-Hibiscus tiliaceus (leaf) (9.24 ug/mL) (Table 4.8). When the combination of 
Cisplatin-ethacrynic acid was statistically compared (ANOVA) with the other 
combinations, the difference was significant (P < 0.05) for Cisplatin-Andrographis 
paniculata (leaf), Cisplatin-Lawsonia inermis (branch), Cisplatin- Leptospermum 
flavescens (leaf), Cisplatin-Garcinia mangostana (leaf) and Cisplatin-Peltophorum 
pterocarpum (leaf), but not for the others. 
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Table 4.8 : Cytotoxicity effects of cisplatin, alone or in combination, on HT-29 cells 
Test sample 
 
IC50 of cisplatin cytotoxicity on HT-29 
(μg/mL) 
Cisplatin alone 9.49 ± 0.13 
In combination with:  
Ethacrynic acid  8.78 ± 0.15 
Ethanolic extract  
Anacardium occidentale (branch) 8.66 ± 0.13 
Andrographis paniculata (leaf) 4.70 ± 0.18 
Cinnamomum zeylanicum (branch) 9.23 ± 0.07 
Euodia redlevi (fruit&flower) 8.55 ± 0.06 
Garcinia atroviridis (branch) 8.30 ± 0.12 
Garcinia mangostana (branch) 9.24 ± 0.55 
Garcinia mangostana (leaf) 6.74 ± 0.38 
Hibiscus tiliaceus (leaf) 9.24 ± 0.30 
Lawsonia inermis (branch) 5.46 ± 0.30 
Leptospermum flavescens (leaf) 6.33 ± 0.40 
Oxalis barrelieri (root) 8.33 ± 0.24 
Peltophorum pterocarpum (leaf) 7.16 ± 0.19 
Tetracera indica (fruit) 8.47 ± 0.26 
Fraction  
50% MeOH 2% acetic acid fraction of L. 
flavescens (leaf) ethanolic extract 
8.38 ± 0.36 
* MeOH= Methanol. IC50 values indicated are the means (± standard deviation, S.D.) of 
three independent experiments. Multiple comparisons versus control group (cisplatin 
alone) using Holm-Sidak method indicated an overall significance level equal to 0.05. 
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5.0 DISCUSSION 
5.1 PLANT EXTRACTION 
The application of natural resources in primary health care has become more and 
more important especially in developing countries. In recent years, there is a revival of 
interest in drug discovery from natural products including medicinal plants. Numbers of 
pharmacognostical and pharmacological investigations are undergoing to identify 
potential drugs or structural models for the design and development of novel therapeutic 
drugs used in the treatment of diseases such as cancer and infectious disease. Analysis 
of the origin of newly identified therapeutic drugs has revealed a significant role of 
natural products in discovery and development of medication drugs (Newman et al., 
2003).  
In present study, the plant extraction was done according to the fractionation 
protocol introduced by Claeson et al. (1998). This polypeptide isolation protocol was 
selected because our study is dedicated to extract bioactive peptides from local plants. 
Furthermore, the fractionation procedures removed ubiquitous compounds known to 
interfere with bioassays often used in pharmacological investigations. Peptide inhibitors 
were targeted in this study because many peptides have been discovered as therapeutic 
pharmaceutical drugs, vasodilators, hormones and neuropeptides (da Rocha Pitta et al., 
2010; Daly et al., 2012; Reglodi et al., 2011; Lico et al., 2012). 
43 local plant samples (31 species with different plant parts) selected in this 
study were pre-extracted with dichloromethane, followed by aqueous alcohol extraction 
with 50% ethanol and lyophilized. Pre-extraction with dichloromethane removed 
lipophilic substances such as lipids, chlorophyll and low molecular weight compounds 
(example, terpenoids). Since polypeptides are insoluble in dichloromethane, it will 
remain in the plant residue and thus extraction with 50% ethanol had extracted most of 
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the polypeptides of the plant sample. Polypeptides were extracted with 50% ethanol 
instead of pure water or alcohol due to better solubility of polypeptides and preservative 
properties of aqueous alcohol. In addition, polysaccharides and enzymes are removed 
from the ethanolic extract since these compounds are insoluble in 50% ethanol (Claeson 
et al., 1998). Plant ethanolic extracts were then lyophilized and stored at 4°C because 
lyophilization enhanced stability of sample in dry state and removed water without 
excessive heating which may affect the bioactivities of sample (Food and Drug 
Administration, 2009). 
 
5.2 HT-29 CELL LINE 
HT-29 cell line is one of the best described cell line among several 
adenocarcinoma cell lines and has been extensively used in pharmacological study. This 
cell line was derived from human primary colon adenocarcinoma (von Kleist et al., 
1975).  From Figure 4.3, we can see that the cells have epitheloid morphology and cells 
were roughly spherical. Some of the ultrastructural features of HT-29 cells described by 
ATCC (2013) were captured in Figure 4.3, such as large vacuolated mitochondria with 
dark granules, lipid droplets and lysosomes. The cells were grown in monolayer which 
attached to the surface of the culture flask. 
HT-29 cell line was often used in the studies related to GST inhibition, 
especially for GST-P (Ciaccio et al., 1995; Tashiro et al., 2001; Shen et al., 2003). High 
expression of GST-P and multidrug resistance nature of HT-29 cell line made it the first 
choice in clonogenic assays related to drug potentiation through GST inhibition 
(Morgan et al., 1996; Tew et al., 1988). GST-P was targeted as a model for the 
synthesis of specific inhibitor which could be used as adjuvant in chemotherapy (Oakley 
et al., 1997).  
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5.3 GST-P PURIFICATION AND IDENTIFICATION 
GST-P was purified and identified with a combination of affinity 
chromatography, enzyme assays, SDS-PAGE and IEF analysis, and ionization mass 
spectrometry of MALDI-TOF. GST-P was isolated from the HT-29 cell lysate by 
affinity chromatography. Catalytic activity of GST towards CDNB was measured for 
unbound fraction and GST eluate (result no shown). GST activity is only detectable in 
GST eluate. GST eluate was then concentrated with protein concentrator with the 
purpose of remove excessive buffer and GSH in the eluate. Specific activity of the 
isolated GST-P was 0.032 μmol/min/mg. Based on the result of peptide mass fingerprint 
analysis (Appendix IV), the identified nominal mass and pI value of isolated GST-P 
were 23.3 kDa and 5.4 respectively. The mass obtained was slightly different from the 
mass determined by SDS-PAGE (23.8 kDa). This is probably due to the difference in 
separating parameter of the two methods in which SDS-PAGE separated proteins by 
their size while MALDI-TOF separated the proteins by molecular mass. The pI value 
obtained from IEF analysis (Section 4.3.4) was matched with the pI value obtained from 
MALDI-TOF (Appendix IV). Single band on IEF gel (Figure 4.6) indicates that there is 
only one isoform of GST-P isolated from HT-29 cell line. 
Since there is only GST-P isolated in this investigation, the finding is in 
agreement with those of Beaumont et al. (1998) who reported that only GST-P was 
expressed in HT-29 cells but not for alpha or mu-class of GST, and Schultz et al. (1997) 
who showed that only mRNA of GST-P quantified from HT-29 cell line. 
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5.4 PRELIMINARY SCREENING ON GST-P INHIBITION 
A total of 43 plant ethanolic extracts which extracted from 31 local plant species 
(with different plant parts) were screened for their inhibitory effects on GST-P. To our 
knowledge, this is the first report of detailed study in in vitro inhibition of human GST-
P by local plant extracts. 30 ethanolic extracts showed inhibitory effects on GST-P with 
relative changes in the range of 4-100% reduction (Table 4.1). The remaining 13 
ethanolic extracts increased activity of GST-P. Ethanolic extracts which enhanced the 
activity of GST-P were not continued with downstream experiments due to the reason 
that GST-P activator is not expected for this experiment. However, the finding of the 
GST activator in plant has implications for developing functional foods to boost up 
body immune system and also food-related precautions during chemotherapy to prevent 
drug resistance contributed by activation of GST-P. 
Among the 30 ethanolic extracts which have inhibitory effects on GST-P, only 
ethanolic extracts with GST-P inhibition percentage higher than 50% were selected for 
downstream. This is because of the criteria for reporting IC50 which require maximum 
inhibition percentage to be greater than 50% (National Institutes of Health, 2010). The 
selected samples include Anacardium occidentale (branch), Andrographis paniculata 
(leaf), Cinnamomum zeylanicum (branch), Euodia redlevi (fruit&flower), Garcinia 
atroviridis (branch), Garcinia mangostana (branch and leaf), Hibiscus tiliaceus (leaf),  
Lawsonia inermis (branch), Leptospermum flavescens (leaf), Oxalis barrelieri (root), 
Peltophorum pterocarpum (leaf) and Tetracera indica (fruit) ethanolic extracts.  
Results in Table 4.1 demonstrated different parts of the same plant could exert 
distinct effects on GST-P. For example, branch and fruit of Piper nigrum. Piper nigrum 
(branch) ethanolic extract inhibited 21% of GST-P activity while Piper nigrum (fruit) 
ethanolic extract induced 97% of GST-P activity. A possible explanation for this might 
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be the variation in chemical constituents of different plant parts (Padalia et al., 2012; 
Das et al., 2002).  
 
5.5 BIOASSAY-GUIDED FRACTIONATION 
Based on the results of preliminary screening on GST-P inhibition by plant 
ethanolic extracts (Table 4.1), Garcinia atroviridis (branch) and Leptospermum 
flavescens (leaf) ethanolic extracts has a 100% inhibition on GST-P activity and thus 
proceeded with bioassay-guided fractionation using polyamide chromatography. 
Undesired polyphenolic compounds of plant ethanolic extract, such as tannins, were 
removed when passed through polyamide column. Polyphenolic compounds were 
irreversibly bound to polyamide and thus retained in the column. Peptides were not bind 
to polyamide and thus eluted with 2% acetic acid. 2% acetic acid was used as eluting 
solvent due to the facts that lower pH increases binding affinity of polyamide towards 
tannins, increases solubility of proteins and reduces effects of proteases (Claeson et al., 
1998; Ohishi et al., 2003). However, there were certain peptides insoluble in 2% acetic 
acid and these peptides were then eluted with 50% methanol 2% acetic acid. Proteins 
insoluble in 2% acetic acid are protein with high surface hydrophobicity (Okada et al., 
1988).   
Based on the results in Table 4.2, we found that only the 50% methanol 2% 
acetic acid fractions of Garcinia atroviridis (branch) and Leptospermum flavescens (leaf) 
ethanolic extracts demonstrated inhibition activity on GST-P. It seems possible that the 
acetic acid-insoluble peptides present in 50% methanol 2% acetic acid fraction have 
higher surface hydrophobicity (Okada et al., 1988). This is also consistent with those of 
other studies suggested that GST-P tends to bind with hydrophobic substances at the 
ligandin site of the enzyme. The GSH and ligand binding sites of GST are located at 
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different parts of the same active site cleft, and the ligand site is located in the 
electrophile binding site (Oakley et al., 1997, 1999; Vararattanavech et al., 2006). 
Fractions of Garcinia atroviridis (branch) ethanolic extract lose their inhibitory activity 
after polyamide fractionation and this inconsistency may be due to the reason that the 
inhibitory agents in ethanolic extract of Garcinia atroviridis (branch) inhibited GST-P 
synergistically instead of individually.  
From Table 4.2, we also found that only 50% methanol 2% acetic acid fraction 
of Leptospermum flavescens (leaf) ethanolic extract retained its high inhibition on GST-
P activity. Then, we tried to further fractionate this sample in order to isolate the pure 
form of the inhibitor. Firstly, we injected the 50% methanol 2% acetic acid fraction of L. 
flavescens (leaf) ethanolic extract into a C18 reversed-phase choromatography (RPC) 
column and ran with 0.12% Trifluoroacetic acid (TFA). The peptides were eluted in 
gradients with 70% methanol: 0.1% TFA. The fractions obtained were then subjected to 
GST-P inhibitory assay. Unfortunately, there was no inhibitory activity found for all the 
fractions tested. Then, we tried with a series of hydrophobic interaction chromatography 
(HIC) columns consist of Phenyl Sepharose, Butyl Sepharose, Butyl-S Sepharose and 
Octyl Sepharose. The running buffer used was 50 mM sodium phosphate, 1 M 
ammonium sulphate, pH 7.0, and the eluting buffer was 50 mM sodium phosphate, pH 
7.0 (as recommended by manufacturer). The fractions collected were subjected to GST-
P inhibitory activity assays and the results obtained (no shown) were either less or no 
reduction in GST-P activity. After that, we switched to another column, which is 
Superdex G-75 gel filtration chromatography column. The running buffer used was 50 
mM sodium phosphate, pH 7.0. The GST-P inhibitory effects of fractions collected was 
also found to be very low.  
Despite repeated attempts to separate the mixture by different types of 
chromatography, it does not prove possible to separate the components in 50% 
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methanol 2% acetic acid fraction of Leptospermum flavescens (leaf) ethanolic extract. 
We assumed that probably the peptides were degraded during the process of isolation or 
there might be synergy effects of different peptides on inhibition of GST-P, which will 
be diminish if the peptides exist in pure form. The synergism may also appear as 
interaction of more than one agent which results a combined effect greater than the sum 
of individual parts (that is addictive effect) (Pengelly, 2004). 
 
5.6 IC50 OF GST-P INHIBITORY ASSAYS 
IC50 value is the half maximal inhibitory concentration of inhibitor. It is a 
quantitative measurement of the effectiveness of a compound in inhibiting an enzymatic 
reaction at a fixed concentration of substrate (Copeland, 2000). The IC50 values of plant 
samples were determined from dose-response curve relating the concentration of plant 
sample (ethanolic extract/fraction) to the percentage of inhibition on GST activity, at 
fixed concentration of GST-P and substrates (GSH and CDNB) (Appendix IV). 
A total of 14 plant samples (ethanolic extract/fraction) were tested in this 
experiment. All of the plant samples (ethanolic extract/fraction) were significantly (P < 
0.5) inhibited GST-P in dose-dependent manner (Appendix IV). Cinnamomum 
zeylanicum (branch) is the most active sample with IC50 value of 0.07 mg/mL, followed 
by ethanolic extracts of Leptospermum flavescens (leaf), Hibiscus tiliaceus (leaf), 
Garcinia mangostana (leaf), Garcinia mangostana (branch) Tetracera indica (fruit), 
Oxalis barrelieri (root), Garcinia atroviridis (branch), Anacardium occidentale (branch), 
Euodia redlevi (fruit&flower), 50% MeOH 2% acetic acid fraction of L. flavescens 
(leaf), Peltophorum pterocarpum (leaf), Andrographis paniculata (leaf) and Lawsonia 
inermis (branch) ethanolic extracts which have IC50 values of 0.09-0.46 mg/mL. 
Compared to previous reported plant extract inhibition activity on GST, some of our 
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ethanolic extracts have higher potency. Çoruh et al. (2007) reported that extracts of 
Gundelia tournefortii L. aerial and seeds have IC50 values of 0.155 and 0.097 mg/mL 
respectively. Príncipe and Spira (2009) described GST inhibitory effects of Bauhinia 
forficate, Jacaranda puberula and Pimenta pseudocaryophyllus extracts, which IC50 
values are 0.1-1, > 0.1 and > 0.1 mg/mL respectively. 
The results obtained in this experiment (Section 4.5) were not consistent with 
previous screening results (section 4.4). There are several possible explanations for the 
results, such as (1) samples are in mixture and probably there are presence of 
compounds (for example, tannins and pigments) which might interfere with the 
bioassays (Claeson et al., 1998), (2) samples have steep dose-response curves that 
different from stoichiometric inhibition which predicts that changes of IC50 should be 
linear with enzyme concentration, (3) more than one type of inhibitors exist in the 
sample mixture, (4) physical phase transition of inhibitory agent and (5) enzyme 
concentration is greater than the dissociation constant (Kd) of inhibitor (Shoichet, 2006). 
 
5.7 KINETIC STUDIES 
Enzyme kinetics is the study of enzyme catalysis reactions. Measurement and 
mathematical description of rate of reaction and its associated constants are investigated 
in enzyme kinetics study (Rogers and Gibon, 2009). In this study, inhibitory kinetics of 
plant samples (ethanolic extract/fraction) on the Vmax and Km values of GST-P were 
determined. Vmax and Km values of GST-P with or without binding of inhibitor were 
determined by Michaelis-Menten equation. 
Based on the results in Table 4.4, Anacardium occidentale (branch), 
Cinnamomum zeylanicum (branch), Euodia redlevi (fruit&flower), Garcinia atroviridis 
(branch), Garcinia mangostana (branch), Hibiscus tiliaceus (leaf), Leptospermum 
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flavescens (leaf), Oxalis barrelieri (root), Peltophorum pterocarpum (leaf), Tetracera 
indica (fruit) ethanolic extracts and 50% MeOH 2% acetic acid fraction of L. flavescens 
(leaf) ethanolic extract were displayed mixed mode inhibition on GST-P with reduced 
Vmax and increased Km of GST-P. Increased Km was due to the interference of inhibitors 
with substrate binding while reduced Vmax owed to hindered catalysis of enzyme-
substrate complex (Segel, 1993). The mechanism of mixed mode inhibition comprised 
of competitive, noncompetitive and uncompetitive inhibition (Rogers and Gibon, 2009). 
Findings of mixed mode inhibition further support the idea of more than one type of 
inhibitors exist in the sample mixture, different inhibitors exerted different types of 
inhibition on GST-P. Several other plant extracts were reported to exhibit mixed type of 
inhibition on enzyme, for instance, Theobroma cacao extract which inhibited pancreatic 
lipase in mixed mode (Gu, et al., 2011) and Olea europaea L. leaf extract which 
displayed mixed mode inhibition on xanthine oxidase (Flemmig, 2011). Mixed 
inhibition of Anacardium occidentale (branch), Euodia redlevi (fruit&flower), Garcinia 
atroviridis (branch), Peltophorum pterocarpum (leaf) ethanolic extracts and 50% 
MeOH 2% acetic acid fraction of L. flavescens (leaf) ethanolic extract on GST-P greatly 
reduced the substrate binding affinity of GST-P (high Km values, ≥ 3.0 mM).  
On the other hand, Andrographis paniculata (leaf), Garcinia mangostana (leaf) 
and Lawsonia inermis (branch) ethanolic extracts uncompetitively inhibited GST-P with 
respect to varied GSH concentration (Table 4.4). Uncompetitive inhibitors in these 
ethanolic extracts bind to the enzyme-substrate complex thus lowering the Km and Vmax 
of GST-P. Lowered Km and Vmax were due to the reduction in effective concentration of 
enzyme–substrate complex which leads to the increases in enzyme’s affinity for its 
substrate and decreases in maximum activity of enzyme (Copeland, 2000). Previously 
reported plant extracts which have uncompetitive inhibitory activities include aerial 
extracts of Citrullus colocynthis and Ipomoea pescaprae which uncompetitively 
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inhibited alpha-glucosidase (Gurudeeban et al., 2012), extract of Manilkara indica 
containing Isoaffinetin which is an uncompetitive inhibitor of aldose reductase 
(Haraguchi et al., 2003) and aqueous stem bark extract of Adenium obesum which 
demonstrated uncompetitive inhibition on acetyl cholinesterase activity (Mgbojikwe, 
2000). 
 
5.8 CYTOTOXICITY EFFECTS OF SAMPLES ON MRC-5 AND HT-29 CELLS 
MRC-5 cell line derived from fetal lung tissue was first introduced by Jacobs et 
al. (1970). The human normal cell line, MRC-5, was initially established in the 
development of vaccines (Chonmaitree et al., 1988; Gregory and Menegus, 1983; 
Shinohara et al., 2002), but later on it was also widely used in biocompatibility assays 
for pharmacological investigations (Grare et al., 2007; Malek et al., 2009). In this study, 
MRC-5 cell line was used in biocompatibility testing of plant samples (ethanolic 
extract/fraction) cytotoxicity on normal cells. MRC-5 was selected because the cell line 
has rapid growth rate, longer life span, normal characteristics with no neoplatic 
properties and tolerance to environmental changes (Jacobs et al., 1970; Friedman and 
Koropchak, 1978). 
From the results obtained in section 4.7 and 4.8, all of the plant samples 
(ethanolic extract/fraction) tested was not toxic to both MRC-5 and HT-29 cell lines at 
concentration up to 50 μg/mL. That mean, with the presence of the plant sample 
(ethanolic extract/fraction) alone will not trigger apoptosis in the cells at concentration 
below 50 μg/mL. Besides, all of the plant samples (ethanolic extract/fraction) have IC50 
values higher than 100 μg/mL for both HT-29 and MRC-5 cells and according to the 
selection criteria of American National Cancer Institute (NCI), only crude extract with 
IC50 lower than 30 mg/mL promising the presence of cytotoxic agents (Suffness and 
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Pezzuto, 1990). At the concentration of 100 μg/mL, Garcinia mangostana (branch), 
Lawsonia inermis (branch) and Tetracera indica (fruit) ethanolic extracts have minor 
cytotoxic effect on MRC-5 with up to 35% cell killed. On the other hand, Andrographis 
paniculata (leaf) ethanolic extract was slightly toxic to HT-29 cells, with 43% cell 
killed at concentration of 100 μg/mL. The reason for this is not clear but it might be 
related to the activation of apoptotic pathways with increased concentration of the plant 
sample (ethanolic extract/fraction). 
There were three commercial drugs tested in this investigation that is 
doxorubicin hydrochloride, cisplatin and ethacrynic acid. Doxorubicin and cisplatin are 
common chemotherapy drugs used in cancer treatment while ethacrynic acid is a well-
known GST-P inhibitor. Among the three drugs, doxorubicin hydrochloride was most 
cyotoxic to both MRC-5 and HT-29 cells with IC50 values of 0.82 and 0.79 μg/mL 
respectively, followed by cisplatin (IC50= 4.07 μg/mL for MRC-5, 9.49 μg/mL for HT-
29) and ethacrynic acid (IC50= 22.71 μg/mL for MRC-5, 19.0 μg/mL for HT-29). Based 
on the IC50 values obtained, doxorubicin hydrochloride and ethacrynic acid have higher 
toxicity effect on HT-29 cells compared to MRC-5 cells while cisplatin more toxic to 
MRC-5 cells compared to HT-29 cells. The results obtained were consistent with those 
reported by Malek et al. (2011) and Park et al. (2012), but not for ethacrynic acid which 
is not reported before. Ehtacrynic acid was later on used as reference compound in 
combination assays for its known inhibition effect on GST-P. 
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5.9 COMBINATION EFFECTS OF PLANT SAMPLES AND DOXORUBICIN 
HYDROCHLORIDE ON CYTOTOXICITY OF HT-29 CELLS 
Doxorubicin is a type of anthacycline antibiotic commonly used in cancer 
chemotherapy. It has demonstrated significant antitumor activity against different types 
of cancer in various in vitro and in vivo human tumor xenograft models and clinical 
trials (Kratz et al., 1998; Wendel et al., 2004; Kattan et al., 1992). Nevertheless, life-
threatening illness of neutropenia is the dose-limiting toxicity of doxorubicin. 
Combination treatment of doxorubicin with other agents was suggested to palliate the 
drug toxicity which is an important consideration (Seiden et al., 2002). 
In this experiment, HT-29 cells were treated with doxorubicin hydrochloride in 
combination with non-cytotoxic doses of plant samples (ethanolic extract/fraction) in 
order to see the potentiation effects of plant samples (ethanolic extract/fraction) on 
doxorubicin cytotoxicity of HT-29. Since the concentration of plant sample (50 μg/mL) 
used in combination assays showed no cytotoxic effect on HT-29, the cytotoxicity on 
HT-29 resulted by the treatment of combinations of doxorubicin hydrochloride and 
plant samples (ethanolic extract/fraction) were solely dependent on the concentration of 
doxorubicin hydrochloride.  
By referring to Figure 4.9, we can see that all of the plant samples (ethanolic 
extract/fraction) and ethacrynic acid (reference compound) potentiated cytotoxicity 
effects of doxorubicin hydrochloride on HT-29 cells. The combination of doxo-
ethacrynic acid has the lowest IC50 value of 0.19 μg/mL. Ethacrynic acid at non-
cytotoxic concentration (10 μg/mL) has resulted a substantial increase in cytotoxic 
activity of doxorubicin hydrochloride by 76% reduction in IC50 value (from 0.79 μg/mL 
to 0.19 μg/mL). Among the combinations of doxorubicin hydrochloride and plant 
samples (ethanolic extract/fraction), combination of doxo-Cinnamomum zeylanicum 
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(branch) has the lowest IC50 value with IC50= 0.22 μg/mL. This is corroborated by the 
findings in GST-P inhibitory assays which showed that Cinnamomum zeylanicum 
(branch) ethanolic extract is the most active extract inhibitor of GST-P. The strength of 
enhancement in doxorubicin hydrochloride cytotoxicity by plant samples (ethanolic 
extract/fraction) with respect to reduction of IC50 values are such as Cinnamomum 
zeylanicum (branch) > Andrographis paniculata (leaf) > Lawsonia inermis (branch) > 
50% MeOH 2% acetic acid fraction of L. flavescens (leaf) > Garcinia mangostana (leaf) 
≥ Tetracera indica (fruit) > Oxalis barrelieri (root) ≥ Garcinia atroviridis (branch) ≥ 
Hibiscus tiliaceus (leaf) > Leptospermum flavescens (leaf) ≥ Garcinia mangostana 
(branch) > Euodia redlevi (fruit&flower) > Peltophorum pterocarpum (leaf) > 
Anacardium occidentale (branch).  
Thus, with GST-P inhibition by plant samples (ethanolic extract/fraction) and 
ethacrynic acid and significant (P < 0.05) enhancement of doxorubicin hydrochloride 
cytotoxicity on HT-29 cells by combinations of doxorubicin hydrochloride with either 
plant samples (ethanolic extract/fraction) or ethacrynic acid, it is possible that inhibition 
of GST-P potentiated doxorubicin cytotoxicity in HT-29 cells.  
Although the results obtained was differ from the finding of Beaumont et al. 
(1998) who showed that neither ethacrynic acid nor other GST inhibitors able to 
potentiate antitumor effect of doxorubicin, they are consistent with those of Nagourney 
et al. (1990), Tew et al. (1988) and Maeda (1993) who demonstrated enhancement on 
antitumor activity of antineoplatic drug by GST inhibition. Hence, our findings further 
support the idea of inhibition on GST-P able to enhance the anticancer effects of 
doxorubicin. Indeed, GST-P may play a role in multidrug resistance mechanism of 
doxorubicin-resistant cancer cells. 
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5.10 COMBINATION EFFECTS OF PLANT SAMPLES AND CISPLATIN ON 
CYTOTOXICITY OF HT-29 CELLS 
Cisplatin is a type of platinum-based chemotherapy drug used in the treatment of 
various cancers for over three decades. The initial respond of treatment with cisplatin is 
usually high but most of the patient developed relapse after a certain period of treatment 
due to the development of cisplatin resistance (Stordal and Davey, 2007; Gerl et al., 
1997). The mechanisms of cisplatin resistance proposed by Rabik and Dolan (2007) 
include reduced uptake and increased efflux of the drug, detoxification of the drug, 
DNA tolerance and recovery. So, combination of treatment of cisplatin and agent which 
able to sensitize the cancer cells to the drug will lead to improvements in the treatment 
of many cancers. 
In this experiment, HT-29 cells were treated with cisplatin in combination with 
non-cytotoxic doses of plant samples (ethanolic extract/fraction) in order to see the 
sensitization effects of plant samples (ethanolic extract/fraction) on cisplatin 
cytotoxicity of HT-29. Non-cytotoxic doses of plant samples (50 μg/mL) used in 
combination assays are independent factor in the determination of cytotoxic effect of 
combination of cisplatin with plant sample (ethanolic extract/fraction) on HT-29 cell 
line. Hence, the cytotoxicity on HT-29 was solely dependent on the concentration of 
cisplatin. 
The cytotoxic effect of combination of ethacrynic acid and cisplatin (IC50 = 8.78 
μg/mL) on HT-29 cells was not much different from the effect of cisplatin alone (IC50 = 
9.49 μg/mL). The possible explanation is the cells were resistant to cisplatin which may 
be due to the reasons that (1) induction of GST-P expression by ethacrynic acid 
enhanced resistance of cells to cisplatin and (2) increase in expression of other 
detoxifying agents such as dihydrodiol dehydrogenase (DDH) and gamma-
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glutamylcysteine synthetase by alteration of intraclellular thiol status or generation of 
oxidative stress resulted from exposure of cells to ethacrynic acid (Ciaccio et al., 1995). 
Since cisplatin resistance is multifactorial and to overcome the resistance may depends 
on the specific inhibition on particular pathway (Stordal and Davey, 2007), yet 
inhibition on GST-P had no sensitizing effect on cytotoxicity of cisplatin, suggesting 
that the inhibition of GST-P was not directly involve in cisplatin resistance. 
Based on results in Table 4.8, Anacardium occidentale (branch), Cinnamomum 
zeylanicum (branch), Euodia redlevi (fruit&flower), Garcinia atroviridis (branch), 
Garcinia mangostana (branch), Hibiscus tiliaceus (leaf), Oxalis barrelieri (root), 
Tetracera indica (fruit) ethanolic extracts and 50% MeOH 2% acetic acid fraction of L. 
flavescens (leaf) ethanolic extract showed no or less enhancement on cisplatin 
cytotoxicity in HT-29 cells, with ≤ 13% reduction of IC50 values of cisplatin. Garcinia 
mangostana (leaf), Leptospermum flavescens (leaf) and Peltophorum pterocarpum (leaf) 
ethanolic extracts have little enhancement little enhancement on cisplatin cytotoxicity in 
HT-29 cells, with 29%, 33% and 25% of reduction in IC50 values of cisplatin 
respectively. The enhancement by these ethanolic extracts might be due to mechanisms 
other than GST-P inhibition. However, ethanolic extracts of Andrographis paniculata 
(leaf) and Lawsonia inermis (branch) incredibly increased the cytotoxicity of cisplatin 
on HT-29 cells. This is probably caused by the inhibition of not only GST-P but also for 
other signaling pathways (such as multidrug resistance and apoptosis) which induced 
apoptosis in HT-29 cells. Besides, combinations of cisplatin with either Andrographis 
paniculata (leaf) or Lawsonia inermis (branch) ethanolic extracts might be more 
effective in inhibiting GST activity than plant sample (ethanolic extract/fraction) alone 
(synergism effect). Hence, lowered application dosage of cisplatin might be able to 
reduce its cytotoxicity to normal cells. 
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6.0 CONCLUSION 
In conclusion, the results of this study showed that local plants have potent 
inhibitors of GST pi which able to overcome the drug resistance of cancerous cells. 
Based on the results of preliminary GST-P inhibition screening, 30 ethanolic extracts 
displayed inhibition activity on GST-P and 13 out of the 30 ethanolic extracts have 
inhibition effects higher than 50%. Garcinia atroviridis (branch) and Leptospermum 
flavescens (leaf) ethanolic extracts have the highest inhibitory effect with a 100% 
inhibition on GST pi activity. The 13 ethanolic extracts were subjected for downstream 
experiments consist of IC50 determination, kinetic studies and cytotoxicity assays. 
Results of IC50 determination assay suggested that the most active GST-P inhibiting 
sample was Cinnamomum zeylanicum (branch) ethanolic extract with IC50 value of 0.07 
mg/mL, followed by Leptospermum flavescens (leaf) and Hibiscus tiliaceus (leaf) 
ethanolic extracts with IC50 values of 0.09 and 0.10 mg/mL respectively. Meanwhile for 
the kinetic analysis, all of the ethanolic extracts shown mixed mode inhibition on GST-
P activity, except for the ethanolic extracts of Andrographis paniculata (leaf), Garcinia 
mangostana (leaf) and Lawsonia inermis (branch) which uncompetitively inhibited 
GST-P. All of the ethanolic extracts were showed to be non toxic to both MRC-5 and 
HT-29 cell lines, with IC50 value >100 μg/mL. Combination studies indicated that GST-
P inhibition able to potentiate the cytotoxicity of doxorubicin hydrochloride on HT-29 
cells, but not for cisplatin. Combination of doxorubicin hydrochloride-Cinnamomum 
zeylanicum (branch) ethanolic extract has the lowest IC50 value with IC50= 0.22 μg/mL. 
Nevertheless, Andrographis paniculata (leaf) and Lawsonia inermis (branch) ethanolic 
extracts were incredibly increase the cytotoxicity of cisplatin on HT-29 cells with IC50 
values of 4.70 and 5.46 μg/mL respectively. On the other hand, bioassay-guided 
fractionation of Leptospermum flavescens (leaf) ethanolic extract obtained a fraction of 
50% methanol 2% acetic acid which has 95% inhibition on GST-P activity. 50% 
126 
 
methanol 2% acetic acid fraction of L. flavescens (leaf) extract inhibited GST-P in 
mixed mode with IC50 value of 0.19 mg/mL. This fraction was not toxic to both HT-29 
and MRC-5 cells with IC50 value >100 μg/mL. Combination of doxorubicin 
hydrochloride with 50% methanol 2% acetic acid fraction of L. flavescens (leaf) extract 
enhanced doxorubicin hydrochloride cytotoxicity on HT-29 cells with IC50= 0.26 
μg/mL whereas combination of cisplatin-50% methanol 2% acetic acid fraction of L. 
flavescens (leaf) extract gave an IC50 value of 8.38 μg/mL on cytotoxicity of HT-29 
cells. Our results show that local plants can be source of GST-P inhibitors which able to 
enhance cytotoxicity of anticancer drugs on tumor cells. 
Following the investigations described in this dissertation, the future work could 
be involving extensive strategy of the isolation and structural determination of the 
inhibitor molecules and thus refine the kinetic evaluation of its behavior towards GST-P. 
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APPENDICES 
APPENDIX I: AUTHENTICATION OF PLANT SAMPLES 
Table 7.1 : Plant authentication 
Plant sample Authenticated by Place of 
collection  
Parts used  
(reference 
number) 
 
Anacardium occidentale  
(Linnaeus, 1753a) 
Prof. Dr. Ong Hean 
Chooi 
Pantai Dalam, 
Kuala Lumpur 
Branch (AO1); 
fruit & flower 
(AO2) 
Andrographis paniculata 
(Wallich, 1832) 
 
Prof. Dr. Ong Hean 
Chooi 
Pantai Dalam, 
Kuala Lumpur 
Branch (AP1); 
leaf (AP2) 
Artocarpus heterophyllus  
(Lamarck and Poiret, 
1789) 
 
Prof. Dr. Ong Hean 
Chooi 
Pantai Dalam, 
Kuala Lumpur 
Leaf (AH1) 
 
Averrhoa bilimbi  
(Linnaeus, 1753a) 
 
Prof. Dr. Ong Hean 
Chooi 
Pantai Dalam, 
Kuala Lumpur 
Branch (AB1); 
leaf (AB2) 
Cinnamomum zeylanicum 
(Blume, 1826a) 
 
 
Prof. Dr. Ong Hean 
Chooi 
 
Jabatan 
Kejuruteraan, 
Universiti 
Malaya 
Branch (CZ1) 
 
Commelina nudiflora 
(Linnaeus, 1753a) 
Prof. Dr. Ong Hean 
Chooi 
 
Ladang ISB, 
Universiti 
Malaya 
Whole plant 
(CN1) 
 
Euodia redlevi 
(David, 1995) 
Prof. Dr. Ong Hean 
Chooi 
 
Kebun ISB, 
Universiti 
Malaya 
Flower & fruit 
(ER1) 
 
Eupatorium odoratum 
(Linnaeus, 1759) 
 
Prof. Dr. Ong Hean 
Chooi 
Gombak, Kuala 
Lumpur 
Branch (EO1) 
 
Fagraea fragrans 
(Roxburgh, 1824) 
Prof. Dr. Ong Hean 
Chooi 
 
Jabatan 
Pergigian, 
Universiti 
Malaya 
Leaf & branch 
(FF1); fruit & 
flower (FF2) 
 
Ficus auriculata 
(Loureiro, 1790) 
 
Prof. Dr. Ong Hean 
Chooi 
Pantai Dalam, 
Kuala Lumpur 
Leaf (FA1) 
 
Garcinia atroviridis 
(Hooker, 1875) 
 
Prof. Dr. Ong Hean 
Chooi 
Pantai Dalam, 
Kuala Lumpur 
Branch (GA1) 
 
Garcinia mangostana 
(Linnaeus, 1753a) 
 
Prof. Dr. Ong Hean 
Chooi 
Pantai Dalam, 
Kuala Lumpur 
Branch (GM1); 
leaf (GM2) 
Hibiscus tiliaceus 
(Linnaeus, 1753b) 
Prof. Dr. Ong Hean 
Chooi 
Kerinchi, Kuala 
Lumpur 
Leaf (HT1) 
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Table 7.1, continued 
Plant sample Authenticated by Place of 
collection  
Parts used  
(reference 
number) 
 
Ipomoea aquatica 
(Forsskåll, 1775) 
 
Prof. Dr. Ong Hean 
Chooi 
Pantai Dalam, 
Kuala Lumpur 
Leaf (IA1) 
 
Justicia gendarussa 
(Burman, 1768) 
Prof. Dr. Ong Hean 
Chooi 
 
Pantai Dalam, 
Kuala Lumpur 
Branch (JG1) 
 
Lagerstroemia speciosa 
(Persoon, 1806) 
Prof. Dr. Ong Hean 
Chooi 
 
Jabatan 
Pergigian, 
Universiti 
Malaya 
Fruit (LS1); leaf 
(LS2) 
Lawsonia inermis 
(Linnaeus, 1753a) 
Prof. Dr. Ong Hean 
Chooi 
 
Pantai Dalam, 
Kuala Lumpur 
Branch (LI1) 
Leptospermum flavescens 
(Smith, 1797) 
Prof. Dr. Ong Hean 
Chooi 
 
Genting 
Highlands, 
Pahang 
Leaf (LF1); 
branch (LF2) 
Macaranga conifera 
(Müller Argoviensis, 
1866) 
 
Prof. Dr. Ong Hean 
Chooi 
 
Bukit Universiti 
Malaya 
Branch (MC1) 
Melaleuca cajuputi 
(Roxburgh, 1814) 
Prof. Dr. Ong Hean 
Chooi 
 
Pantai Dalam, 
Kuala Lumpur 
Fruit & flower 
(MeC1) 
Moringa oleifera 
(Lamarck and Poiret, 
1785) 
 
Prof. Dr. Ong Hean 
Chooi 
 
Kebun ISB, 
Universiti 
Malaya 
Branch (MO1) 
Orthosiphon stamineus 
(Wallich, 1830) 
Prof. Dr. Ong Hean 
Chooi 
 
Pantai Dalam, 
Kuala Lumpur 
Leaf (OS1) 
Oxalis barrelieri 
(Linnaeus, 1762) 
Prof. Dr. Ong Hean 
Chooi 
 
Jabatan Kimia, 
Universiti 
Malaya 
Root (OB1) 
Peltophorum pterocarpum 
(Heyne, 1927) 
Prof. Dr. Ong Hean 
Chooi 
 
Pusat Sukan, 
Universiti 
Malaya 
Fruit (PP1); leaf 
(PP2) 
Pereskia bleo (Candolle, 
1828) 
Prof. Dr. Ong Hean 
Chooi 
 
Kebun ISB, 
Universiti 
Malaya 
Fruit (PB1) 
Piper nigrum  
(Linnaeus, 1753a) 
Prof. Dr. Ong Hean 
Chooi 
 
Rimba Ilmu, 
Universiti 
Malaya 
Leaf (PN1); 
branch (PN2); 
fruit (PN3) 
 
Scoparia dulcis 
(Linnaeus, 1753a) 
Prof. Dr. Ong Hean 
Chooi 
 
Sementa, Kuala 
Selangor 
Root (SD1) 
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Table 7.1, continued 
Plant sample Authenticated by Place of 
collection  
Parts used  
(reference 
number) 
 
Strobilanthes crispa 
(Blume, 1826b) 
Prof. Dr. Ong Hean 
Chooi 
 
Rimba Ilmu, 
Universiti 
Malaya 
Branch (SC1) 
Tetracera indica  
(Merrill, 1917) 
Prof. Dr. Ong Hean 
Chooi 
 
Pantai Dalam, 
Kuala Lumpur 
Fruit (TI1) 
Vitex sp. 
(Linnaeus, 1753b) 
Prof. Dr. Ong Hean 
Chooi 
 
Pantai Dalam, 
Kuala Lumpur 
Branch (V1); 
leaf (V2) 
Vitex trifolia ‘purpurea’ 
(Linnaeus, 1753b) 
Prof. Dr. Ong Hean 
Chooi 
 
Pantai Dalam, 
Kuala Lumpur 
Branch (VT1); 
leaf (VT2) 
 
 
APPENDIX II: PREPARATION OF MEDIA, DILUENTS, BUFFERS AND 
SOLUTIONS 
BASIC RPMI 1640 MEDIUM 
To prepare 1 L of basic RPMI 1640 medium, 10.4 g of RPMI 1640 powder 
(with L-glutamine, without sodium bicarbonate), 2 g of sodium bicarbonate and 0.5206 
g of HEPES were dissolved in 1 L of autoclaved distilled water and mixed well. pH of 
the medium was then adjusted to pH 7.4 with either sodium hydroxide or hydrochloric 
acid. The basic medium was then filtered and kept at 4°C for further use.  
 
10% SUPPLEMENTED RPMI 1640 MEDIUM 
To prepare 100 mL of 10% supplemented RPMI 1640 medium, 90 mL of basic 
RPMI 1640 medium, 10 mL of heat-inactivated FBS, 1 mL of amphotericin B and 2 mL 
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of penicillin/streptomycin were mixed together. The mixture was then filtered and kept 
at 4°C. 
 
20% SUPPLEMENTED RPMI 1640 MEDIUM 
20% supplemented RPMI 1640 medium was prepared by added in 5 mL of heat-
inactivated FBS into 50 mL of 10% supplemented RPMI 1640 medium. It was then 
filtered sterilized and kept at 4°C.  
 
FREEZING MEDIUM 
To prepare 10 mL of freezing medium, 4 mL of basic RPMI 1640 medium, 5 
mL of heat-inactivated FBS and 1 mL of DMSO were mixed and filtered sterilized. The 
freezing medium was kept in 4°C prior to use. 
 
PHOSPHATE BUFFERED SALINE (PBS), pH 7.4 
To prepare 1 L of 0.01M PBS (with 0.138M of NaCl; 0.0027M of KCl), one 
pouch of PBS powder was dissolved in 1 L of autoclaved distilled water and mixed well. 
pH of the solution was not adjusted. The solution was then filtered and autoclaved. 
Autoclaved PBS was kept at room temperature. 
 
0.4% (w/v) TRYPAN BLUE 
To prepare 50 mL of 0.4% trypan blue, 0.2 g of trypan blue is weighed and 
dissolved in 50 mL of distilled water. 
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25 mM SODIUM PHOSPHATE BUFFER, pH 7.4 
To prepare 1 L of eluting buffer, 25 mM sodium phosphate buffer, 3 g of 
NaH2PO4 was dissolved in approximately 900 mL of distilled water. pH of the solution 
was adjusted to pH 7.4 at 20°C and the volume was topped up to 1 L. 
 
10 mM REDUCED GLUTATHIONE IN 25mM SODIUM PHOSPHATE BUFFER, 
pH 7.4 
To prepare 100 mL of 10 mM reduced glutathione in 25 mM sodium phosphate 
buffer, pH 7.4, 0.307 g of reduced glutathione was dissolved in approximately 90 mL of 
25 mM sodium phosphate buffer. pH of the solution was adjusted to pH 7.4 and the 
volume was then made up to 100 mL. 
 
0.1 M SODIUM PHOSPHATE BUFFER, pH 6.5 (BUFFER A) 
To prepare 1 L of buffer A, 12 g of NaH2PO4 was dissolved in approximately 
900 mL of distilled water. The pH of the solution was adjusted to pH 6.5 and volume 
was then topped up to 1 L. 
 
60 mM REDUCED GLUTATHIONE, pH 7.4 
0.0184 g of reduced glutathione was weighed and dissolved in 1 mL of buffer A. 
The solution was made freshly and kept at 4°C. 
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60 mM 1-CHLORO-2,4-DINITROBENZENE (CDNB) 
0.2430 g of 1-chloro-2,4-dinitrobenzene was weighed and dissolved in 20 mL of 
ethanol. The solution was kept in dark to avoid the exposure to light. 
 
10% (w/v) SODIUM DODECYL SULFATE (SDS) SOLUTION 
10% SDS solution was prepared by dissolved 10 g of SDS in 100 mL of de-
ionized water. 
 
10% (w/v) AMMONIUM PERSULFATE (APS) SOLUTION 
10% APS solution was prepared freshly by dissolved 100 mg of APS in 1 mL of 
de-ionized water. 
 
 SDS RUNNING BUFFER, pH 8.3 
To prepare 1 L of SDS running buffer, 3.03 g of Tris base, 14.40 g of glycine 
and 1.0 g of SDS were dissolved in 1 L of de-ionized water. The solution was kept at 
4°C prior to use. 
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SAMPLE BUFFER (SDS REDUCING BUFFER) 
Sample buffer was prepared as shown in Table 7.2.  
Table 7.2 : Sample buffer formulation 
Solution Volume (mL) 
De-ionized water 3.55 
0.5 M Tris-HCl, pH 6.8 1.25 
Glycerol 2.50 
10% (w/v) SDS 2.00 
0.5% (w/v) Bromophenol blue 0.20 
The sample buffer was stored at room temperature. 
 
4% STACKING: 12% RESOLVING GEL MONOMER SOLUTIONS 
Table 7.3 : Gel formulation 
Solution Stacking gel 
(4% acrylamide) 
Resolving gel 
(12% acrylamide) 
De-ionized water 6.1 mL 3.4 mL 
30% Acrylamide/Bis 1.3 mL 4.0 mL 
1.5 M Tris-HCl, pH 8.8 - 2.5 mL 
0.5 M Tris-HCl, pH 6.8 2.5 mL - 
10% (w/v) SDS 0.1 mL 0.1 mL 
10% (w/v) APS 50.0 µL 50.0 µL 
TEMED 10.0 µL 5.0 µL 
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COLLOIDAL COOMASSIE BLUE SOLUTION 
Table 7.4 : Colloidal coomassie blue formulation 
Component Amount 
5% (w/v) brilliant blue G-250 20 mL 
Ammonium sulfate, (NH4)2SO4 100 g 
Ortho-phosphoric acid, H3PO4 11.8 mL 
Distilled water ~ 960 mL 
 
5% brilliant blue G-250 solution was prepared by dissolved 1 g of brilliant blue 
G-250 in 20 mL of distilled water. To prepare 1 L of colloidal coomassie blue solution, 
100 g of (NH4)2SO4 was dissolved in 500 mL of distilled water. 11.8 mL of H3PO4 was 
then added into the (NH4)2SO4 solution, followed by 5% brilliant blue solution added 
gradually into the mixture. The mixture was then topped up to 1 L with distilled water. 
 
10% ACETONITRILE (ACN) 
10% ACN was prepared by the dilution of 10 mL of 100% ACN with 90 mL of 
de-ionized water. 
 
50% ACETONITRILE (ACN) 
50% ACN was prepared by the dilution of 50 mL of 100% ACN with 50 mL of 
de-ionized water. 
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40 mM AMMONIUM BICARBONATE, (NH4)HCO3,  IN 10% ACN 
To prepare 5 mL of 40 mM (NH4)HCO3 in 10% ACN, 0.0158 g of (NH4)HCO3 
was dissolved in 5 mL of 10% ACN. 
 
200 mM AMMONIUM BICARBONATE, (NH4)HCO3, IN 50% ACN 
To prepare 100 mL of 200 mM (NH4)HCO3 in 50% ACN, 1.58 g of (NH4)HCO3 
was dissolved in 100 mL of 50% ACN. 
 
0.1% TRIFLUOROACETIC ACID (TFA) 
To prepare 10 mL of 0.1% TFA, 0.01 mL of 100% TFA was diluted with 9.99 
mL of de-ionized water. 
 
20 mg/mL OF α-CYANO-4-HYDROXYCINNAMIC ACID (CHCA) IN 0.1% TFA: 50% 
ACN SOLUTION (1: 1) (CHCA MATRIX SOLUTION) 
To prepare 10 mL of matrix solution, 200 mg of CHCA was dissolved in 10 mL 
of 0.1%TFA: 50% ACN solution (5 mL of 0.1% TFA: 5 mL of 50% ACN). 
 
2 mg/mL OF α-CYANO-4-HYDROXYCINNAMIC ACID (CHCA) IN ACN 
(DILUTED CHCA MATRIX SOLUTION) 
Diluted CHCA matrix solution was prepared by dissolving 4 mg of CHCA in 2 
mL of 100% ACN. 
164 
 
IEF ANODE BUFFER 
To prepare 1 L of 1X anode buffer, 20 mL of 50X anode buffer is added to 980 
mL of de-ionized water. 
 
IEF CATHODE BUFFER 
To prepare 200 mL of cathode buffer, 20 mL of 10X cathode buffer pH 3-10 is 
added to 180 mL of de-ionized water. 
 
FIXING SOLUTION 
To prepare 1 L of fixing solution, 120 mL of glacial acetic acid is added to 500 
mL of methanol and 475 μL of formaldehyde. The final volume was brought up to 1 L 
with de-ionized water. 
 
WASHING SOLUTION 
To make 1 L of washing solution, 350 mL of ethanol is added to 650 mL of de-
ionized water. 
 
SENSITIZING SOLUTION 
To prepare 1 L of sensitizing solution, 250 mg of sodium thiosulfate (Na2S2O3) 
was added to small volume of de-ionized water, mixed well and brought up to the final 
volume of 1 L with de-ionized water. 
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STAINING SOLUTION 
To prepare 1 L of staining solution, 2 g of silver nitrate (AgNO3) and 720 μL of 
formaldehyde were added to a small volume of de-ionized water. Mixed well and 
brought up to 1 L with de-ionized water. 
 
DEVELOPING SOLUTION 
To make 1 L of developing solution, 60 g of sodium carbonate (Na2CO3) and 
473 μL of formaldehyde were added to 20 mL of sensitizing solution. Mixed well and 
the final volume was brought up to 1 L with de-ionized water. 
 
TERMINATING SOLUTION 
To prepare 1 L of terminating solution, 120 mL of glacial acetic acid was added 
to 500 mL of methanol. The final volume was brought up to 1 L with de-ionized water.  
 
PRESERVATION SOLUTION 
To make 1 L of preservation solution, 10 mL of glacial acetic acid was added to 
990 mL of de-ionized water. 
 
12% TRICHLOROACETIC ACID 
To prepare 100 mL of 12% trichloroacetic acid, 12 g of trichloroacetic acid was 
dissolved in 100 mL of de-ionized water. 
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2% ACETIC ACID 
To prepare 1 L of 2% acetic acid, 20 mL of glacial acetic acid was added to 980 
mL of de-ionized water. 
 
50% METHANOL 2% ACETIC ACID 
To prepare 1 L of 50% methanol 2% acetic acid, 500 mL of methanol was added 
to 20 mL of glacial acetic acid and brought up to 1 L with de-ionized water. 
 
DILUENT X, DILUENT Y AND DILUENT Z 
Basically, the diluents are tissue culture media with or without addition of 
DMSO. Diluent X is 10% supplemented Eagle Minimum Essential Medium (EMEM) 
prepared by EMEM containing L-glutamine, sodium bicarbonate, sodium pyruvate and 
HEPES, supplemented with 10% heat-inactivated FBS, 2% penicillin-streptomycin, 1% 
amphotericin B. Diluent Y was prepared by RPMI EMEM containing L-glutamine, 
sodium bicarbonate, sodium pyruvate and HEPES, supplemented with 10% heat-
inactivated FBS, 2% penicillin-streptomycin, 1% amphotericin B and 0.2% DMSO 
while Diluent Z was prepared by EMEM containing L-glutamine, sodium bicarbonate, 
sodium pyruvate and HEPES, supplemented with 10% heat-inactivated FBS, 2% 
penicillin-streptomycin, 1% amphotericin B and 0.4% DMSO. All of the diluents were 
kept at 4°C. 
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MTT REAGENT 
To prepared 1 mL of 5 mg/mL of MTT reagent, 5 mg of MTT was dissolved in 
1 mL of PBS and filtered. The reagent was kept in dark at 4°C. 
 
DILUENT A, DILUENT B AND DILUENT C 
The diluents are tissue culture media with or without addition of DMSO. Diluent 
A is 10% supplemented RPMI 1640 medium prepared by RPMI 1640 medium 
containing L-glutamine, sodium bicarbonate and HEPES, supplemented with 10% heat-
inactivated FBS, 2% penicillin-streptomycin, 1% amphotericin B. Diluent B was 
prepared by RPMI 1640 medium containing L-glutamine, sodium bicarbonate and 
HEPES, supplemented with 10% heat-inactivated FBS, 2% penicillin-streptomycin, 1% 
amphotericin B and 0.2% DMSO while Diluent C was prepared by RPMI 1640 medium 
containing L-glutamine, sodium bicarbonate and HEPES, supplemented with 10% heat-
inactivated FBS, 2% penicillin-streptomycin, 1% amphotericin B and 0.4% DMSO. All 
of the diluents were kept at 4°C. 
 
 
 
 
 
 
 
168 
 
APPENDIX III: TEMPLATES FOR CYTOTOXICITY ASSAYS 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B             
C             
D             
E             
F             
G             
H             
Figure 7.1 : Template of serial dilution of sample used in cytotoxicity assays. 
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Sample 1 
 
Sample 2 
 
Sample 3 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
B
la
n
k
 
100 μg/mL 
B
la
n
k
 
100 μg/mL 
B
la
n
k
 
100 μg/mL 
B 50 μg/mL 50 μg/mL 50 μg/mL 
C 25 μg/mL 25 μg/mL 25 μg/mL 
D 12.5 μg/mL 12.5 μg/mL 12.5 μg/mL 
E 6.25 μg/mL 6.25 μg/mL 6.25 μg/mL 
F 3.13 μg/mL 3.13 μg/mL 3.13 μg/mL 
G 1.56 μg/mL 1.56 μg/mL 1.56 μg/mL 
H Negative control Negative control Negative control 
Figure 7.2 : Template of a 96-well microplate used for cytotoxicity assays with cells 
treated with plant samples (ethanolic extract/fraction) in a series of 
concentration (μg/mL), with final DMSO concentration of 0.2%. 
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Ethacrynic acid 
 
Cisplatin 
 
Doxorubicin 
hydrochloride 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
B
la
n
k
 
100 μg/mL 
B
la
n
k
 
10 μg/mL 
B
la
n
k
 
10 μg/mL 
B 50 μg/mL 5 μg/mL 5 μg/mL 
C 25 μg/mL 2.5 μg/mL 2.5 μg/mL 
D 12.5 μg/mL 1.25 μg/mL 1.25 μg/mL 
E 6.25 μg/mL 0.625 μg/mL 0.625 μg/mL 
F 3.13 μg/mL 0.313 μg/mL 0.313 μg/mL 
G 1.56 μg/mL 0.156 μg/mL 0.156 μg/mL 
H Negative control Negative 
control 
Negative control 
Figure 7.3 : Template of a 96-well microplate used for cytotoxicity assays with cells 
treated with drugs in a series of concentrations (μg/mL), with final DMSO 
concentration of 0.2%.  
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 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B             
C             
D             
E             
F             
G             
H             
Figure 7.4 : Template of serial dilution of drugs used in combination assay. 
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Doxo + Plant 
sample  
 
Doxo + EA 
 
Doxo only 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
B
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n
k
 
10 μg/mL + 50 
μg/mL sample 
B
la
n
k
 
10 μg/mL  + 10 
μg/mL EA 
B
la
n
k
 
10 μg/mL 
B 5 μg/mL + 50 
μg/mL sample 
5 μg/mL + 10 
μg/mL EA 
5 μg/mL 
C 2.5 μg/mL + 50 
μg/mL sample 
2.5 μg/mL + 10 
μg/mL EA 
2.5 μg/mL 
D 1.25 μg/mL + 
50 μg/mL 
sample 
1.25 μg/mL + 
10 μg/mL EA 
1.25 μg/mL 
E 0.625 μg/mL + 
50 μg/mL 
sample 
0.625 μg/mL + 
10 μg/mL EA 
0.625 μg/mL 
F 0.313 μg/mL + 
50 μg/mL 
sample 
0.313 μg/mL + 
10 μg/mL EA 
0.313 μg/mL 
G 0.156 μg/mL + 
50 μg/mL 
sample 
0.156 μg/mL + 
10 μg/mL EA 
0.156 μg/mL 
H Negative control Negative control Negative control 
Figure 7.5 : Template of a 96-well microplate used for combination assay with HT-29 
cells treated with doxorubicin hydrochloride (Doxo) in a series of 
concentrations (μg/mL) with fixed concentration of plant sample 
(ethanolic extract/fraction) or ethacrynic acid (EA). Final concentration of 
DMSO was maintained at 0.2%.  
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Cisplatin + Plant 
sample 
 
Cisplatin + EA 
 
Cisplatin only 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
B
la
n
k
 
10 μg/mL + 50 
μg/mL sample 
B
la
n
k
 
10 μg/mL + 10 
μg/mL EA 
B
la
n
k
 
10 μg/mL 
B 5 μg/mL + 50 
μg/mL sample 
5 μg/mL + 10 
μg/mL EA 
5 μg/mL 
C 2.5 μg/mL + 50 
μg/mL sample 
2.5 μg/mL + 10 
μg/mL EA 
2.5 μg/mL 
D 1.25 μg/mL + 
50 μg/mL 
sample 
1.25 μg/mL + 
10 μg/mL EA 
1.25 μg/mL 
E 0.625 μg/mL + 
50 μg/mL 
sample 
0.625 μg/mL + 
10 μg/mL EA 
0.625 μg/mL 
F 0.313 μg/mL + 
50 μg/mL 
sample 
0.313 μg/mL + 
10 μg/mL EA 
0.313 μg/mL 
G 0.156 μg/mL + 
50 μg/mL 
sample 
0.156 μg/mL + 
10 μg/mL EA 
0.156 μg/mL 
H Negative control Negative control Negative control 
Figure 7.6 : Template of a 96-well microplate used for combination assay with HT-29 
cells treated with cisplatin in a series of concentrations (μg/mL) with fixed 
concentration of plant sample (ethanolic extract/fraction) or ethacrynic 
acid (EA). Final concentration of DMSO was maintained at 0.2%.  
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APPENDIX IV: SOURCE OF DATA 
GST-P IDENTIFICATION WITH MALDI-TOF 
 Mascot Search Results 
 
Protein View 
Match to: GSTP1_HUMAN Score: 184 Expect: 1e-013 
Glutathione S-transferase P (EC 2.5.1.18) (GST class-pi) (GSTP1-1) - 
Homo sapiens (Human) 
 
Nominal mass (Mr): 23341; Calculated pI value: 5.43 
NCBI BLAST search of GSTP1_HUMAN against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Homo sapiens 
 
Variable modifications: Carbamidomethyl (C),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 21% 
 
Matched peptides shown in Bold Red 
 
     1 MPPYTVVYFP VRGRCAALRM LLADQGQSWK EEVVTVETWQ EGSLKASCLY  
    51 GQLPKFQDGD LTLYQSNTIL RHLGRTLGLY GKDQQEAALV DMVNDGVEDL  
   101 RCKYISLIYT NYEAGKDDYV KALPGQLKPF ETLLSQNQGG KTFIVGDQIS  
   151 FADYNLLDLL LIHEVLAPGC LDAFPLLSAY VGRLSARPKL KAFLASPEYV  
   201 NLPINGNGKQ  
Show predicted peptides also
 
Sort Peptides By
  Residue Number  Increasing Mass  Decreasing 
Mass  
 Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
     2 - 12     1337.71  1336.70  1336.72    -0.01     0  
M.PPYTVVYFPVR.G  (Ions score 59) 
     2 - 12     1337.71  1336.70  1336.72    -0.01     0  
M.PPYTVVYFPVR.G  (No match) 
    56 - 71     1883.91  1882.90  1882.94    -0.04     0  
K.FQDGDLTLYQSNTILR.H  (Ions score 72) 
    56 - 71     1883.91  1882.90  1882.94    -0.04     0  
K.FQDGDLTLYQSNTILR.H  (No match) 
    83 - 101    2116.94  2115.93  2115.97    -0.05     0  
K.DQQEAALVDMVNDGVEDLR.C  (Ions score 21) 
    83 - 101    2116.94  2115.93  2115.97    -0.05     0  
K.DQQEAALVDMVNDGVEDLR.C  (No match) 
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with 
RT   glutathione and various inhibitors at high resolution."; 
RL   J. Mol. Biol. 274:84-100(1997). 
RN   [21] 
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS). 
RX   MEDLINE=98035452; PubMed=9351803; DOI=10.1016/S0969-
2126(97)00281-5; 
RA   Prade L., Huber R., Manoharan T.H., Fahl W.E., Reuter W.; 
RT   "Structures of class pi glutathione S-transferase from human 
placenta 
RT   in complex with substrate, transition-state analogue and 
inhibitor."; 
RL   Structure 5:1287-1295(1997). 
RN   [22] 
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS). 
RX   MEDLINE=99371665; PubMed=10441116; DOI=10.1021/bi990668u; 
RA   Ji X., Blaszczyk J., Xiao B., O'Donnell R., Hu X., Herzog C., 
RA   Singh S.V., Zimniak P.; 
RT   "Structure and function of residue 104 and water molecules in the 
RT   xenobiotic substrate-binding site in human glutathione S-
transferase 
RT   P1-1."; 
RL   Biochemistry 38:10231-10238(1999). 
RN   [23] 
RP   STRUCTURE BY NMR. 
RX   MEDLINE=98153187; PubMed=9485454; DOI=10.1021/bi971902o; 
RA   Nicotra M., Paci M., Sette M., Oakley A.J., Parker M.W., Lo Bello 
M., 
RA   Caccuri A.M., Federici G., Ricci G.; 
RT   "Solution structure of glutathione bound to human glutathione 
RT   transferase P1-1: comparison of NMR measurements with the crystal 
RT   structure."; 
RL   Biochemistry 37:3020-3027(1998). 
RN   [24] 
RP   MUTAGENESIS. 
RX   MEDLINE=93165656; PubMed=8433974; DOI=10.1093/protein/6.1.93; 
RA   Kong K.-H., Inoue H., Takahashi K.; 
RT   "Site-directed mutagenesis study on the roles of evolutionally 
RT   conserved aspartic acid residues in human glutathione S-
transferase 
RT   P1-1."; 
RL   Protein Eng. 6:93-99(1993). 
CC   -!- FUNCTION: Conjugation of reduced glutathione to a wide number 
of 
CC       exogenous and endogenous hydrophobic electrophiles. 
CC   -!- CATALYTIC ACTIVITY: RX + glutathione = HX + R-S-glutathione. 
CC   -!- SUBUNIT: Homodimer. 
CC   -!- INTERACTION: 
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CC       Q99683:MAP3K5; NbExp=1; IntAct=EBI-353467, EBI-476263; 
CC       Q16539:MAPK14; NbExp=1; IntAct=EBI-353467, EBI-73946; 
CC       Q12933:TRAF2; NbExp=3; IntAct=EBI-353467, EBI-355744; 
CC   -!- SIMILARITY: Belongs to the GST superfamily. Pi family. 
CC   -!- WEB RESOURCE: NAME=SHMPD; 
CC       NOTE=The Singapore human mutation and polymorphism database; 
CC       URL="http://shmpd.bii.a-
star.edu.sg/gene.php?genestart=A&genename=GSTP1". 
CC   -----------------------------------------------------------------
------ 
CC   Copyrighted by the UniProt Consortium, see 
http://www.uniprot.org/terms 
CC   Distributed under the Creative Commons Attribution-NoDerivs 
License 
CC   -----------------------------------------------------------------
------ 
DR   EMBL; X06547; CAA29794.1; -; mRNA. 
DR   EMBL; M24485; AAA56823.1; -; Genomic_DNA. 
DR   EMBL; X08058; CAA30847.1; -; Genomic_DNA. 
DR   EMBL; X08094; CAA30894.1; -; Genomic_DNA. 
DR   EMBL; X08095; CAA30894.1; JOINED; Genomic_DNA. 
DR   EMBL; X08096; CAA30894.1; JOINED; Genomic_DNA. 
DR   EMBL; X15480; CAA33508.1; -; mRNA. 
DR   EMBL; U12472; AAA64919.1; -; Genomic_DNA. 
DR   EMBL; U30897; AAC51280.1; -; mRNA. 
DR   EMBL; U62589; AAC51237.1; -; mRNA. 
DR   EMBL; U21689; AAC13869.1; -; Genomic_DNA. 
DR   EMBL; BT019949; AAV38752.1; -; mRNA. 
DR   EMBL; BT019950; AAV38753.1; -; mRNA. 
DR   EMBL; CR450361; CAG29357.1; -; mRNA. 
DR   EMBL; AY324387; AAP72967.1; -; Genomic_DNA. 
DR   EMBL; BC010915; AAH10915.1; -; mRNA. 
DR   PIR; JS0153; A37378. 
DR   UniGene; Hs.523836; -. 
DR   PDB; 10GS; X-ray; A/B=1-210. 
DR   PDB; 11GS; X-ray; A/B=1-210. 
DR   PDB; 12GS; X-ray; A/B=1-210. 
DR   PDB; 13GS; X-ray; A/B=1-210. 
DR   PDB; 14GS; X-ray; A/B=1-210. 
DR   PDB; 16GS; X-ray; A/B=1-210. 
DR   PDB; 17GS; X-ray; A/B=1-210. 
DR   PDB; 18GS; X-ray; A/B=1-210. 
DR   PDB; 19GS; X-ray; A/B=1-210. 
DR   PDB; 1AQV; X-ray; A/B=1-210. 
DR   PDB; 1AQW; X-ray; A/B/C/D=1-210. 
DR   PDB; 1AQX; X-ray; A/B/C/D=1-210. 
DR   PDB; 1EOG; X-ray; A/B=3-210. 
DR   PDB; 1EOH; X-ray; A/B/C/D/E/F/G/H=1-210. 
DR   PDB; 1GSS; X-ray; A/B=1-210. 
DR   PDB; 1KBN; X-ray; A/B=1-210. 
DR   PDB; 1LBK; X-ray; A/B=-. 
DR   PDB; 1MD3; X-ray; A/B=1-210. 
DR   PDB; 1MD4; X-ray; A/B=1-210. 
DR   PDB; 1PGT; X-ray; A/B=1-210. 
DR   PDB; 1PX6; X-ray; A/B=1-210. 
DR   PDB; 1PX7; X-ray; A/B=1-210. 
DR   PDB; 1ZGN; X-ray; A/B=1-210. 
DR   PDB; 20GS; X-ray; A/B=1-210. 
DR   PDB; 21GS; X-ray; A/B=1-210. 
DR   PDB; 22GS; X-ray; A/B=1-210. 
DR   PDB; 2A2R; X-ray; A/B=1-210. 
DR   PDB; 2A2S; X-ray; A/B=1-210. 
DR   PDB; 2GSS; X-ray; A/B=1-210. 
DR   PDB; 2J9H; X-ray; A/B=-. 
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DR   PDB; 2PGT; X-ray; A/B=1-210. 
DR   PDB; 3GSS; X-ray; A/B=1-210. 
DR   PDB; 3PGT; X-ray; A/B=1-210. 
DR   PDB; 4GSS; X-ray; A/B=1-210. 
DR   PDB; 4PGT; X-ray; A/B=1-210. 
DR   PDB; 5GSS; X-ray; A/B=1-210. 
DR   PDB; 6GSS; X-ray; A/B=1-210. 
DR   PDB; 7GSS; X-ray; A/B=1-210. 
DR   PDB; 8GSS; X-ray; A/B/C=1-210. 
DR   PDB; 9GSS; X-ray; A/B=1-210. 
DR   IntAct; P09211; -. 
DR   SWISS-2DPAGE; P09211; HUMAN. 
DR   Aarhus/Ghent-2DPAGE; 5101; IEF. 
DR   Cornea-2DPAGE; P09211; HUMAN. 
DR   DOSAC-COBS-2DPAGE; P09211; HUMAN. 
DR   HSC-2DPAGE; P09211; HUMAN. 
DR   OGP; P09211; -. 
DR   PHCI-2DPAGE; P09211; -. 
DR   REPRODUCTION-2DPAGE; P09211; HUMAN. 
DR   Siena-2DPAGE; P09211; -. 
DR   Ensembl; ENSG00000084207; Homo sapiens. 
DR   KEGG; hsa:2950; -. 
DR   H-InvDB; HIX0009866; -. 
DR   HGNC; HGNC:4638; GSTP1. 
DR   MIM; 134660; gene. 
DR   Reactome; REACT_2063.3; Xenobiotic metabolism. 
DR   DrugBank; APRD00253; Clomipramine. 
DR   LinkHub; P09211; -. 
DR   ArrayExpress; P09211; -. 
DR   GermOnline; ENSG00000084207; Homo sapiens. 
DR   RZPD-ProtExp; IOH12222; -. 
DR   RZPD-ProtExp; L0008; -. 
DR   RZPD-ProtExp; RZPDo834C083; -. 
DR   RZPD-ProtExp; RZPDo839D0264; -. 
DR   RZPD-ProtExp; RZPDo839D0274; -. 
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB. 
DR   GO; GO:0005515; F:protein binding; IPI:IntAct. 
DR   GO; GO:0006916; P:anti-apoptosis; TAS:UniProtKB. 
DR   GO; GO:0007417; P:central nervous system development; TAS:ProtInc. 
DR   InterPro; IPR004046; GST_C. 
DR   InterPro; IPR010987; GST_C_like. 
DR   InterPro; IPR004045; GST_N. 
DR   InterPro; IPR003082; GST_pi. 
DR   InterPro; IPR012336; Thiordxn-like_fd. 
DR   InterPro; IPR012335; Thioredoxin_fold. 
DR   Gene3D; G3DSA:3.40.30.10; Thioredoxin_fold; 1. 
DR   Pfam; PF00043; GST_C; 1. 
DR   Pfam; PF02798; GST_N; 1. 
DR   PRINTS; PR01268; GSTRNSFRASEP. 
KW   3D-structure; Direct protein sequencing; Polymorphism; 
Transferase. 
FT   INIT_MET      1      1       Removed. 
FT   CHAIN         2    210       Glutathione S-transferase P. 
FT                                /FTId=PRO_0000185900. 
FT   VARIANT     105    105       I -> V (in allele GSTP1*B and allele 
FT                                GSTP1*C; dbSNP:rs1695). 
FT                                /FTId=VAR_014499. 
FT   VARIANT     114    114       A -> V (in allele GSTP1*C; 
FT                                dbSNP:rs1138272). 
FT                                /FTId=VAR_014500. 
FT   CONFLICT    186    186       A -> P (in Ref. 2). 
FT   STRAND        3      7 
FT   HELIX        12     14 
FT   HELIX        15     23 
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FT   STRAND       28     32 
FT   HELIX        35     39 
FT   HELIX        42     46 
FT   STRAND       54     57 
FT   STRAND       60     64 
FT   HELIX        65     76 
FT   HELIX        83    109 
FT   HELIX       111    134 
FT   HELIX       137    139 
FT   STRAND      143    147 
FT   HELIX       150    165 
FT   TURN        167    172 
FT   HELIX       174    184 
FT   HELIX       187    194 
FT   HELIX       196    199 
SQ   SEQUENCE   210 AA;  23356 MW;  409E33FFAA338396 CRC64; 
     MPPYTVVYFP VRGRCAALRM LLADQGQSWK EEVVTVETWQ EGSLKASCLY GQLPKFQDGD 
     LTLYQSNTIL RHLGRTLGLY GKDQQEAALV DMVNDGVEDL RCKYISLIYT NYEAGKDDYV 
     KALPGQLKPF ETLLSQNQGG KTFIVGDQIS FADYNLLDLL LIHEVLAPGC LDAFPLLSAY 
     VGRLSARPKL KAFLASPEYV NLPINGNGKQ 
Mascot:  http://www.matrixscience.com/ 
 
 
 
 
 
 
 
 
 
 
 
 
 
182 
 
IC50 VALUE DETERMINATION WITH GST ACTIVITY ASSAYS 
Figure 7.7 shows effects of Anacardium occidentale (branch) ethanolic extract 
on GST-P activity. The extract was inhibited the enzyme in dose-dependent manner. At 
the extract concentrations of 0.2 and 0.4 mg/mL, GST-P activities were inhibited 54 and 
98% respectively. The IC50 value of A. occidentale (branch) ethanolic extract generated 
from the dose-response graph is 0.18 ± 0.006 mg/mL. Comparison of inhibition activity 
among concentrations using ANOVA indicates statistically significant difference with P 
= <0.001.  
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Figure 7.7 : Inhibitory effects of A. occidentale (branch) ethanolic extract on GST-P. 
Each bar represents the mean ± S.D. calculated from three independent 
determinations.  
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One Way Analysis of Variance  
 
Data source: Anacardium occidentale (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.154) 
 
Equal Variance Test: Passed (P = 0.526) 
 
Group Name N  Missing Mean Std Dev SEM  
0.4 4 1 92.473 2.988 1.725  
0.2 4 1 54.287 0.955 0.551  
0.1 4 1 29.043 4.237 2.446  
0.05 4 1 16.577 1.028 0.593  
0 4 1 0.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 15643.943 3910.986 677.909 <0.001  
Residual 10 57.692 5.769    
Total 14 15701.635     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 0.4 92.473 47.153 <0.001 Yes   
0 vs. 0.2 54.287 27.681 <0.001 Yes   
0 vs. 0.1 29.043 14.809 <0.001 Yes   
0 vs. 0.05 16.577  8.453 <0.001 Yes   
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Figure 7.8 shows effects of Andrographis paniculata (leaf) ethanolic extract on 
GST-P activity. GST-P activity was inhibited dose-dependently by the extract up to 
54%, at 0.4 mg/mL. The IC50 value of A. paniculata (leaf) ethanolic extract genenrated 
from the dose-response graph is 0.32 ± 0.021 mg/mL. Comparison of inhibition activity 
among concentrations using ANOVA indicates statistically significant difference with P 
= <0.001.  
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Figure 7.8 : Inhibitory effects of A. paniculata (leaf) ethanolic extract on GST-P. Each 
bar represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Andrographis paniculata (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.395) 
 
Equal Variance Test: Passed (P = 0.153) 
 
Group Name N  Missing Mean Std Dev SEM  
0.4 4 1 54.067 0.955 0.551  
0.2 4 1 44.443 1.097 0.633  
0.1 4 1 36.170 1.299 0.750  
0.05 4 1 11.670 1.529 0.883  
0 4 1 0.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 6177.623 1544.406 1257.748 <0.001  
Residual 10 12.279 1.228    
Total 14 6189.902     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 0.4 54.067 59.757 <0.001 Yes   
0 vs. 0.2 44.443 49.121 <0.001 Yes   
0 vs. 0.1 36.170 39.977 <0.001 Yes   
0 vs. 0.05 11.670 12.898 <0.001 Yes   
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Figure 7.9 shows effects of Cinnamomum zeylanicum (branch) ethanolic extract 
on GST-P activity. GST-P activity was inhibited in dose-dependent manner by the 
extract. Inhibition at the concentrations of 0.1, 0.2 and 0.4 mg/mL are higher than 50%, 
which is 66, 75 and 80% respectively. The IC50 value of C. zeylanicum (branch) 
ethanolic extract generated from the dose-response graph is 0.07 ± 0.006 mg/mL. 
Comparison of inhibition activity among concentrations using ANOVA indicates 
statistically significant difference with P = <0.001.  
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Figure 7.9 : Inhibitory effects of C. zeylanicum (branch) ethanolic extract on GST-P. 
Each bar represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Cinnamomum zeylanicum (branch) 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Failed (P < 0.050) 
 
Group Name N  Missing Mean Std Dev SEM  
0.4 4 1 79.540 0.930 0.537  
0.2 4 1 75.223 0.885 0.511  
0.1 4 1 65.543 0.647 0.373  
0.05 4 1 40.740 6.577 3.797  
0 4 1 0.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 12935.296 3233.824 356.793 <0.001  
Residual 10 90.636 9.064    
Total 14 13025.931     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 0.4 79.540 32.358 <0.001 Yes   
0 vs. 0.2 75.223 30.602 <0.001 Yes   
0 vs. 0.1 65.543 26.664 <0.001 Yes   
0 vs. 0.05 40.740 16.574 <0.001 Yes   
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Figure 7.10 shows effects of Euodia redlevi (fruit&flower) ethanolic extract on 
GST-P activity. GST-P activity was inhibited in dose-dependent manner by the extract. 
Inhibition at the concentrations of 0.2, 0.4 and 0.8 mg/mL are higher than 50%, which is 
52, 63 and 65% respectively. However, at concentration higher than 0.4 mg/mL, the 
inhibition seems to be not much different. The IC50 value of E. redleri (fruit&flower) 
ethanolic extract generated from the dose-response graph is 0.19 ± 0.031 mg/mL. 
Comparison of inhibition activity among concentrations using ANOVA indicates 
statistically significant difference with P = <0.001.  
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Figure 7.10 : Inhibitory effects of E. redleri (fruit&flower) ethanolic extract on GST-P. 
Each bar represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Euodia redlevi (fruit&flower) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.639) 
 
Equal Variance Test: Passed (P = 0.822) 
 
Group Name N  Missing Mean Std Dev SEM  
0.8 4 1 64.467 2.535 1.463  
0.4 4 1 62.780 3.945 2.277  
0.2 4 1 52.100 4.790 2.766  
0.1 4 1 26.827 3.518 2.031  
0 4 1 0.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 9089.613 2272.403 198.271 <0.001  
Residual 10 114.611 11.461    
Total 14 9204.223     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 0.8 64.467 23.322 <0.001 Yes   
0 vs. 0.4 62.780 22.712 <0.001 Yes   
0 vs. 0.2 52.100 18.848 <0.001 Yes   
0 vs. 0.1 26.827 9.705 <0.001 Yes   
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Figure 7.11 shows effects of Garcinia atroviridis (branch) ethanolic extract on 
GST-P activity. GST-P activity was dose-dependently inhibited by the extract up to 
93%, at 0.4 mg/mL. The inhibition at the concentrations of 0.05 and 0.1 mg/mL are 
lower than 50%, which is 21 and 39% respectively. However, at concentration of 0.2 
mg/mL, the inhibition observed was 60%. The IC50 value of G. atroviridis (branch) 
ethanolic extract generated from the dose-response graph is 0.16 ± 0.005 mg/mL. 
Comparison of inhibition activity among concentrations using ANOVA indicates 
statistically significant difference with P = <0.001.  
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Figure 7.11 : Inhibitory effects of G. atroviridis (branch) ethanolic extract on GST-P. 
Each bar represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Garcinia atroviridis (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.094) 
 
Equal Variance Test: Passed (P = 0.627) 
 
Group Name N  Missing Mean Std Dev SEM  
0.4 4 1 97.580 0.942 0.544  
0.2 4 1 57.987 1.593 0.920  
0.1 4 1 38.610 0.000 0.000  
0.05 4 1 20.513 2.002 1.156  
0 4 1 0.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 16732.439 4183.110 2813.436 <0.001  
Residual 10 14.868 1.487    
Total 14 16747.307     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 0.4 97.580 98.011 <0.001 Yes   
0 vs. 0.2 57.987 58.243 <0.001 Yes   
0 vs. 0.1 38.610 38.781 <0.001 Yes   
0 vs. 0.05 20.513 20.604 <0.001 Yes   
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Figure 7.12 shows effects of Garcinia mangostana (branch) ethanolic extract on 
GST-P activity. With the addition of this extract, GST-P activity was inhibited in dose-
dependent manner. The inhibition at the concentrations of 0.2 and 0.4 mg/mL are higher 
than 50%, which is 72 and 93% respectively. However, at concentration of 0.05 and 0.1 
mg/mL, the inhibition observed was only 36 and 43% respectively. The IC50 value of G. 
mangostana (branch) ethanolic extract generated from the dose-response graph is 0.12 ± 
0.002 mg/mL. Comparison of inhibition activity among concentrations using ANOVA 
indicates statistically significant difference with P = <0.001.  
 
 
0
10
20
30
40
50
60
70
80
90
100
0.40.20.10.05
P
er
ce
n
ta
g
e 
o
f 
in
h
ib
it
io
n
 o
n
 G
S
T
 
a
ct
iv
it
y
 (
%
)
Concentration (mg/mL)
 
Figure 7.12 : Inhibitory effects of G. mangostana (branch) ethanolic extract on GST-P. 
Each bar represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Garcinia mangostana (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.214) 
 
Equal Variance Test: Passed (P = 0.057) 
 
Group Name N  Missing Mean Std Dev SEM  
0.4 4 1 93.120 0.422 0.244  
0.2 4 1 72.090 0.930 0.537  
0.1 4 1 43.120 0.920 0.531  
0.05 4 1 36.100 0.636 0.367  
0 4 1 0.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 15244.926 3811.231 8306.956 <0.001  
Residual 10 4.588 0.459    
Total 14 15249.514     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 0.4 93.120 168.375 <0.001 Yes   
0 vs. 0.2 72.090 130.349 <0.001 Yes   
0 vs. 0.1 43.120 77.967 <0.001 Yes   
0 vs. 0.05 36.100 65.274 <0.001 Yes   
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Figure 7.13 shows effects of Garcinia mangostana (leaf) ethanolic extract on 
GST-P activity. With the addition of this extract, GST-P activity was inhibited in dose-
dependent manner. The inhibition at the concentrations of 0.2 and 0.4 mg/mL are higher 
than 50%, which is 67 and 77% respectively. However, at concentration of 0.05 and 0.1 
mg/mL, the inhibition observed was only 32 and 50% respectively. The IC50 value of G. 
mangostana (leaf) ethanolic extract generated from the dose-response graph is 0.11 ± 
0.006 mg/mL. Comparison of inhibition activity among concentrations using ANOVA 
indicates statistically significant difference with P = <0.001.  
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Figure 7.13 : Inhibitory effects of G. mangostana (leaf) ethanolic extract on GST-P. 
Each bar represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Garcinia mangostana (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.377) 
 
Equal Variance Test: Passed (P = 0.423) 
 
Group Name N  Missing Mean Std Dev SEM  
0.4 4 1 76.480 2.105 1.215  
0.2 4 1 66.803 2.054 1.186  
0.1 4 1 48.597 1.391 0.803  
0.05 4 1 32.370 0.312 0.180  
0 4 1 0.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 10991.148 2747.787 1286.108 <0.001  
Residual 10 21.365 2.137    
Total 14 11012.514     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 0.4 76.480 64.083 <0.001 Yes   
0 vs. 0.2 66.803 55.975 <0.001 Yes   
0 vs. 0.1 48.597 40.719 <0.001 Yes   
0 vs. 0.05 32.370 27.123 <0.001 Yes   
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Figure 7.14 shows effects of Hibiscus tiliaceus (leaf) ethanolic extract on GST-P 
activity. The extract inhibited GST-P activity in dose-dependent manner. Inhibition at 
the concentrations of 0.1, 0.2 and 0.4 mg/mL are higher than 50%, which is 50, 71 and 
79% respectively. However, the inhibition at 0.05 mg/mL was only 31%. The IC50 value 
of H. tiliaceus (leaf) ethanolic extract generated from the dose-response graph is 0.10 ± 
0.000 mg/mL. Comparison of inhibition activity among concentrations using ANOVA 
indicates statistically significant difference with P = <0.001. 
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Figure 7.14 : Inhibitory effects of H. tiliaceus (leaf) ethanolic extract on GST-P. Each 
bar represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Hibiscus tiliaceus (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.060) 
 
Equal Variance Test: Passed (P = 0.395) 
 
Group Name N  Missing Mean Std Dev SEM  
0.4 4 1 79.273 0.682 0.394  
0.2 4 1 70.870 1.873 1.082  
0.1 4 1 50.240 0.000 0.000  
0.05 4 1 31.330 1.720 0.993  
0 4 1 0.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 12222.693 3055.673 2203.388 <0.001  
Residual 10 13.868 1.387    
Total 14 12236.561     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 0.4 79.273 82.445 <0.001 Yes   
0 vs. 0.2 70.870 73.706 <0.001 Yes   
0 vs. 0.1 50.240 52.250 <0.001 Yes   
0 vs. 0.05 31.330 32.584 <0.001 Yes   
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Figure 7.15 shows effects of Lawsonia inermis (branch) ethanolic extract on 
GST-P activity. The extract inhibited GST-P activity in dose-dependent manner up to 
85%, at 1.6 mg/mL. Inhibition at the concentration of 0.8 mg/mL is 65%, while the 
inhibition at 0.2 and 0.4 mg/mL were lower than 50%, which are 23 and 46% 
respectively. The IC50 value of L. inermis (branch) ethanolic extract generated from the 
dose-response graph is 0.46 ± 0.042 mg/mL. Comparison of inhibition activity among 
concentrations using ANOVA indicates statistically significant difference with P = 
<0.001. 
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Figure 7.15 : Inhibitory effects of L. inermis (branch) ethanolic extract on GST-P. Each 
bar represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Lawsonia inermis (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.088) 
 
Equal Variance Test: Passed (P = 0.510) 
 
Group Name N  Missing Mean Std Dev SEM  
1.6 4 1 85.420 0.901 0.520  
0.8 4 1 65.320 0.779 0.450  
0.4 4 1 46.010 2.935 1.695  
0.2 4 1 23.477 2.930 1.691  
0 4 1 0.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 13594.188 3398.547 912.801 <0.001  
Residual 10 37.232 3.723    
Total 14 13631.420     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 1.6 85.420 54.218 <0.001 Yes   
0 vs. 0.8 65.320 41.460 <0.001 Yes   
0 vs. 0.4 46.010 29.204 <0.001 Yes   
0 vs. 0.2 23.477 14.901 <0.001 Yes   
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Figure 7.16 shows effects of Leptospermum flavescens (leaf) ethanolic extract 
on GST-P activity. The extract inhibited GST-P activity in dose-dependent manner. The 
inhibition at the concentrations of 0.1 and 0.2 mg/mL are higher than 50%, which is 53 
and 69% respectively. However, at concentration of 0.025 and 0.05 mg/mL, the 
inhibition observed was only 28 and 40% respectively. The IC50 value of L. flavescens 
(leaf) ethanolic extract generated from the dose-response graph is 0.09 ± 0.002 mg/mL. 
Comparison of inhibition activity among concentrations using ANOVA indicates 
statistically significant difference with P = <0.001. 
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Figure 7.16 : Inhibitory effects of L. flavescens (leaf) ethanolic extract on GST-P. Each 
bar represents the mean ± S.D. calculated from three independent 
determinations. 
 
 
 
201 
 
One Way Analysis of Variance  
 
Data source: Leptospermum flavescens (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 1.000) 
 
Group Name N  Missing Mean Std Dev SEM  
0.4 4 1 68.780 0.000 0.000  
0.1 4 1 53.117 0.525 0.303  
0.05 4 1 40.397 0.981 0.567  
0.025 4 1 27.620 4.641 2.680  
0 4 1 0.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 8200.247 2050.062 449.913 <0.001  
Residual 10 45.566 4.557    
Total 14 8245.813     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 0.4 68.780 39.463 <0.001 Yes   
0 vs. 0.1 53.117 30.476 <0.001 Yes   
0 vs. 0.05 40.397 23.178 <0.001 Yes   
0 vs. 0.025 27.620 15.847 <0.001 Yes   
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Figure 7.17 shows effects of Oxalis barrelieri (root) ethanolic extract on GST-P 
activity. The extract inhibited GST-P activity in dose-dependent manner. The inhibition 
at the concentrations of 0.2 and 0.4 mg/mL are higher than 50%, which is 62 and 76% 
respectively. However, at concentration of 0.05 and 0.1 mg/mL, the inhibition observed 
was only 33 and 38% respectively. The IC50 value of O. barrelieri (root) ethanolic 
extract generated from the dose-response graph is 0.15 ± 0.012 mg/mL. Comparison of 
inhibition activity among concentrations using ANOVA indicates statistically 
significant difference with P = <0.001. 
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Figure 7.17 : Inhibitory effects of O. barrelieri (root) ethanolic extract on GST-P. Each 
bar represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Oxalis barrelieri (root) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.547) 
 
Equal Variance Test: Passed (P = 0.228) 
 
Group Name N  Missing Mean Std Dev SEM  
0.4 4 1 76.233 2.330 1.345  
0.2 4 1 61.907 4.316 2.492  
0.1 4 1 37.653 1.415 0.817  
0.05 4 1 33.000 1.179 0.681  
0 4 1 0.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 10295.396 2573.849 468.837 <0.001  
Residual 10 54.899 5.490    
Total 14 10350.295     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 0.4 76.233 39.848 <0.001 Yes   
0 vs. 0.2 61.907 32.360 <0.001 Yes   
0 vs. 0.1 37.653 19.682 <0.001 Yes   
0 vs. 0.05 33.000 17.250 <0.001 Yes   
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Figure 7.18 shows effects of Peltophorum pterocarpum (leaf) ethanolic extract 
on GST-P activity. The extract inhibited GST-P activity in dose-dependent manner. The 
inhibition at the concentrations of 0.4 and 0.8 mg/mL are higher than 50%, which is 58 
and 98% respectively. However, at concentration of 0.1 and 0.2 mg/mL, the inhibition 
observed was only 11 and 45% respectively. The IC50 value of P. pterocarpum (leaf) 
ethanolic extract generated from the dose-response graph is 0.25 ± 0.025 mg/mL. 
Comparison of inhibition activity among concentrations using ANOVA indicates 
statistically significant difference with P = <0.001. 
 
 
0
10
20
30
40
50
60
70
80
90
100
0.80.40.20.1
P
er
ce
n
ta
g
e 
o
f 
in
h
ib
it
io
n
 o
n
 G
S
T
 
a
ct
iv
it
y
 (
%
)
Concentration (mg/mL)
 
Figure 7.18 : Inhibitory effects of P. pterocarpum (leaf) ethanolic extract on GST-P. 
Each bar represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Peltophorum pterocarpum (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.260) 
 
Equal Variance Test: Passed (P = 0.322) 
 
Group Name N  Missing Mean Std Dev SEM  
0.8 4 1 98.250 0.650 0.375  
0.4 4 1 58.177 0.543 0.313  
0.2 4 1 45.317 1.921 1.109  
0.1 4 1 11.303 1.735 1.002  
0 4 1 0.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 18423.529 4605.882 3105.159 <0.001  
Residual 10 14.833 1.483    
Total 14 18438.362     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 0.8 98.250 98.802 <0.001 Yes   
0 vs. 0.4 58.177 58.503 <0.001 Yes   
0 vs. 0.2 45.317 45.571 <0.001 Yes   
0 vs. 0.1 11.303 11.367 <0.001 Yes   
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Figure 7.19 shows effects of Tetracera indica (fruit) ethanolic extract on GST-P 
activity. The extract inhibited GST-P activity in dose-dependent manner. The inhibition 
at the concentrations of 0.2 and 0.4 mg/mL are higher than 50%, which is 63 and 79% 
respectively. However, at concentration of 0.05 and 0.1 mg/mL, the inhibition observed 
was only 34 and 46% respectively. The IC50 value of T. indica (fruit) ethanolic extract 
generated from the dose-response graph is 0.12 ± 0.006 mg/mL. Comparison of 
inhibition activity among concentrations using ANOVA indicates statistically 
significant difference with P = <0.001. 
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Figure 7.19 : Inhibitory effects of T. indica (fruit) ethanolic extract on GST-P. Each bar 
represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Tetracera indica (fruit) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.202) 
 
Equal Variance Test: Passed (P = 0.512) 
 
Group Name N  Missing Mean Std Dev SEM  
0.4 4 1 78.983 2.050 1.183  
0.2 4 1 63.363 2.270 1.311  
0.1 4 1 46.140 1.502 0.867  
0.05 4 1 33.890 0.485 0.280  
0 4 1 0.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 10921.303 2730.326 1152.273 <0.001  
Residual 10 23.695 2.370    
Total 14 10944.998     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 0.4 78.983 62.842 <0.001 Yes   
0 vs. 0.2 63.363 50.414 <0.001 Yes   
0 vs. 0.1 46.140 36.711 <0.001 Yes   
0 vs. 0.05 33.890 26.964 <0.001 Yes   
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Figure 7.20 shows effects of 50% methanol 2% acetic acid fraction of L. 
flavescens (leaf) ethanolic extract on GST-P activity. The fraction inhibited GST-P 
activity in dose-dependent manner. The inhibition at the concentrations of 0.2 and 0.4 
mg/mL are higher than 50%, which is 53 and 92% respectively. However, at 
concentration of 0.05 and 0.1 mg/mL, the inhibition observed was only 6 and 18% 
respectively. The IC50 value of 50% methanol 2% acetic acid fraction of L. flavescens 
(leaf) ethanolic extract generated from the dose-response graph is 0.19 ± 0.004 mg/mL. 
Comparison of inhibition activity among concentrations using ANOVA indicates 
statistically significant difference with P = <0.001. 
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Figure 7.20 : Inhibitory effects of 50% methanol 2% acetic acid fraction of L. flavescens 
(leaf) ethanolic extract on GST-P. Each bar represents the mean ± S.D. 
calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: 50% methanol 2% acetic acid fraction of L. flavescens (leaf) extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Failed (P < 0.050) 
 
Group Name N  Missing Mean Std Dev SEM  
0.4 4 1 91.933 6.004 3.467  
0.2 4 1 53.127 1.045 0.603  
0.1 4 1 17.447 1.201 0.693  
0.05 4 1 6.220 0.697 0.402  
0 4 1 0.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 17770.552 4442.638 568.509 <0.001  
Residual 10 78.145 7.815    
Total 14 17848.698     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 0.4 91.933 40.278 <0.001 Yes   
0 vs. 0.2 53.127 23.276 <0.001 Yes   
0 vs. 0.1 17.447 7.644 <0.001 Yes   
0 vs. 0.05 6.220 2.725 0.021 Yes   
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One Way Analysis of Variance  
 
Data source: Overall IC50 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 0.131) 
 
Group Name  N  Missing Mean Std Dev SEM  
Anacardium occidentale (branch 3 0 0.182 0.00624 0.00361  
Andrographis paniculata (leaf) 3 0 0.315 0.0210 0.0121  
Cinnamomum zeylanicum (bran 3 0 0.0650 0.00624 0.00361  
Euodia redlevi (fruit&flower) 3 0 0.194 0.0309 0.0179  
Garcinia atroviridis (branch) 3 0 0.159 0.00458 0.00265  
Garcinia mangostana (branch) 3 0 0.124 0.00200 0.00115  
Garcinia mangostana (leaf) 3 0 0.107 0.00608 0.00351  
Hibiscus tiliaceus (leaf) 3 0 0.0990 0.000 0.000  
Lawsonia inermis (branch) 3 0 0.460 0.0418 0.0241  
Leptospermum flavescens (leaf) 3 0 0.0843 0.00153 0.000882  
Oxalis barrelieri (root) 3 0 0.146 0.0122 0.00702  
Peltophorum pterocarpum (leaf) 3 0 0.253 0.0252 0.0146  
Tetracera indica (fruit) 3 0 0.122 0.00603 0.00348  
50% MeOH 2% acetic acid fracti3 0 0.189 0.00416 0.00240  
0 3 0 0.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 14 0.524 0.0374 136.123 <0.001  
Residual 30 0.00824 0.000275    
Total 44 0.532     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050 
  
0 vs. Lawsonia ine 0.460 34.016 <0.001 Yes   
0 vs. Andrographis 0.315 23.277 <0.001 Yes   
0 vs. Peltophorum  0.253 18.695 <0.001 Yes   
0 vs. Euodia redle 0.194 14.311 <0.001 Yes   
0 vs. 50% MeOH 2%  0.189 13.941 <0.001 Yes   
0 vs. Anacardium o 0.182 13.449 <0.001 Yes   
0 vs. Garcinia atr 0.159 11.749 <0.001 Yes   
0 vs. Oxalis barrelieri (root) 0.146 10.788 <0.001 Yes   
0 vs. Garcinia man 0.124 9.163 <0.001 Yes   
0 vs. Tetracera indica (fruit) 0.122 8.990 <0.001 Yes   
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0 vs. Garcinia man 0.107 7.907 <0.001 Yes   
0 vs. Hibiscus til 0.0990 7.315 <0.001 Yes   
0 vs. Leptospermum 0.0843 6.232 <0.001 Yes   
0 vs. Cinnamomum z 0.0650 4.803 <0.001 Yes   
 
 
 
KINETIC STUDIES 
Kinetics of GST-P alone 
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Kinetics of GST-P in the presence of Anacardium occidentale (branch) ethanolic extract 
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Kinetics of GST-P in the presence of Andrographis paniculata (leaf) ethanolic extract 
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Kinetics of GST-P in the presence of Cinnamomum zeylanicum (branch) ethanolic 
extract 
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Kinetics of GST-P in the presence of Euodia redlevi (fruit&flower) ethanolic extract 
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Kinetics of GST-P in the presence of Garcinia atroviridis (branch) ethanolic extract 
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Kinetics of GST-P in the presence of Garcinia mangostana (branch) ethanolic extract 
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Kinetics of GST-P in the presence of Garcinia mangostana (leaf) ethanolic extract 
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Kinetics of GST-P in the presence of Hibiscus tiliaceus (leaf) ethanolic extract 
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Kinetics of GST-P in the presence of Lawsonia inermis (branch) ethanolic extract 
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Kinetics of GST-P in the presence of Leptospermum flavescens (leaf) ethanolic extract 
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Kinetics of GST-P in the presence of Oxalis barrelieri (root) ethanolic extract 
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Kinetics of GST-P in the presence of Peltophorum pterocarpum (leaf) ethanolic extract 
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Kinetics of GST-P in the presence of Tetracera indica (fruit) ethanolic extract 
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Kinetics of GST-P in the presence of 50% methanol 2% acetic acid fraction of L. 
flavescens (leaf) ethanolic extract 
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TOXICITY EFFECTS OF SAMPLES ON MRC-5 CELLS 
Figure 7.21 shows in vitro cytotoxicity effects of doxorubicin hydrochloride on 
MRC-5 cells. The drug inhibited MRC-5 cell proliferation in dose-dependent manner. 
The IC50 value of doxorubicin hydrochloride generated from the dose-response graph is 
0.82 ± 0.011 μg/mL. Comparison of inhibition activity among concentrations using 
ANOVA indicates statistically significant difference with P = <0.001. 
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Figure 7.21 : Cytotoxicity effects of doxorubicin hydrochloride on MRC-5 cells. Each 
bar represents the mean ± S.D. calculated from three independent 
determinations. 
 
 
 
 
227 
 
One Way Analysis of Variance  
 
Data source: doxorubicin hydrochloride 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.401) 
 
Equal Variance Test: Passed (P = 0.972) 
 
Group Name N  Missing Mean Std Dev SEM  
1 3 0 33.653 1.345 0.776  
0.5 3 0 78.071 1.222 0.705  
0.25 3 0 84.929 2.394 1.382  
0.125 3 0 87.314 2.187 1.262  
0.0625 3 0 88.254 2.768 1.598  
0.0313 3 0 90.941 2.261 1.305  
0.0156 3 0 93.648 2.019 1.165  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 8905.078 1272.154 331.931 <0.001  
Residual 16 61.321 3.833    
Total 23 8966.399     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
0 vs. 1 66.347 41.507 <0.001 Yes   
0 vs. 0.5 21.929 13.719 <0.001 Yes   
0 vs. 0.25 15.071 9.428 <0.001 Yes   
0 vs. 0.125 12.686 7.936 <0.001 Yes   
0 vs. 0.0625 11.746 7.348 <0.001 Yes   
0 vs. 0.0313 9.059 5.667 <0.001 Yes   
0 vs. 0.0156 6.352 3.974 0.001 Yes   
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Figure 7.22 shows in vitro cytotoxicity effects of cisplatin on MRC-5 cells. The 
drug inhibited MRC-5 cell proliferation in dose-dependent manner. The IC50 value of 
cisplatin generated from the dose-response graph is 4.07 ± 0.04 μg/mL. Comparison of 
inhibition activity among concentrations using ANOVA indicates statistically 
significant difference with P = <0.001. 
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Figure 7.22 : Cytotoxicity effects of cisplatin on MRC-5 cells. Each bar represents the 
mean ± S.D. calculated from three independent determinations. 
 
 
 
 
 
229 
 
One Way Analysis of Variance  
 
Data source: cisplatin 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.098) 
 
Equal Variance Test: Passed (P = 0.582) 
 
Group Name N  Missing Mean Std Dev SEM  
10 3 0 19.025 1.146 0.661  
5 3 0 35.055 0.789 0.456  
2.5 3 0 75.305 0.686 0.396  
1.25 3 0 90.811 1.037 0.599  
.625 3 0 91.682 0.970 0.560  
.313 3 0 99.868 0.178 0.103  
.156 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 21325.131 3046.447 5470.122 <0.001  
Residual 16 8.911 0.557    
Total 23 21334.042     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 10 80.975 132.892 <0.001 Yes   
0 vs. 5 64.945 106.584 <0.001 Yes   
0 vs. 2.5 24.695 40.528 <0.001 Yes   
0 vs. 1.25 9.189 15.080 <0.001 Yes   
0 vs. .625 8.318 13.651 <0.001 Yes   
0 vs. .313 0.132 0.217 0.971 No   
0 vs. .156 0.000 0.000 1.000 No   
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Figure 7.23 shows in vitro cytotoxicity effects of ethacrynic acid on MRC-5 
cells. The drug inhibited MRC-5 cell proliferation in dose-dependent manner. The IC50 
value of ethacrynic acid generated from the dose-response graph is 22.71 ± 0.24 μg/mL. 
Comparison of inhibition activity among concentrations using ANOVA indicates 
statistically significant difference with P = <0.001.  
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Figure 7.23 : Cytotoxicity effects of ethacrynic acid on MRC-5 cells. Each bar 
represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: ethacrynic acid 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.267) 
 
Equal Variance Test: Passed (P = 0.901) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 1.247 1.076 0.621  
50 3 0 2.515 0.362 0.209  
25 3 0 41.938 0.687 0.396  
12.5 3 0 85.996 1.659 0.958  
6.25 3 0 97.566 0.552 0.319  
3.13 3 0 98.091 0.770 0.444  
1.56 3 0 98.976 0.948 0.547  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 40414.290 5773.470 7320.315 <0.001  
Residual 16 12.619 0.789    
Total 23 40426.910     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 100 98.753 136.189 <0.001 Yes   
0 vs. 50 97.485 134.440 <0.001 Yes   
0 vs. 25 58.062 80.073 <0.001 Yes   
0 vs. 12.5 14.004 19.313 <0.001 Yes   
0 vs. 6.25 2.434 3.356 0.012 Yes   
0 vs. 3.13 1.909 2.632 0.036 Yes   
0 vs. 1.56 1.024 1.412 0.177 No   
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Figure 7.24 shows in vitro cytotoxicity effects of Anacardium occidentale 
(branch) ethanolic extract on MRC-5 cells. The IC50 value of A. occidentale (branch) 
ethanolic extract generated from the dose-response graph is >100 μg/mL. Comparison 
of inhibition activity among concentrations using ANOVA indicates that there is not a 
statistically significant difference with P = 0.466. 
 
 
0
10
20
30
40
50
60
70
80
90
100
0 1.56 3.13 6.25 12.5 25 50 100P
er
ce
n
ta
g
e 
o
f 
ce
ll
 v
ia
b
il
it
y
 (
%
)
Concentration (μg/mL)
 
Figure 7.24 : Cytotoxicity effects of A. occidentale (branch) ethanolic extract on MRC-5 
cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Anacardium occidentale (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 1.000) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 100.000 0.000 0.000  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 100.000 0.000 0.000  
6.25 3 0 100.000 0.000 0.000  
3.13 3 0 100.000 0.000 0.000  
1.56 3 0 99.970 0.0517 0.0299  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 0.00234 0.000335 1.000 0.466  
Residual 16 0.00535 0.000335    
Total 23 0.00770     
 
The differences in the mean values among the treatment groups are not great enough to 
exclude the possibility that the difference is due to random sampling variability; there is 
not a statistically significant difference  (P = 0.466). 
 
Power of performed test with alpha = 0.050: 0.050 
 
The power of the performed test (0.050) is below the desired power of 0.800. 
Less than desired power indicates you are less likely to detect a difference when one 
actually exists. Negative results should be interpreted cautiously. 
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Figure 7.25 shows in vitro cytotoxicity effects of Andrographis paniculata (leaf) 
ethanolic extract on MRC-5 cells. The IC50 value of A. paniculata (leaf) ethanolic 
extract generated from the dose-response graph is >100 μg/mL. Comparison of 
inhibition activity among concentrations using ANOVA indicates statistically 
significant difference with P = <0.001. 
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Figure 7.25 : Cytotoxicity effects of A. paniculata (leaf) ethanolic extract on MRC-5 
cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Andrographis paniculata (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.106) 
 
Equal Variance Test: Passed (P = 0.784) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 93.859 0.498 0.287  
50 3 0 95.473 1.084 0.626  
25 3 0 97.512 1.110 0.641  
12.5 3 0 98.642 0.924 0.533  
6.25 3 0 98.337 0.339 0.196  
3.13 3 0 100.000 0.000 0.000  
1.56 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 108.888 15.555 34.339 <0.001  
Residual 16 7.248 0.453    
Total 23 116.135     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 100 6.141 11.175 <0.001 Yes   
0 vs. 50 4.527 8.238 <0.001 Yes   
0 vs. 25 2.488 4.528 0.002 Yes   
0 vs. 6.25 1.663 3.027 0.032 Yes   
0 vs. 12.5 1.358 2.470 0.074 No   
0 vs. 3.13 0.000 0.000 1.000 No   
0 vs. 1.56 0.000 0.000 1.000 No   
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Figure 7.26 shows in vitro cytotoxicity effects of Cinnamomum zeylanicum 
(branch) ethanolic extract on MRC-5 cells. The IC50 value of C. zeylanicum (branch) 
ethanolic extract generated from the dose-response graph is >100 μg/mL. Comparison 
of inhibition activity among concentrations using ANOVA indicates statistically 
significant difference with P = <0.001. 
 
 
0
10
20
30
40
50
60
70
80
90
100
0 1.56 3.13 6.25 12.5 25 50 100P
er
ce
n
ta
g
e 
o
f 
ce
ll
 v
ia
b
il
it
y
 (
%
)
Concentration (μg/mL)
 
Figure 7.26 : Cytotoxicity effects of C. zeylanicum (branch) ethanolic extract on MRC-5 
cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Cinnamomum zeylanicum (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 0.256) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 96.916 0.960 0.554  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 100.000 0.000 0.000  
6.25 3 0 99.946 0.0933 0.0538  
3.13 3 0 98.106 1.699 0.981  
1.56 3 0 99.736 0.458 0.264  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 28.989 4.141 8.230 <0.001  
Residual 16 8.051 0.503    
Total 23 37.041     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 0.996 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 100 3.084 5.324 <0.001 Yes   
0 vs. 3.13 1.894 3.270 0.029 Yes   
0 vs. 1.56 0.264 0.456 0.995 No   
0 vs. 6.25 0.0538 0.0930 1.000 No   
0 vs. 12.5 0.000 0.000 1.000 No   
0 vs. 25 0.000 0.000 1.000 No   
0 vs. 50 0.000 0.000 1.000 No   
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Figure 7.27 shows in vitro cytotoxicity effects of Euodia redlevi (fruit&flower) 
ethanolic extract on MRC-5 cells. The IC50 value of E. redleri (fruit&flower) ethanolic 
extract generated from the dose-response graph is >100 μg/mL. Comparison of 
inhibition activity among concentrations using ANOVA indicates statistically 
significant difference with P = 0.005. 
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Figure 7.27 : Cytotoxicity effects of E. redleri (fruit&flower) ethanolic extract on MRC-
5 cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Euodia redlevi (fruit&flower) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 1.000) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 100.000 0.000 0.000  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 100.000 0.000 0.000  
6.25 3 0 98.805 0.956 0.552  
3.13 3 0 100.000 0.000 0.000  
1.56 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 3.747 0.535 4.682 0.005  
Residual 16 1.829 0.114    
Total 23 5.576     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = 0.005). 
 
Power of performed test with alpha = 0.050: 0.878 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 6.25 1.195 4.328 0.004 Yes   
0 vs. 12.5 0.000 0.000 1.000 No   
0 vs. 1.56 0.000 0.000 1.000 No   
0 vs. 3.13 0.000 0.000 1.000 No   
0 vs. 100 0.000 0.000 1.000 No   
0 vs. 25 0.000 0.000 1.000 No   
0 vs. 50 0.000 0.000 1.000 No   
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Figure 7.28 shows in vitro cytotoxicity effects of Garcinia atroviridis (branch) 
ethanolic extract on MRC-5 cells. The IC50 value of G. atroviridis (branch) ethanolic 
extract generated from the dose-response graph is >100 μg/mL. Comparison of 
inhibition activity among concentrations using ANOVA indicates that there is not a 
statistically significant difference with P = 0.533. 
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Figure 7.28 : Cytotoxicity effects of G. atroviridis (branch) ethanolic extract on MRC-5 
cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Garcinia atroviridis (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 1.000) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 100.000 0.000 0.000  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 100.000 0.000 0.000  
6.25 3 0 99.803 0.342 0.197  
3.13 3 0 99.545 0.788 0.455  
1.56 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 0.578 0.0826 0.896 0.533  
Residual 16 1.475 0.0922    
Total 23 2.053     
 
The differences in the mean values among the treatment groups are not great enough to 
exclude the possibility that the difference is due to random sampling variability; there is 
not a statistically significant difference  (P = 0.533). 
 
Power of performed test with alpha = 0.050: 0.050 
 
The power of the performed test (0.050) is below the desired power of 0.800. 
Less than desired power indicates you are less likely to detect a difference when one 
actually exists. Negative results should be interpreted cautiously. 
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Figure 7.29 shows in vitro cytotoxicity effects of Garcinia mangostana (branch) 
ethanolic extract on MRC-5 cells. The IC50 value of G. mangostana (branch) ethanolic 
extract generated from the dose-response graph is >100 μg/mL. Comparison of 
inhibition activity among concentrations using ANOVA indicates statistically 
significant difference with P = <0.001. 
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Figure 7.29 : Cytotoxicity effects of G. mangostana (branch) ethanolic extract on MRC-
5 cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Garcinia mangostana (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 0.057) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 79.951 0.200 0.115  
50 3 0 95.223 2.356 1.360  
25 3 0 100.000 0.000 0.000  
12.5 3 0 99.814 0.323 0.186  
6.25 3 0 100.000 0.000 0.000  
3.13 3 0 100.000 0.000 0.000  
1.56 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 1039.832 148.547 208.648 <0.001  
Residual 16 11.391 0.712    
Total 23 1051.223     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 100 20.049 29.101 <0.001 Yes   
0 vs. 50 4.777 6.933 <0.001 Yes   
0 vs. 12.5 0.186 0.270 1.000 No   
0 vs. 25 0.000 0.000 1.000 No   
0 vs. 6.25 0.000 0.000 1.000 No   
0 vs. 3.13 0.000 0.000 1.000 No   
0 vs. 1.56 0.000 0.000 1.000 No   
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Figure 7.30 shows in vitro cytotoxicity effects of Garcinia mangostana (leaf) 
ethanolic extract on MRC-5 cells. The IC50 value of G. mangostana (leaf) ethanolic 
extract generated from the dose-response graph is >100 μg/mL. Comparison of 
inhibition activity among concentrations using ANOVA indicates that there is not a 
statistically significant difference with P = 1.0. 
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Figure 7.30 : Cytotoxicity effects of G. mangostana (leaf) ethanolic extract on MRC-5 
cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Garcinia mangostana (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 1.000) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 100.000 0.000 0.000  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 100.000 0.000 0.000  
6.25 3 0 100.000 0.000 0.000  
3.13 3 0 100.000 0.000 0.000  
1.56 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 0.000 0.000 1.000 1.000  
Residual 16 0.000 0.000    
Total 23 0.000     
 
The differences in the mean values among the treatment groups are not great enough to 
exclude the possibility that the difference is due to random sampling variability; there is 
not a statistically significant difference  (P = 1.000). 
 
Power of performed test with alpha = 0.050: 1.000 
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Figure 7.31 shows in vitro cytotoxicity effects of Hibiscus tiliaceus (leaf) 
ethanolic extract on MRC-5 cells. The IC50 value of H. tiliaceus (leaf) ethanolic extract 
generated from the dose-response graph is >100 μg/mL. Comparison of inhibition 
activity among concentrations using ANOVA indicates that there is not a statistically 
significant difference with P = 1.0. 
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Figure 7.31 : Cytotoxicity effects of H. tiliaceus (leaf) ethanolic extract on MRC-5 cells. 
Each bar represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Hibiscus tiliaceus (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 1.000) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 100.000 0.000 0.000  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 100.000 0.000 0.000  
6.25 3 0 100.000 0.000 0.000  
3.13 3 0 100.000 0.000 0.000  
1.56 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 0.000 0.000 1.000 1.000  
Residual 16 0.000 0.000    
Total 23 0.000     
 
The differences in the mean values among the treatment groups are not great enough to 
exclude the possibility that the difference is due to random sampling variability; there is 
not a statistically significant difference  (P = 1.000). 
 
Power of performed test with alpha = 0.050: 1.000 
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Figure 7.32 shows in vitro cytotoxicity effects of Lawsonia inermis (branch) 
ethanolic extract on MRC-5 cells. The IC50 value of L. inermis (branch) ethanolic 
extract generated from the dose-response graph is >100 μg/mL. Comparison of 
inhibition activity among concentrations using ANOVA indicates statistically 
significant difference with P = <0.001. 
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Figure 7.32 : Cytotoxicity effects of L. inermis (branch) ethanolic extract on MRC-5 
cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Lawsonia inermis (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.433) 
 
Equal Variance Test: Passed (P = 0.057) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 75.381 1.371 0.792  
50 3 0 99.284 1.240 0.716  
25 3 0 98.733 0.947 0.547  
12.5 3 0 98.561 0.344 0.199  
6.25 3 0 95.346 0.459 0.265  
3.13 3 0 96.648 0.985 0.569  
1.56 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 1442.246 206.035 293.546 <0.001  
Residual 16 11.230 0.702    
Total 23 1453.476     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 100 24.619 35.990 <0.001 Yes   
0 vs. 6.25 4.654 6.804 <0.001 Yes   
0 vs. 3.13 3.352 4.900 <0.001 Yes   
0 vs. 12.5 1.439 2.103 0.191 No   
0 vs. 25 1.267 1.852 0.228 No   
0 vs. 50 0.716 1.047 0.525 No   
0 vs. 1.56 0.000 0.000 1.000 No   
 
 
 
 
250 
 
Figure 7.33 shows in vitro cytotoxicity effects of Leptospermum flavescens (leaf) 
ethanolic extract on MRC-5 cells. The IC50 value of L. flavescens (leaf) ethanolic 
extract generated from the dose-response graph is >100 μg/mL. Comparison of 
inhibition activity among concentrations using ANOVA indicates that there is not a 
statistically significant difference with P = 1.0. 
 
 
0
10
20
30
40
50
60
70
80
90
100
0 1.56 3.13 6.25 12.5 25 50 100P
er
ce
n
ta
g
e 
o
f 
ce
ll
 v
ia
b
il
it
y
 (
%
)
Concentration (μg/mL)
 
Figure 7.33 : Cytotoxicity effects of L. flavescens (leaf) ethanolic extract on MRC-5 
cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Leptospermum flavescens (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 1.000) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 100.000 0.000 0.000  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 100.000 0.000 0.000  
6.25 3 0 100.000 0.000 0.000  
3.13 3 0 100.000 0.000 0.000  
1.56 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 0.000 0.000 1.000 1.000  
Residual 16 0.000 0.000    
Total 23 0.000     
 
The differences in the mean values among the treatment groups are not great enough to 
exclude the possibility that the difference is due to random sampling variability; there is 
not a statistically significant difference  (P = 1.000). 
 
Power of performed test with alpha = 0.050: 1.000 
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Figure 7.34 shows in vitro cytotoxicity effects of Oxalis barrelieri (root) 
ethanolic extract on MRC-5 cells. The IC50 value of O. barrelieri (root) ethanolic 
extract generated from the dose-response graph is >100 μg/mL. Comparison of 
inhibition activity among concentrations using ANOVA indicates statistically 
significant difference with P = <0.001. 
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Figure 7.34 : Cytotoxicity effects of O. barrelieri (root) ethanolic extract on MRC-5 
cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Oxalis barrelieri (root) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 1.000) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 88.344 1.264 0.730  
50 3 0 99.763 0.411 0.237  
25 3 0 100.000 0.000 0.000  
12.5 3 0 100.000 0.000 0.000  
6.25 3 0 100.000 0.000 0.000  
3.13 3 0 100.000 0.000 0.000  
1.56 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 354.740 50.677 229.541 <0.001  
Residual 16 3.532 0.221    
Total 23 358.272     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 100 11.656 30.383 <0.001 Yes   
0 vs. 50 0.237 0.618 0.991 No   
0 vs. 12.5 0.000 0.000 1.000 No   
0 vs. 1.56 0.000 0.000 1.000 No   
0 vs. 3.13 0.000 0.000 1.000 No   
0 vs. 6.25 0.000 0.000 1.000 No   
0 vs. 25 0.000 0.000 1.000 No   
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Figure 7.35 shows in vitro cytotoxicity effects of Peltophorum pterocarpum 
(leaf) ethanolic extract on MRC-5 cells. The IC50 value of P. pterocarpum (leaf) 
ethanolic extract generated from the dose-response graph is >100 μg/mL. Comparison 
of inhibition activity among concentrations using ANOVA indicates statistically 
significant difference with P = <0.001. 
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Figure 7.35 : Cytotoxicity effects of P. pterocarpum (leaf) ethanolic extract on MRC-5 
cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Peltophorum pterocarpum (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 0.414) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 99.045 0.830 0.479  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 98.899 0.132 0.0760  
6.25 3 0 99.849 0.261 0.151  
3.13 3 0 100.000 0.000 0.000  
1.56 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 4.613 0.659 6.812 <0.001  
Residual 16 1.548 0.0967    
Total 23 6.160     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 0.984 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 12.5 1.101 4.335 0.004 Yes   
0 vs. 100 0.955 3.759 0.010 Yes   
0 vs. 6.25 0.151 0.593 0.984 No   
0 vs. 50 0.000 0.000 1.000 No   
0 vs. 25 0.000 0.000 1.000 No   
0 vs. 3.13 0.000 0.000 1.000 No   
0 vs. 1.56 0.000 0.000 1.000 No   
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Figure 7.36 shows in vitro cytotoxicity effects of Tetracera indica (fruit) 
ethanolic extract on MRC-5 cells. The IC50 value of T. indica (fruit) ethanolic extract 
generated from the dose-response graph is >100 μg/mL. Comparison of inhibition 
activity among concentrations using ANOVA indicates statistically significant 
difference with P = <0.001. 
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Figure 7.36 : Cytotoxicity effects of T. indica (fruit) ethanolic extract on MRC-5 cells. 
Each bar represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Tetracera indica (fruit) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 0.820) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 78.083 0.321 0.185  
50 3 0 99.549 0.399 0.230  
25 3 0 100.000 0.000 0.000  
12.5 3 0 100.000 0.000 0.000  
6.25 3 0 100.000 0.000 0.000  
3.13 3 0 100.000 0.000 0.000  
1.56 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 1253.990 179.141 5469.757 <0.001  
Residual 16 0.524 0.0328    
Total 23 1254.514     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 100 21.917 148.321 <0.001 Yes   
0 vs. 50 0.451 3.055 0.045 Yes   
0 vs. 12.5 0.000 0.000 1.000 No   
0 vs. 1.56 0.000 0.000 1.000 No   
0 vs. 3.13 0.000 0.000 1.000 No   
0 vs. 6.25 0.000 0.000 1.000 No   
0 vs. 25 0.000 0.000 1.000 No   
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Figure 7.37 shows in vitro cytotoxicity effects of 50% MeOH 2% acetic acid 
fraction of L. flavescens (leaf) ethanolic extract on MRC-5 cells. The IC50 value of 50% 
MeOH 2% acetic acid fraction of L. flavescens (leaf) ethanolic extract generated from 
the dose-response graph is >100 μg/mL. Comparison of inhibition activity among 
concentrations using ANOVA indicates statistically significant difference with P = 
0.001. 
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Figure 7.37 : Cytotoxicity effects of 50% MeOH 2% acetic acid fraction of L. flavescens 
(leaf) ethanolic extract on MRC-5 cells. Each bar represents the mean ± 
S.D. calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: 50% MeOH 2% acetic acid fraction of L. flavescens (leaf) ethanolic 
extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 1.000) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 96.998 2.068 1.194  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 100.000 0.000 0.000  
6.25 3 0 100.000 0.000 0.000  
3.13 3 0 100.000 0.000 0.000  
1.56 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 23.660 3.380 6.324 0.001  
Residual 16 8.551 0.534    
Total 23 32.211     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = 0.001). 
 
Power of performed test with alpha = 0.050: 0.973 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 100 3.002 5.030 <0.001 Yes   
0 vs. 12.5 0.000 0.000 1.000 No   
0 vs. 1.56 0.000 0.000 1.000 No   
0 vs. 3.13 0.000 0.000 1.000 No   
0 vs. 6.25 0.000 0.000 1.000 No   
0 vs. 25 0.000 0.000 1.000 No   
0 vs. 50 0.000 0.000 1.000 No   
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EFFECTS OF SAMPLES ON HT-29 CELL PROLIFERATION 
Figure 7.38 shows in vitro cytotoxicity effects of doxorubicin hydrochloride on 
HT-29 cells. The drug inhibited HT-29 cell proliferation in dose-dependent manner. The 
IC50 value of doxorubicin hydrochloride generated from the dose-response graph is 0.79 
± 0.046 μg/mL. Comparison of inhibition activity among concentrations using ANOVA 
indicates statistically significant difference with P = <0.001. 
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Figure 7.38 : Cytotoxicity effects of doxorubicin hydrochloride on HT-29 cells. Each 
bar represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Doxorubicin hydrochloride 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.338) 
 
Equal Variance Test: Passed (P = 0.757) 
 
Group Name N  Missing Mean Std Dev SEM  
0 3 0 100.000 0.000 0.000  
0.0156 3 0 99.354 1.118 0.646  
0.0313 3 0 93.979 2.372 1.369  
0.0625 3 0 89.105 3.780 2.182  
0.125 3 0 86.716 4.519 2.609  
0.25 3 0 85.241 4.842 2.796  
0.5 3 0 63.752 2.811 1.623  
1 3 0 40.025 1.717 0.991  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 8838.523 1262.646 133.118 <0.001  
Residual 16 151.763 9.485    
Total 23 8990.286     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
0 vs. 1 59.975 23.850 <0.001 Yes   
0 vs. 0.5 36.248 14.415 <0.001 Yes   
0 vs. 0.25 14.759 5.869 <0.001 Yes   
0 vs. 0.125 13.284 5.283 <0.001 Yes   
0 vs. 0.0625 10.895 4.333 0.002 Yes   
0 vs. 0.0313 6.021 2.395 0.058 No   
0 vs. 0.0156 0.646 0.257 0.801 No   
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Figure 7.39 shows in vitro cytotoxicity effects of cisplatin on HT-29 cells. The 
drug inhibited HT-29 cell proliferation in dose-dependent manner. The IC50 value of 
cisplatin generated from the dose-response graph is 9.49 ± 0.13 μg/mL. Comparison of 
inhibition activity among concentrations using ANOVA indicates statistically 
significant difference with P = <0.001. 
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Figure 7.39 : Cytotoxicity effects of cisplatin on HT-29 cells. Each bar represents the 
mean ± S.D. calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Cisplatin 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.620) 
 
Equal Variance Test: Passed (P = 0.706) 
 
Group Name N  Missing Mean Std Dev SEM  
10 3 0 48.203 0.499 0.288  
5 3 0 65.538 0.236 0.136  
2.5 3 0 75.463 1.895 1.094  
1.25 3 0 79.041 1.524 0.880  
.625 3 0 86.214 2.302 1.329  
.313 3 0 93.391 1.947 1.124  
.156 3 0 97.230 1.899 1.097  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 6459.801 922.829 390.245 <0.001  
Residual 16 37.836 2.365    
Total 23 6497.637     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 10 51.797 41.253 <0.001 Yes   
0 vs. 5 34.462 27.447 <0.001 Yes   
0 vs. 2.5 24.537 19.542 <0.001 Yes   
0 vs. 1.25 20.959 16.693 <0.001 Yes   
0 vs. .625 13.786 10.979 <0.001 Yes   
0 vs. .313 6.609 5.264 <0.001 Yes   
0 vs. .156 2.770 2.206 0.042 Yes   
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Figure 7.40 shows in vitro cytotoxicity effects of ethacrynic acid on HT-29 cells. 
The drug inhibited HT-29 cell proliferation in dose-dependent manner. The IC50 value 
of ethacrynic acid generated from the dose-response graph is 19.0 ± 0.26 μg/mL. 
Comparison of inhibition activity among concentrations using ANOVA indicates 
statistically significant difference with P = <0.001. 
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Figure 7.40 : Cytotoxicity effects of ethacrynic acid on HT-29 cells. Each bar represents 
the mean ± S.D. calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Ethacrynic acid 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.179) 
 
Equal Variance Test: Passed (P = 0.601) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 1.238 0.0982 0.0567  
50 3 0 1.873 0.322 0.186  
25 3 0 12.030 1.326 0.766  
12.5 3 0 91.141 2.098 1.211  
10 3 0 98.895 0.451 0.260  
6.25 3 0 98.452 1.341 0.774  
3.13 3 0 99.259 1.286 0.743  
1.56 3 0 99.823 0.306 0.177  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 8 52152.764 6519.096 5854.124 <0.001  
Residual 18 20.045 1.114    
Total 26 52172.809     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 100 98.762 114.624 <0.001 Yes   
0 vs. 50 98.127 113.886 <0.001 Yes   
0 vs. 25 87.970 102.099 <0.001 Yes   
0 vs. 12.5 8.859 10.282 <0.001 Yes   
0 vs. 6.25 1.548 1.797 0.312 No   
0 vs. 10 1.105 1.283 0.518 No   
0 vs. 3.13 0.741 0.860 0.642 No   
0 vs. 1.56 0.177 0.205 0.840 No   
 
 
 
 
266 
 
Figure 7.41 shows in vitro cytotoxicity effects of Anacardium occidentale 
(branch) ethanolic extract on HT-29 cells. The extract inhibited HT-29 cell proliferation 
in dose-dependent manner. The IC50 value of A. occidentale (branch) ethanolic extract 
generated from the dose-response graph is >100 μg/mL. Comparison of inhibition 
activity among concentrations using ANOVA indicates statistically significant 
difference with P = <0.001. 
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Figure 7.41 : Cytotoxicity effects of A. occidentale (branch) ethanolic extract on HT-29 
cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Anacardium occidentale (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 1.000) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 79.505 0.526 0.303  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 99.917 0.144 0.0831  
6.25 3 0 100.000 0.000 0.000  
3.13 3 0 100.000 0.000 0.000  
1.56 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 1101.362 157.337 4239.902 <0.001  
Residual 16 0.594 0.0371    
Total 23 1101.955     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 100 20.495 130.303 <0.001 Yes   
0 vs. 12.5 0.0831 0.528 0.996 No   
0 vs. 25 0.000 0.000 1.000 No   
0 vs. 50 0.000 0.000 1.000 No   
0 vs. 6.25 0.000 0.000 1.000 No   
0 vs. 3.13 0.000 0.000 1.000 No   
0 vs. 1.56 0.000 0.000 1.000 No   
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Figure 7.42 shows in vitro cytotoxicity effects of Andrographis paniculata (leaf) 
ethanolic extract on HT-29 cells. The extract inhibited HT-29 cell proliferation in dose-
dependent manner. The IC50 value of A. paniculata (leaf) ethanolic extract generated 
from the dose-response graph is >100 μg/mL. Comparison of inhibition activity among 
concentrations using ANOVA indicates statistically significant difference with P = 
<0.001. 
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Figure 7.42 : Cytotoxicity effects of A. paniculata (leaf) ethanolic extract on HT-29 
cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Andrographis paniculata (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Failed (P < 0.050) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 56.795 0.735 0.425  
50 3 0 95.480 2.490 1.438  
25 3 0 99.712 0.498 0.288  
12.5 3 0 98.570 0.856 0.494  
6.25 3 0 100.000 0.000 0.000  
3.13 3 0 100.000 0.000 0.000  
1.56 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 4751.001 678.714 703.169 <0.001  
Residual 16 15.444 0.965    
Total 23 4766.444     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 100 43.205 53.860 <0.001 Yes   
0 vs. 50 4.520 5.634 <0.001 Yes   
0 vs. 12.5 1.430 1.783 0.388 No   
0 vs. 25 0.288 0.358 0.994 No   
0 vs. 6.25 0.000 0.000 1.000 No   
0 vs. 3.13 0.000 0.000 1.000 No   
0 vs. 1.56 0.000 0.000 1.000 No   
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Figure 7.43 shows in vitro cytotoxicity effects of Cinnamomum zeylanicum 
(branch) ethanolic extract on HT-29 cells. The IC50 value of C. zeylanicum (branch) 
ethanolic extract generated from the dose-response graph is >100 μg/mL. Comparison 
of inhibition activity among concentrations using ANOVA indicates statistically 
significant difference with P = <0.001. 
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Figure 7.43 : Cytotoxicity effects of C. zeylanicum (branch) ethanolic extract on HT-29 
cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Cinnamomum zeylanicum (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 0.516) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 99.063 0.922 0.532  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 100.000 0.000 0.000  
6.25 3 0 98.169 1.158 0.668  
3.13 3 0 95.755 1.968 1.136  
1.56 3 0 99.742 0.447 0.258  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 47.133 6.733 8.603 <0.001  
Residual 16 12.523 0.783    
Total 23 59.656     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 0.998 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 3.13 4.245 5.877 <0.001 Yes   
0 vs. 6.25 1.831 2.535 0.125 No   
0 vs. 100 0.937 1.297 0.698 No   
0 vs. 1.56 0.258 0.357 0.994 No   
0 vs. 12.5 0.000 0.000 1.000 No   
0 vs. 25 0.000 0.000 1.000 No   
0 vs. 50 0.000 0.000 1.000 No   
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Figure 7.44 shows in vitro cytotoxicity effects of Euodia redlevi (fruit&flower) 
ethanolic extract on HT-29 cells. The IC50 value of E. redleri (fruit&flower) ethanolic 
extract generated from the dose-response graph is >100 μg/mL. Comparison of 
inhibition activity among concentrations using ANOVA indicates that there is not a 
statistically significant difference with P = 0.099. 
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Figure 7.44 : Cytotoxicity effects of E. redleri (fruit&flower) ethanolic extract on HT-
29 cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Euodia redlevi (fruit&flower) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 1.000) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 100.000 0.000 0.000  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 100.000 0.000 0.000  
6.25 3 0 99.372 1.088 0.628  
3.13 3 0 98.625 1.297 0.749  
1.56 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 5.350 0.764 2.133 0.099  
Residual 16 5.734 0.358    
Total 23 11.084     
 
The differences in the mean values among the treatment groups are not great enough to 
exclude the possibility that the difference is due to random sampling variability; there is 
not a statistically significant difference  (P = 0.099). 
 
Power of performed test with alpha = 0.050: 0.335 
 
The power of the performed test (0.335) is below the desired power of 0.800. 
Less than desired power indicates you are less likely to detect a difference when one 
actually exists. Negative results should be interpreted cautiously. 
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Figure 7.45 shows in vitro cytotoxicity effects of Garcinia atroviridis (branch) 
ethanolic extract on HT-29 cells. The IC50 value of G. atroviridis (branch) ethanolic 
extract generated from the dose-response graph is >100 μg/mL. Comparison of 
inhibition activity among concentrations using ANOVA indicates that there is not a 
statistically significant difference with P = 0.346. 
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Figure 7.45 : Cytotoxicity effects of G. atroviridis (branch) ethanolic extract on HT-29 
cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Garcinia atroviridis (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Failed (P < 0.050) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 100.000 0.000 0.000  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 98.311 2.925 1.689  
6.25 3 0 99.324 0.788 0.455  
3.13 3 0 97.974 2.077 1.199  
1.56 3 0 99.812 0.184 0.106  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 14.482 2.069 1.224 0.346  
Residual 16 27.053 1.691    
Total 23 41.534     
 
The differences in the mean values among the treatment groups are not great enough to 
exclude the possibility that the difference is due to random sampling variability; there is 
not a statistically significant difference (P = 0.346). 
 
Power of performed test with alpha = 0.050: 0.093 
 
The power of the performed test (0.093) is below the desired power of 0.800. 
Less than desired power indicates you are less likely to detect a difference when one 
actually exists. Negative results should be interpreted cautiously. 
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Figure 7.46 shows in vitro cytotoxicity effects of Garcinia mangostana (branch) 
ethanolic extract on HT-29 cells. The IC50 value of G. mangostana (branch) ethanolic 
extract generated from the dose-response graph is >100 μg/mL. Comparison of 
inhibition activity among concentrations using ANOVA indicates that there is not a 
statistically significant difference with P = 1.0. 
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Figure 7.46 : Cytotoxicity effects of G. mangostana (branch) ethanolic extract on HT-29 
cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Garcinia mangostana (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 1.000) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 100.000 0.000 0.000  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 100.000 0.000 0.000  
6.25 3 0 100.000 0.000 0.000  
3.13 3 0 100.000 0.000 0.000  
1.56 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 0.000 0.000 1.000 1.000  
Residual 16 0.000 0.000    
Total 23 0.000     
 
The differences in the mean values among the treatment groups are not great enough to 
exclude the possibility that the difference is due to random sampling variability; there is 
not a statistically significant difference  (P = 1.000). 
 
Power of performed test with alpha = 0.050: 1.000 
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Figure 7.47 shows in vitro cytotoxicity effects of Garcinia mangostana (leaf) 
ethanolic extract on HT-29 cells. The IC50 value of G. mangostana (leaf) ethanolic 
extract generated from the dose-response graph is >100 μg/mL. Comparison of 
inhibition activity among concentrations using ANOVA indicates that there is not a 
statistically significant difference with P = 1.0. 
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Figure 7.47 : Cytotoxicity effects of G. mangostana (leaf) ethanolic extract on HT-29 
cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Garcinia mangostana (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 1.000) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 100.000 0.000 0.000  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 100.000 0.000 0.000  
6.25 3 0 100.000 0.000 0.000  
3.13 3 0 100.000 0.000 0.000  
1.56 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 0.000 0.000 1.000 1.000  
Residual 16 0.000 0.000    
Total 23 0.000     
 
The differences in the mean values among the treatment groups are not great enough to 
exclude the possibility that the difference is due to random sampling variability; there is 
not a statistically significant difference  (P = 1.000). 
 
Power of performed test with alpha = 0.050: 1.000 
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Figure 7.48 shows in vitro cytotoxicity effects of Hibiscus tiliaceus (leaf) 
ethanolic extract on HT-29 cells. The IC50 value of H. tiliaceus (leaf) ethanolic extract 
generated from the dose-response graph is >100 μg/mL. Comparison of inhibition 
activity among concentrations using ANOVA indicates statistically significant 
difference with P = <0.001. 
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Figure 7.48 : Cytotoxicity effects of H. tiliaceus (leaf) ethanolic extract on HT-29 cells. 
Each bar represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Hibiscus tiliaceus (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 1.000) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 96.442 1.552 0.896  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 100.000 0.000 0.000  
6.25 3 0 100.000 0.000 0.000  
3.13 3 0 99.733 0.462 0.267  
1.56 3 0 99.771 0.397 0.229  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 32.185 4.598 13.231 <0.001  
Residual 16 5.560 0.348    
Total 23 37.746     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 100 3.558 7.392 <0.001 Yes   
0 vs. 3.13 0.267 0.554 0.995 No   
0 vs. 1.56 0.229 0.476 0.994 No   
0 vs. 12.5 0.000 0.000 1.000 No   
0 vs. 6.25 0.000 0.000 1.000 No   
0 vs. 25 0.000 0.000 1.000 No   
0 vs. 50 0.000 0.000 1.000 No   
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Figure 7.49 shows in vitro cytotoxicity effects of Lawsonia inermis (branch) 
ethanolic extract on HT-29 cells. The IC50 value of L. inermis (branch) ethanolic extract 
generated from the dose-response graph is >100 μg/mL. Comparison of inhibition 
activity among concentrations using ANOVA indicates that there is not a statistically 
significant difference with P = 0.214. 
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Figure 7.49 : Cytotoxicity effects of L. inermis (branch) ethanolic extract on HT-29 
cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Lawsonia inermis (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 1.000) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 100.000 0.000 0.000  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 99.353 1.120 0.647  
6.25 3 0 100.000 0.000 0.000  
3.13 3 0 99.793 0.359 0.207  
1.56 3 0 98.020 2.448 1.413  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 10.136 1.448 1.571 0.214  
Residual 16 14.749 0.922    
Total 23 24.885     
 
The differences in the mean values among the treatment groups are not great enough to 
exclude the possibility that the difference is due to random sampling variability; there is 
not a statistically significant difference  (P = 0.214). 
 
Power of performed test with alpha = 0.050: 0.176 
 
The power of the performed test (0.176) is below the desired power of 0.800. 
Less than desired power indicates you are less likely to detect a difference when one 
actually exists. Negative results should be interpreted cautiously. 
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Figure 7.50 shows in vitro cytotoxicity effects of Leptospermum flavescens (leaf) 
ethanolic extract on HT-29 cells. The IC50 value of L. flavescens (leaf) ethanolic extract 
generated from the dose-response graph is >100 μg/mL. Comparison of inhibition 
activity among concentrations using ANOVA indicates statistically significant 
difference with P = <0.001. 
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Figure 7.50 : Cytotoxicity effects of L. flavescens (leaf) ethanolic extract on HT-29 cells. 
Each bar represents the mean ± S.D. calculated from three independent 
determinations. 
 
 
 
 
 
285 
 
One Way Analysis of Variance  
 
Data source: Leptospermum flavescens (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 1.000) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 82.897 1.163 0.671  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 100.000 0.000 0.000  
6.25 3 0 100.000 0.000 0.000  
3.13 3 0 100.000 0.000 0.000  
1.56 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 767.877 109.697 648.759 <0.001  
Residual 16 2.705 0.169    
Total 23 770.582     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 100 17.103 50.941 <0.001 Yes   
0 vs. 12.5 0.000 0.000 1.000 No   
0 vs. 1.56 0.000 0.000 1.000 No   
0 vs. 3.13 0.000 0.000 1.000 No   
0 vs. 6.25 0.000 0.000 1.000 No   
0 vs. 25 0.000 0.000 1.000 No   
0 vs. 50 0.000 0.000 1.000 No   
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Figure 7.51 shows in vitro cytotoxicity effects of Oxalis barrelieri (root) 
ethanolic extract on HT-29 cells. The IC50 value of O. barrelieri (root) ethanolic extract 
generated from the dose-response graph is >100 μg/mL. Comparison of inhibition 
activity among concentrations using ANOVA indicates statistically significant 
difference with P = 0.002. 
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Figure 7.51 : Cytotoxicity effects of O. barrelieri (root) ethanolic extract on HT-29 cells. 
Each bar represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Oxalis barrelieri (root) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 0.628) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 100.000 0.000 0.000  
50 3 0 100.000 0.000 0.000  
25 3 0 99.544 0.465 0.268  
12.5 3 0 96.711 1.218 0.703  
6.25 3 0 95.783 1.914 1.105  
3.13 3 0 97.623 2.096 1.210  
1.56 3 0 98.172 1.489 0.860  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 57.885 8.269 5.523 0.002  
Residual 16 23.954 1.497    
Total 23 81.839     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = 0.002). 
 
Power of performed test with alpha = 0.050: 0.942 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 6.25 4.217 4.221 0.005 Yes   
0 vs. 12.5 3.289 3.292 0.027 Yes   
0 vs. 3.13 2.377 2.380 0.142 No   
0 vs. 1.56 1.828 1.830 0.302 No   
0 vs. 25 0.456 0.457 0.959 No   
0 vs. 100 0.000 0.000 1.000 No   
0 vs. 50 0.000 0.000 1.000 No   
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Figure 7.52 shows in vitro cytotoxicity effects of Peltophorum pterocarpum 
(leaf) ethanolic extract on HT-29 cells. The IC50 value of P. pterocarpum (leaf) 
ethanolic extract generated from the dose-response graph is >100 μg/mL. Comparison 
of inhibition activity among concentrations using ANOVA indicates statistically 
significant difference with P = <0.001. 
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Figure 7.52 : Cytotoxicity effects of P. pterocarpum (leaf) ethanolic extract on HT-29 
cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: Peltophorum pterocarpum (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 1.000) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 81.929 0.442 0.255  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 100.000 0.000 0.000  
6.25 3 0 100.000 0.000 0.000  
3.13 3 0 100.000 0.000 0.000  
1.56 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 857.192 122.456 5010.607 <0.001  
Residual 16 0.391 0.0244    
Total 23 857.583     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 100 18.071 141.571 <0.001 Yes   
0 vs. 12.5 0.000 0.000 1.000 No   
0 vs. 1.56 0.000 0.000 1.000 No   
0 vs. 3.13 0.000 0.000 1.000 No   
0 vs. 6.25 0.000 0.000 1.000 No   
0 vs. 25 0.000 0.000 1.000 No   
0 vs. 50 0.000 0.000 1.000 No   
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Figure 7.53 shows in vitro cytotoxicity effects of Tetracera indica (fruit) 
ethanolic extract on HT-29 cells. The IC50 value of T. indica (fruit) ethanolic extract 
generated from the dose-response graph is >100 μg/mL. Comparison of inhibition 
activity among concentrations using ANOVA indicates statistically significant 
difference with P = 0.020. 
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Figure 7.53 : Cytotoxicity effects of T. indica (fruit) ethanolic extract on HT-29 cells. 
Each bar represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Tetracera indica (fruit) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 0.280) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 100.000 0.000 0.000  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 99.354 0.622 0.359  
6.25 3 0 99.543 0.792 0.457  
3.13 3 0 100.000 0.000 0.000  
1.56 3 0 98.732 0.726 0.419  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 4.594 0.656 3.406 0.020  
Residual 16 3.083 0.193    
Total 23 7.677     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = 0.020). 
 
Power of performed test with alpha = 0.050: 0.677 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 1.56 1.268 3.538 0.019 Yes   
0 vs. 12.5 0.646 1.802 0.433 No   
0 vs. 6.25 0.457 1.276 0.712 No   
0 vs. 25 0.000 0.000 1.000 No   
0 vs. 100 0.000 0.000 1.000 No   
0 vs. 3.13 0.000 0.000 1.000 No   
0 vs. 50 0.000 0.000 1.000 No   
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Figure 7.54 shows in vitro cytotoxicity effects of 50% MeOH 2% acetic acid 
fraction of L. flavescens (leaf) ethanolic extract on HT-29 cells. The IC50 value of 50% 
MeOH 2% acetic acid fraction of L. flavescens (leaf) ethanolic extract generated from 
the dose-response graph is >100 μg/mL. Comparison of inhibition activity among 
concentrations using ANOVA indicates statistically significant difference with P = 
<0.001. 
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Figure 7.54 : Cytotoxicity effects of 50% MeOH 2% acetic acid fraction of L. flavescens 
(leaf) ethanolic extract on HT-29 cells. Each bar represents the mean ± S.D. 
calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: 50% MeOH 2% acetic acid fraction of L. flavescens (leaf) ethanolic 
extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 0.314) 
 
Group Name N  Missing Mean Std Dev SEM  
100 3 0 100.000 0.000 0.000  
50 3 0 100.000 0.000 0.000  
25 3 0 100.000 0.000 0.000  
12.5 3 0 99.536 0.431 0.249  
6.25 3 0 99.420 0.504 0.291  
3.13 3 0 97.534 0.943 0.544  
1.56 3 0 99.720 0.242 0.140  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 14.751 2.107 12.156 <0.001  
Residual 16 2.774 0.173    
Total 23 17.524     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 3.13 2.466 7.255 <0.001 Yes   
0 vs. 6.25 0.580 1.705 0.495 No   
0 vs. 12.5 0.464 1.365 0.654 No   
0 vs. 1.56 0.280 0.823 0.889 No   
0 vs. 100 0.000 0.000 1.000 No   
0 vs. 25 0.000 0.000 1.000 No   
0 vs. 50 0.000 0.000 1.000 No   
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COMBINATION EFFECTS OF PLANT SAMPLES AND DOXORUBICIN 
HYDROCHLORIDE ON CYTOTOXICITY OF HT-29 CELLS 
Figure 7.55 shows in vitro cytotoxicity effects of doxorubicin hydrochloride, in 
combination with ethacrynic acid, on HT-29 cells. The IC50 value of doxorubicin 
hydrochloride generated from the dose-response graph is 0.19 ± 0.01 μg/mL. 
Concentration of ethacrynic acid was fixed at 10 μg/mL while concentration of 
doxorubicin hydrochloride varied (0-1 μg/mL). Comparison of inhibition activity 
among concentrations using ANOVA indicates statistically significant difference with P 
= <0.001. 
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Figure 7.55 : Cytotoxicity effects of doxorubicin hydrochloride, in combination with 
ethacrynic acid, on HT-29 cells. Each bar represents the mean ± S.D. 
calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Ethacrynic acid 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.672) 
 
Equal Variance Test: Passed (P = 0.971) 
 
Group Name N  Missing Mean Std Dev SEM  
1 3 0 8.585 1.691 0.976  
0.5 3 0 19.418 1.610 0.930  
0.25 3 0 37.410 1.792 1.034  
0.125 3 0 62.743 2.614 1.509  
0.0625 3 0 83.269 2.493 1.439  
0.0313 3 0 92.002 2.184 1.261  
0.0156 3 0 99.594 0.703 0.406  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 28425.527 4060.790 1204.392 <0.001  
Residual 16 53.946 3.372    
Total 23 28479.473     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
0 vs. 1 91.415 60.973 <0.001 Yes   
0 vs. 0.5 80.582 53.748 <0.001 Yes   
0 vs. 0.25 62.590 41.747 <0.001 Yes   
0 vs. 0.125 37.257 24.850 <0.001 Yes   
0 vs. 0.0625 16.731 11.160 <0.001 Yes   
0 vs. 0.0313 7.998 5.334 <0.001 Yes   
0 vs. 0.0156 0.406 0.271 0.790 No   
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Figure 7.56 shows in vitro cytotoxicity effects of doxorubicin hydrochloride, in 
combination with Anacardium occidentale (branch) ethanolic extract, on HT-29 cells. 
The IC50 value of doxorubicin hydrochloride generated from the dose-response graph is 
0.59 ± 0.03 μg/mL. Concentration of A. occidentale (branch) ethanolic extract was fixed 
at 50 μg/mL while concentration of doxorubicin hydrochloride varied (0-1 μg/mL). 
Comparison of inhibition activity among concentrations using ANOVA indicates 
statistically significant difference with P = <0.001. 
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Figure 7.56 : Cytotoxicity effects of doxorubicin hydrochloride, in combination with A. 
occidentale (branch) ethanolic extract, on HT-29 cells. Each bar 
represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Anacardium occidentale (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 0.407) 
 
Group Name N  Missing Mean Std Dev SEM  
1 3 0 35.243 0.427 0.247  
0.5 3 0 53.101 1.095 0.632  
0.25 3 0 68.111 0.164 0.0947  
0.125 3 0 73.567 0.268 0.155  
0.0625 3 0 80.321 1.270 0.733  
0.0313 3 0 95.082 1.679 0.969  
0.0156 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 11362.946 1623.278 2196.866 <0.001  
Residual 16 11.822 0.739    
Total 23 11374.769     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
0 vs. 1 64.757 92.266 <0.001 Yes   
0 vs. 0.5 46.899 66.821 <0.001 Yes   
0 vs. 0.25 31.889 45.435 <0.001 Yes   
0 vs. 0.125 26.433 37.661 <0.001 Yes   
0 vs. 0.0625 19.679 28.038 <0.001 Yes   
0 vs. 0.0313 4.918 7.007 <0.001 Yes   
0 vs. 0.0156 0.000 0.000 1.000 No   
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Figure 7.57 shows in vitro cytotoxicity effects of doxorubicin hydrochloride, in 
combination with Andrographis paniculata (leaf) ethanolic extract, on HT-29 cells. The 
IC50 value of doxorubicin hydrochloride generated from the dose-response graph is 0.25 
± 0.01 μg/mL. Concentration of A. paniculata (leaf) ethanolic extract was fixed at 50 
μg/mL while concentration of doxorubicin hydrochloride varied (0-1 μg/mL). 
Comparison of inhibition activity among concentrations using ANOVA indicates 
statistically significant difference with P = <0.001. 
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Figure 7.57 : Cytotoxicity effects of doxorubicin hydrochloride, in combination with A. 
paniculata (leaf) ethanolic extract, on HT-29 cells. Each bar represents 
the mean ± S.D. calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Andrographis paniculata (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 0.257) 
 
Group Name N  Missing Mean Std Dev SEM  
1 3 0 18.255 0.209 0.121  
0.5 3 0 35.592 0.293 0.169  
0.25 3 0 49.932 0.621 0.359  
0.125 3 0 54.770 0.421 0.243  
0.0625 3 0 64.926 0.255 0.147  
0.0313 3 0 70.442 0.621 0.359  
0.0156 3 0 81.927 1.652 0.954  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 14037.184 2005.312 4141.143 <0.001  
Residual 16 7.748 0.484    
Total 23 14044.932     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
0 vs. 1 81.745 143.872 <0.001 Yes   
0 vs. 0.5 64.408 113.359 <0.001 Yes   
0 vs. 0.25 50.068 88.120 <0.001 Yes   
0 vs. 0.125 45.230 79.605 <0.001 Yes   
0 vs. 0.0625 35.074 61.731 <0.001 Yes   
0 vs. 0.0313 29.558 52.022 <0.001 Yes   
0 vs. 0.0156 18.073 31.809 <0.001 Yes   
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Figure 7.58 shows in vitro cytotoxicity effects of doxorubicin hydrochloride, in 
combination with Cinnamomum zeylanicum (branch) ethanolic extract, on HT-29 cells. 
The IC50 value of doxorubicin hydrochloride generated from the dose-response graph is 
0.22 ± 0.00 μg/mL. Concentration of C. zeylanicum (branch) ethanolic extract was fixed 
at 50 μg/mL while concentration of doxorubicin hydrochloride varied (0-1 μg/mL). 
Comparison of inhibition activity among concentrations using ANOVA indicates 
statistically significant difference with P = <0.001. 
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Figure 7.58 : Cytotoxicity effects of doxorubicin hydrochloride, in combination with C. 
zeylanicum (branch) ethanolic extract, on HT-29 cells. Each bar 
represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Cinnamomum zeylanicum (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.562) 
 
Equal Variance Test: Passed (P = 0.287) 
 
Group Name N  Missing Mean Std Dev SEM  
1 3 0 18.812 1.214 0.701  
0.5 3 0 34.639 0.610 0.352  
0.25 3 0 45.244 0.560 0.324  
0.125 3 0 62.669 0.857 0.495  
0.0625 3 0 68.918 1.087 0.628  
0.0313 3 0 78.454 2.119 1.223  
0.0156 3 0 93.839 0.189 0.109  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 16997.902 2428.272 2259.206 <0.001  
Residual 16 17.197 1.075    
Total 23 17015.099     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
0 vs. 1 81.188 95.911 <0.001 Yes   
0 vs. 0.5 65.361 77.213 <0.001 Yes   
0 vs. 0.25 54.756 64.685 <0.001 Yes   
0 vs. 0.125 37.331 44.101 <0.001 Yes   
0 vs. 0.0625 31.082 36.718 <0.001 Yes   
0 vs. 0.0313 21.546 25.453 <0.001 Yes   
0 vs. 0.0156 6.161 7.278 <0.001 Yes   
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Figure 7.59 shows in vitro cytotoxicity effects of doxorubicin hydrochloride, in 
combination with Euodia redlevi (fruit&flower) ethanolic extract, on HT-29 cells. The 
IC50 value of doxorubicin hydrochloride generated from the dose-response graph is 0.41 
± 0.01 μg/mL. Concentration of E. redleri (fruit&flower) ethanolic extract was fixed at 
50 μg/mL while concentration of doxorubicin hydrochloride varied (0-1 μg/mL). 
Comparison of inhibition activity among concentrations using ANOVA indicates 
statistically significant difference with P = <0.001. 
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Figure 7.59 : Cytotoxicity effects of doxorubicin hydrochloride, in combination with E. 
redleri (fruit&flower) ethanolic extract, on HT-29 cells. Each bar 
represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Euodia redlevi (fruit&flower) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.542) 
 
Equal Variance Test: Passed (P = 0.636) 
 
Group Name N  Missing Mean Std Dev SEM  
1 3 0 24.028 1.274 0.735  
0.5 3 0 41.885 0.386 0.223  
0.25 3 0 65.156 0.637 0.368  
0.125 3 0 77.142 1.533 0.885  
0.0625 3 0 86.103 0.761 0.439  
0.0313 3 0 91.097 1.325 0.765  
0.0156 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 16206.241 2315.177 2699.412 <0.001  
Residual 16 13.723 0.858    
Total 23 16219.963     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
0 vs. 1 75.972 100.471 <0.001 Yes   
0 vs. 0.5 58.115 76.856 <0.001 Yes   
0 vs. 0.25 34.844 46.080 <0.001 Yes   
0 vs. 0.125 22.858 30.229 <0.001 Yes   
0 vs. 0.0625 13.897 18.378 <0.001 Yes   
0 vs. 0.0313 8.903 11.773 <0.001 Yes   
0 vs. 0.0156 0.000 0.000 1.000 No   
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Figure 7.60 shows in vitro cytotoxicity effects of doxorubicin hydrochloride, in 
combination with Garcinia atroviridis (branch) ethanolic extract, on HT-29 cells. The 
IC50 value of doxorubicin hydrochloride generated from the dose-response graph is 0.33 
± 0.02 μg/mL. Concentration of G. atroviridis (branch) ethanolic extract was fixed at 50 
μg/mL while concentration of doxorubicin hydrochloride varied (0-1 μg/mL). 
Comparison of inhibition activity among concentrations using ANOVA indicates 
statistically significant difference with P = <0.001. 
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Figure 7.60 : Cytotoxicity effects of doxorubicin hydrochloride, in combination with G. 
atroviridis (branch) ethanolic extract, on HT-29 cells. Each bar represents 
the mean ± S.D. calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Garcinia atroviridis (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.274) 
 
Equal Variance Test: Passed (P = 0.647) 
 
Group Name N  Missing Mean Std Dev SEM  
1 3 0 22.157 1.361 0.786  
0.5 3 0 36.216 0.911 0.526  
0.25 3 0 56.401 1.848 1.067  
0.125 3 0 68.328 0.767 0.443  
0.0625 3 0 77.302 0.661 0.382  
0.0313 3 0 89.517 1.875 1.082  
0.0156 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 17518.578 2502.654 1882.118 <0.001  
Residual 16 21.275 1.330    
Total 23 17539.853     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
0 vs. 1 77.843 82.677 <0.001 Yes   
0 vs. 0.5 63.784 67.746 <0.001 Yes   
0 vs. 0.25 43.599 46.306 <0.001 Yes   
0 vs. 0.125 31.672 33.639 <0.001 Yes   
0 vs. 0.0625 22.698 24.108 <0.001 Yes   
0 vs. 0.0313 10.483 11.135 <0.001 Yes   
0 vs. 0.0156 0.000 0.000 1.000 No   
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Figure 7.61 shows in vitro cytotoxicity effects of doxorubicin hydrochloride, in 
combination with Garcinia mangostana (branch) ethanolic extract, on HT-29 cells. The 
IC50 value of doxorubicin hydrochloride generated from the dose-response graph is 0.39 
± 0.01 μg/mL. Concentration of G. mangostana (branch) ethanolic extract was fixed at 
50 μg/mL while concentration of doxorubicin hydrochloride varied (0-1 μg/mL). 
Comparison of inhibition activity among concentrations using ANOVA indicates 
statistically significant difference with P = <0.001. 
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Figure 7.61 : Cytotoxicity effects of doxorubicin hydrochloride, in combination with G. 
mangostana (branch) ethanolic extract, on HT-29 cells. Each bar 
represents the mean ± S.D. calculated from three independent 
determinations. 
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One Way Analysis of Variance  
 
Data source: Garcinia mangostana (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.056) 
 
Equal Variance Test: Passed (P = 0.144) 
 
Group Name N  Missing Mean Std Dev SEM  
1 3 0 21.312 1.566 0.904  
0.5 3 0 41.772 0.400 0.231  
0.25 3 0 60.587 0.556 0.321  
0.125 3 0 70.610 0.448 0.259  
0.0625 3 0 79.872 2.426 1.401  
0.0313 3 0 87.256 1.636 0.945  
0.0156 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 16354.072 2336.296 1599.407 <0.001  
Residual 16 23.372 1.461    
Total 23 16377.443     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
0 vs. 1 78.688 79.739 <0.001 Yes   
0 vs. 0.5 58.228 59.006 <0.001 Yes   
0 vs. 0.25 39.413 39.939 <0.001 Yes   
0 vs. 0.125 29.390 29.783 <0.001 Yes   
0 vs. 0.0625 20.128 20.397 <0.001 Yes   
0 vs. 0.0313 12.744 12.914 <0.001 Yes   
0 vs. 0.0156 0.000 0.000 1.000 No   
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Figure 7.62 shows in vitro cytotoxicity effects of doxorubicin hydrochloride, in 
combination with Garcinia mangostana (leaf) ethanolic extract, on HT-29 cells. The 
IC50 value of doxorubicin hydrochloride generated from the dose-response graph is 0.30 
± 0.01 μg/mL. Concentration of G. mangostana (leaf) ethanolic extract was fixed at 50 
μg/mL while concentration of doxorubicin hydrochloride varied (0-1 μg/mL). 
Comparison of inhibition activity among concentrations using ANOVA indicates 
statistically significant difference with P = <0.001. 
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Figure 7.62 : Cytotoxicity effects of doxorubicin hydrochloride, in combination with G. 
mangostana (leaf) ethanolic extract, on HT-29 cells. Each bar represents 
the mean ± S.D. calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Garcinia mangostana (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.918) 
 
Equal Variance Test: Passed (P = 0.565) 
 
Group Name N  Missing Mean Std Dev SEM  
1 3 0 21.337 0.839 0.485  
0.5 3 0 35.142 1.220 0.704  
0.25 3 0 53.880 0.895 0.517  
0.125 3 0 64.421 0.866 0.500  
0.0625 3 0 66.521 0.941 0.543  
0.0313 3 0 69.957 1.251 0.722  
0.0156 3 0 82.412 2.400 1.386  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 13171.163 1881.595 1259.036 <0.001  
Residual 16 23.912 1.494    
Total 23 13195.075     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
0 vs. 1 78.663 78.809 <0.001 Yes   
0 vs. 0.5 64.858 64.978 <0.001 Yes   
0 vs. 0.25 46.120 46.205 <0.001 Yes   
0 vs. 0.125 35.579 35.645 <0.001 Yes   
0 vs. 0.0625 33.479 33.541 <0.001 Yes   
0 vs. 0.0313 30.043 30.098 <0.001 Yes   
0 vs. 0.0156 17.588 17.621 <0.001 Yes   
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Figure 7.63 shows in vitro cytotoxicity effects of doxorubicin hydrochloride, in 
combination with Hibiscus tiliaceus (leaf) ethanolic extract, on HT-29 cells. The IC50 
value of doxorubicin hydrochloride generated from the dose-response graph is 0.33 ± 
0.01 μg/mL. Concentration of H. tiliaceus (leaf) ethanolic extract was fixed at 50 μg/mL 
while concentration of doxorubicin hydrochloride varied (0-1 μg/mL). Comparison of 
inhibition activity among concentrations using ANOVA indicates statistically 
significant difference with P = <0.001. 
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Figure 7.63 : Cytotoxicity effects of doxorubicin hydrochloride, in combination with H. 
tiliaceus (leaf) ethanolic extract, on HT-29 cells. Each bar represents the 
mean ± S.D. calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Hibiscus tiliaceus (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.220) 
 
Equal Variance Test: Passed (P = 0.821) 
 
Group Name N  Missing Mean Std Dev SEM  
1 3 0 18.571 0.661 0.382  
0.5 3 0 38.741 0.231 0.133  
0.25 3 0 55.268 1.122 0.648  
0.125 3 0 62.748 0.708 0.409  
0.0625 3 0 71.748 1.634 0.944  
0.0313 3 0 80.539 0.643 0.371  
0.0156 3 0 95.849 0.893 0.515  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 16221.222 2317.317 3023.233 <0.001  
Residual 16 12.264 0.767    
Total 23 16233.486     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
0 vs. 1 81.429 113.911 <0.001 Yes   
0 vs. 0.5 61.259 85.696 <0.001 Yes   
0 vs. 0.25 44.732 62.576 <0.001 Yes   
0 vs. 0.125 37.252 52.112 <0.001 Yes   
0 vs. 0.0625 28.252 39.522 <0.001 Yes   
0 vs. 0.0313 19.461 27.225 <0.001 Yes   
0 vs. 0.0156 4.151 5.807 <0.001 Yes   
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Figure 7.64 shows in vitro cytotoxicity effects of doxorubicin hydrochloride, in 
combination with Lawsonia inermis (branch) ethanolic extract, on HT-29 cells. The IC50 
value of doxorubicin hydrochloride generated from the dose-response graph is 0.26 ± 
0.02 μg/mL. Concentration of L. inermis (branch) ethanolic extract was fixed at 50 
μg/mL while concentration of doxorubicin hydrochloride varied (0-1 μg/mL). 
Comparison of inhibition activity among concentrations using ANOVA indicates 
statistically significant difference with P = <0.001. 
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Figure 7.64 : Cytotoxicity effects of doxorubicin hydrochloride, in combination with L. 
inermis (branch) ethanolic extract, on HT-29 cells. Each bar represents 
the mean ± S.D. calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Lawsonia inermis (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.579) 
 
Equal Variance Test: Passed (P = 0.654) 
 
Group Name N  Missing Mean Std Dev SEM  
1 3 0 24.328 0.401 0.232  
0.5 3 0 38.081 0.826 0.477  
0.25 3 0 50.256 0.873 0.504  
0.125 3 0 59.346 2.280 1.317  
0.0625 3 0 66.549 1.614 0.932  
0.0313 3 0 79.850 1.494 0.863  
0.0156 3 0 97.927 1.978 1.142  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 15475.849 2210.836 1137.063 <0.001  
Residual 16 31.109 1.944    
Total 23 15506.959     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
0 vs. 1 75.672 66.465 <0.001 Yes   
0 vs. 0.5 61.919 54.386 <0.001 Yes   
0 vs. 0.25 49.744 43.692 <0.001 Yes   
0 vs. 0.125 40.654 35.708 <0.001 Yes   
0 vs. 0.0625 33.451 29.381 <0.001 Yes   
0 vs. 0.0313 20.150 17.699 <0.001 Yes   
0 vs. 0.0156 2.073 1.821 0.087 No   
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Figure 7.65 shows in vitro cytotoxicity effects of doxorubicin hydrochloride, in 
combination with Leptospermum flavescens (leaf) ethanolic extract, on HT-29 cells. The 
IC50 value of doxorubicin hydrochloride generated from the dose-response graph is 0.39 
± 0.01 μg/mL. Concentration of L. flavescens (leaf) ethanolic extract was fixed at 50 
μg/mL while concentration of doxorubicin hydrochloride varied (0-1 μg/mL). 
Comparison of inhibition activity among concentrations using ANOVA indicates 
statistically significant difference with P = <0.001. 
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Figure 7.65 : Cytotoxicity effects of doxorubicin hydrochloride, in combination with L. 
flavescens (leaf) ethanolic extract, on HT-29 cells. Each bar represents the 
mean ± S.D. calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Leptospermum flavescens (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.351) 
 
Equal Variance Test: Passed (P = 0.618) 
 
Group Name N  Missing Mean Std Dev SEM  
1 3 0 27.825 0.547 0.316  
0.5 3 0 41.363 0.522 0.302  
0.25 3 0 61.010 0.833 0.481  
0.125 3 0 67.942 2.126 1.228  
0.0625 3 0 70.596 1.269 0.733  
0.0313 3 0 77.469 0.752 0.434  
0.0156 3 0 84.835 1.625 0.938  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 11265.828 1609.404 1214.139 <0.001  
Residual 16 21.209 1.326    
Total 23 11287.036     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
0 vs. 1 72.175 76.778 <0.001 Yes   
0 vs. 0.5 58.637 62.377 <0.001 Yes   
0 vs. 0.25 38.990 41.477 <0.001 Yes   
0 vs. 0.125 32.058 34.102 <0.001 Yes   
0 vs. 0.0625 29.404 31.279 <0.001 Yes   
0 vs. 0.0313 22.531 23.968 <0.001 Yes   
0 vs. 0.0156 15.165 16.132 <0.001 Yes   
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Figure 7.66 shows in vitro cytotoxicity effects of doxorubicin hydrochloride, in 
combination with Oxalis barrelieri (root) ethanolic extract, on HT-29 cells. The IC50 
value of doxorubicin hydrochloride generated from the dose-response graph is 0.33 ± 
0.01 μg/mL. Concentration of O. barrelieri (root) ethanolic extract was fixed at 50 
μg/mL while concentration of doxorubicin hydrochloride varied (0-1 μg/mL). 
Comparison of inhibition activity among concentrations using ANOVA indicates 
statistically significant difference with P = <0.001. 
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Figure 7.66 : Cytotoxicity effects of doxorubicin hydrochloride, in combination with O. 
barrelieri (root) ethanolic extract, on HT-29 cells. Each bar represents the 
mean ± S.D. calculated from three independent determinations. 
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One Way Analysis of Variance   
 
Data source: Oxalis barrelieri (root) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 0.127) 
 
Group Name N  Missing Mean Std Dev SEM  
1 3 0 24.263 1.392 0.804  
0.5 3 0 39.719 0.233 0.135  
0.25 3 0 54.550 0.595 0.343  
0.125 3 0 71.617 3.237 1.869  
0.0625 3 0 75.394 3.197 1.846  
0.0313 3 0 81.766 0.840 0.485  
0.0156 3 0 99.178 0.855 0.494  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 15438.622 2205.517 720.784 <0.001  
Residual 16 48.958 3.060    
Total 23 15487.581     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
0 vs. 1 75.737 53.027 <0.001 Yes   
0 vs. 0.5 60.281 42.206 <0.001 Yes   
0 vs. 0.25 45.450 31.822 <0.001 Yes   
0 vs. 0.125 28.383 19.873 <0.001 Yes   
0 vs. 0.0625 24.606 17.228 <0.001 Yes   
0 vs. 0.0313 18.234 12.767 <0.001 Yes   
0 vs. 0.0156 0.822 0.576 0.573 No   
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Figure 7.67 shows in vitro cytotoxicity effects of doxorubicin hydrochloride, in 
combination with Peltophorum pterocarpum (leaf) ethanolic extract, on HT-29 cells. 
The IC50 value of doxorubicin hydrochloride generated from the dose-response graph is 
0.48 ± 0.02 μg/mL. Concentration of P. pterocarpum (leaf) ethanolic extract was fixed 
at 50 μg/mL while concentration of doxorubicin hydrochloride varied (0-1 μg/mL). 
Comparison of inhibition activity among concentrations using ANOVA indicates 
statistically significant difference with P = <0.001. 
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Figure 7.67 : Cytotoxicity effects of doxorubicin hydrochloride, in combination with P. 
pterocarpum (leaf) ethanolic extract, on HT-29 cells. Each bar represents 
the mean ± S.D. calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Peltophorum pterocarpum (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.536) 
 
Equal Variance Test: Passed (P = 0.382) 
 
Group Name N  Missing Mean Std Dev SEM  
1 3 0 32.302 1.294 0.747  
0.5 3 0 48.683 1.478 0.854  
0.25 3 0 60.742 1.532 0.884  
0.125 3 0 67.020 2.519 1.455  
0.0625 3 0 66.260 0.549 0.317  
0.0313 3 0 78.283 1.748 1.009  
0.0156 3 0 84.975 2.173 1.255  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 9353.775 1336.254 518.038 <0.001  
Residual 16 41.271 2.579    
Total 23 9395.047     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
0 vs. 1 67.698 51.624 <0.001 Yes   
0 vs. 0.5 51.317 39.133 <0.001 Yes   
0 vs. 0.25 39.258 29.937 <0.001 Yes   
0 vs. 0.0625 33.740 25.729 <0.001 Yes   
0 vs. 0.125 32.980 25.150 <0.001 Yes   
0 vs. 0.0313 21.717 16.561 <0.001 Yes   
0 vs. 0.0156 15.025 11.458 <0.001 Yes   
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Figure 7.68 shows in vitro cytotoxicity effects of doxorubicin hydrochloride, in 
combination with Tetracera indica (fruit) ethanolic extract, on HT-29 cells. The IC50 
value of doxorubicin hydrochloride generated from the dose-response graph is 0.30 ± 
0.04 μg/mL. Concentration of T. indica (fruit) ethanolic extract was fixed at 50 μg/mL 
while concentration of doxorubicin hydrochloride varied (0-1 μg/mL). Comparison of 
inhibition activity among concentrations using ANOVA indicates statistically 
significant difference with P = <0.001. 
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Figure 7.68 : Cytotoxicity effects of doxorubicin hydrochloride, in combination with T. 
indica (fruit) ethanolic extract, on HT-29 cells. Each bar represents the 
mean ± S.D. calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Tetracera indica (fruit) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.214) 
 
Equal Variance Test: Passed (P = 0.942) 
 
Group Name N  Missing Mean Std Dev SEM  
1 3 0 21.215 0.592 0.342  
0.5 3 0 38.306 1.641 0.947  
0.25 3 0 53.425 2.675 1.545  
0.125 3 0 64.643 2.060 1.189  
0.0625 3 0 73.677 0.849 0.490  
0.0313 3 0 84.483 1.419 0.819  
0.0156 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 16913.084 2416.155 1125.371 <0.001  
Residual 16 34.352 2.147    
Total 23 16947.436     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
0 vs. 1 78.785 65.853 <0.001 Yes   
0 vs. 0.5 61.694 51.567 <0.001 Yes   
0 vs. 0.25 46.575 38.930 <0.001 Yes   
0 vs. 0.125 35.357 29.553 <0.001 Yes   
0 vs. 0.0625 26.323 22.002 <0.001 Yes   
0 vs. 0.0313 15.517 12.970 <0.001 Yes   
0 vs. 0.0156 0.000 0.000 1.000 No   
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Figure 7.69 shows in vitro cytotoxicity effects of doxorubicin hydrochloride, in 
combination with 50% MeOH 2% acetic acid fraction of L. flavescens (leaf) ethanolic 
extract, on HT-29 cells. The IC50 value of doxorubicin hydrochloride generated from the 
dose-response graph is 0.26 ± 0.00 μg/mL. Concentration of 50% MeOH 2% acetic acid 
fraction of L. flavescens (leaf) ethanolic extract was fixed at 50 μg/mL while 
concentration of doxorubicin hydrochloride varied (0-1 μg/mL). Comparison of 
inhibition activity among concentrations using ANOVA indicates statistically 
significant difference with P = <0.001. 
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Figure 7.69 : Cytotoxicity effects of doxorubicin hydrochloride, in combination with 50% 
MeOH 2% acetic acid fraction of L. flavescens (leaf) ethanolic extract, on 
HT-29 cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
 
323 
 
One Way Analysis of Variance  
 
Data source: 50% MeOH 2% acetic acid fraction of L. flavescens (leaf) ethanolic 
extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.205) 
 
Equal Variance Test: Passed (P = 0.559) 
 
Group Name N  Missing Mean Std Dev SEM  
1 3 0 17.183 0.195 0.112  
0.5 3 0 31.531 0.822 0.474  
0.25 3 0 51.043 0.225 0.130  
0.125 3 0 67.409 0.974 0.562  
0.0625 3 0 68.986 1.040 0.600  
0.0313 3 0 80.349 0.552 0.319  
0.0156 3 0 90.871 0.393 0.227  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 17199.237 2457.034 6041.853 <0.001  
Residual 16 6.507 0.407    
Total 23 17205.743     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
0 vs. 1 82.817 159.055 <0.001 Yes   
0 vs. 0.5 68.469 131.497 <0.001 Yes   
0 vs. 0.25 48.957 94.024 <0.001 Yes   
0 vs. 0.125 32.591 62.592 <0.001 Yes   
0 vs. 0.0625 31.014 59.564 <0.001 Yes   
0 vs. 0.0313 19.651 37.741 <0.001 Yes   
0 vs. 0.0156 9.129 17.533 <0.001 Yes   
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One Way Analysis of Variance  
 
Data source: Overall IC50 for doxo combination 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 0.363) 
 
Group Name  N  Missing Mean Std Dev SEM  
Doxo alone 3 0 0.788 0.0459 0.0265  
Doxo + Ethacrynic acid  3 0 0.187 0.0108 0.00623  
Doxo + Anacardium occidentale 3 0 0.586 0.0249 0.0144  
Doxo + Andrographis paniculata 3 0 0.246 0.0123 0.00713  
Doxo + Cinnamomum zeylanicu 3 0 0.216 0.00208 0.00120  
Doxo + Euodia redlevi (fruit&f 3 0 0.413 0.00529 0.00306  
Doxo + Garcinia atroviridis (b 3 0 0.328 0.0189 0.0109  
Doxo + Garcinia mangostana (br 3 0 0.391 0.00643 0.00371  
Doxo + Garcinia mangostana (le 3 0 0.302 0.0110 0.00633  
Doxo + Hibiscus tiliaceus (lea 3 0 0.329 0.0131 0.00755  
Doxo + Lawsonia inermis (branc 3 0 0.256 0.0159 0.00917  
Doxo + Leptospermum flavesce 3 0 0.390 0.00819 0.00473  
Doxo + Oxalis barrelieri (root 3 0 0.327 0.00808 0.00467  
Doxo + Peltophorum pterocarpu 3 0 0.476 0.0227 0.0131  
Doxo + Tetracera indica (fruit 3 0 0.304 0.0420 0.0242  
Doxo + 50% MeOH 2% acetic a 3 0 0.263 0.00208 0.00120  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 15 1.037 0.0692 173.176 <0.001  
Residual 32 0.0128 0.000399    
Total 47 1.050     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Doxo alone vs. Doxo + Ethac 0.601 36.833 <0.001 Yes   
Doxo alone vs. Doxo + Cinna 0.573 35.097 <0.001 Yes   
Doxo alone vs. Doxo + Andro 0.542 33.217 <0.001 Yes   
Doxo alone vs. Doxo + Lawso 0.532 32.605 <0.001 Yes   
Doxo alone vs. Doxo + 50% M 0.526 32.216 <0.001 Yes   
Doxo alone vs. Doxo + Garci 0.487 29.826 <0.001 Yes   
Doxo alone vs. Doxo + Tetra 0.484 29.683 <0.001 Yes   
Doxo alone vs. Doxo + Oxali 0.462 28.294 <0.001 Yes   
Doxo alone vs. Doxo + Garci 0.460 28.192 <0.001 Yes   
Doxo alone vs. Doxo + Hibis 0.459 28.151 <0.001 Yes   
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Doxo alone vs. Doxo + Lepto 0.398 24.413 <0.001 Yes   
Doxo alone vs. Doxo + Garci 0.398 24.372 <0.001 Yes   
Doxo alone vs. Doxo + Euodi 0.375 23.003 <0.001 Yes   
Doxo alone vs. Doxo + Pelto 0.312 19.142 <0.001 Yes   
Doxo alone vs. Doxo + Anaca 0.203 12.421 <0.001 Yes   
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050 
  
Doxo + Ethac vs. Doxo + Anaca 0.398 28.884 <0.001 Yes   
Doxo + Ethac vs. Doxo + Pelto 0.289 20.931 <0.001 Yes   
Doxo + Ethac vs. Doxo + Euodi 0.226 16.363 <0.001 Yes   
Doxo + Ethac vs. Doxo + Garci 0.203 14.744 <0.001 Yes   
Doxo + Ethac vs. Doxo + Lepto 0.203 14.696 <0.001 Yes   
Doxo + Ethac vs. Doxo + Hibis 0.142 10.272 <0.001 Yes   
Doxo + Ethac vs. Doxo + Garci 0.141 10.224 <0.001 Yes   
Doxo + Ethac vs. Doxo + Oxali 0.139 10.103 <0.001 Yes   
Doxo + Ethac vs. Doxo + Tetra 0.117 8.460 <0.001 Yes   
Doxo + Ethac vs. Doxo + Garci 0.114 8.290 <0.001 Yes   
Doxo + Ethac vs. Doxo + 50% M 0.0753 5.462 <0.001 Yes   
Doxo + Ethac vs. Doxo + Lawso 0.0690 5.003 <0.001 Yes   
Doxo + Ethac vs. Doxo + Andro 0.0590 4.278 <0.001 Yes   
Doxo + Ethac vs. Doxo + Cinna 0.0283 2.054 0.049 Yes   
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COMBINATION EFFECTS OF PLANT SAMPLES AND CISPLATIN ON 
CYTOTOXICITY OF HT-29 CELLS 
Figure 7.70 shows in vitro cytotoxicity effects of cisplatin, in combination with 
ethacrynic acid, on HT-29 cells. The IC50 value of cisplatin generated from the dose-
response graph is 8.78 ± 0.15 μg/mL. Concentration of ethacrynic acid was fixed at 10 
μg/mL while concentration of cisplatin varied (0-10 μg/mL). Comparison of inhibition 
activity among concentrations using ANOVA indicates statistically significant 
difference with P = <0.001. 
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Figure 7.70 : Cytotoxicity effects of cisplatin, in combination with ethacrynic acid, on 
HT-29 cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
 
 
327 
 
One Way Analysis of Variance  
 
Data source: Ethacrynic acid 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.331) 
 
Equal Variance Test: Passed (P = 0.590) 
 
Group Name N  Missing Mean Std Dev SEM  
10 3 0 45.999 0.508 0.293  
5 3 0 62.391 0.736 0.425  
2.5 3 0 73.206 0.679 0.392  
1.25 3 0 76.061 1.339 0.773  
.626 3 0 86.765 2.501 1.444  
.313 3 0 97.231 2.166 1.250  
.156 3 0 97.346 2.023 1.168  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 7713.697 1101.957 487.296 <0.001  
Residual 16 36.182 2.261    
Total 23 7749.878     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 10 54.001 43.981 <0.001 Yes   
0 vs. 5 37.609 30.630 <0.001 Yes   
0 vs. 2.5 26.794 21.822 <0.001 Yes   
0 vs. 1.25 23.939 19.497 <0.001 Yes   
0 vs. .626 13.235 10.779 <0.001 Yes   
0 vs. .313 2.769 2.256 0.075 No   
0 vs. .156 2.654 2.161 0.046 Yes   
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Figure 7.71 shows in vitro cytotoxicity effects of cisplatin, in combination with 
Anacardium occidentale (branch) ethanolic extract, on HT-29 cells. The IC50 value of 
cisplatin generated from the dose-response graph is 8.66 ± 0.13 μg/mL. Concentration 
of A. occidentale (branch) ethanolic extract was fixed at 50 μg/mL while concentration 
of cisplatin varied (0-10 μg/mL). Comparison of inhibition activity among 
concentrations using ANOVA indicates statistically significant difference with P = 
<0.001. 
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Figure 7.71 : Cytotoxicity effects of cisplatin, in combination with A. occidentale 
(branch) ethanolic extract, on HT-29 cells. Each bar represents the mean 
± S.D. calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Anacardium occidentale (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.656) 
 
Equal Variance Test: Passed (P = 0.935) 
 
Group Name N  Missing Mean Std Dev SEM  
10 3 0 44.076 0.900 0.520  
5 3 0 66.153 1.204 0.695  
2.5 3 0 77.359 1.708 0.986  
1.25 3 0 87.205 1.279 0.739  
.626 3 0 86.414 0.573 0.331  
.313 3 0 89.972 1.421 0.820  
.156 3 0 96.287 0.977 0.564  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 7019.977 1002.854 793.294 <0.001  
Residual 16 20.227 1.264    
Total 23 7040.203     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 10 55.924 60.917 <0.001 Yes   
0 vs. 5 33.847 36.869 <0.001 Yes   
0 vs. 2.5 22.641 24.662 <0.001 Yes   
0 vs. .626 13.586 14.799 <0.001 Yes   
0 vs. 1.25 12.795 13.938 <0.001 Yes   
0 vs. .313 10.028 10.923 <0.001 Yes   
0 vs. .156 3.713 4.045 <0.001 Yes   
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Figure 7.72 shows in vitro cytotoxicity effects of cisplatin, in combination with 
Andrographis paniculata (leaf) ethanolic extract, on HT-29 cells. The IC50 value of 
cisplatin generated from the dose-response graph is 4.70 ± 0.18 μg/mL. Concentration 
of A. paniculata (leaf) ethanolic extract was fixed at 50 μg/mL while concentration of 
cisplatin varied (0-10 μg/mL). Comparison of inhibition activity among concentrations 
using ANOVA indicates statistically significant difference with P = <0.001. 
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Figure 7.72 : Cytotoxicity effects of cisplatin, in combination with A. paniculata (leaf) 
ethanolic extract, on HT-29 cells. Each bar represents the mean ± S.D. 
calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Andrographis paniculata (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.097) 
 
Equal Variance Test: Passed (P = 0.280) 
 
Group Name N  Missing Mean Std Dev SEM  
10 3 0 29.058 1.171 0.676  
5 3 0 48.248 1.122 0.648  
2.5 3 0 62.325 0.0915 0.0528  
1.25 3 0 73.391 0.809 0.467  
.626 3 0 77.245 0.171 0.0987  
.313 3 0 88.169 1.073 0.620  
.156 3 0 91.747 1.206 0.696  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 11887.225 1698.175 2291.403 <0.001  
Residual 16 11.858 0.741    
Total 23 11899.083     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 10 70.942 100.928 <0.001 Yes   
0 vs. 5 51.752 73.626 <0.001 Yes   
0 vs. 2.5 37.675 53.599 <0.001 Yes   
0 vs. 1.25 26.609 37.856 <0.001 Yes   
0 vs. .626 22.755 32.374 <0.001 Yes   
0 vs. .313 11.831 16.832 <0.001 Yes   
0 vs. .156 8.253 11.741 <0.001 Yes   
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Figure 7.73 shows in vitro cytotoxicity effects of cisplatin, in combination with 
Cinnamomum zeylanicum (branch) ethanolic extract, on HT-29 cells. The IC50 value of 
cisplatin generated from the dose-response graph is 9.23 ± 0.07 μg/mL. Concentration 
of C. zeylanicum (branch) ethanolic extract was fixed at 50 μg/mL while concentration 
of cisplatin varied (0-10 μg/mL). Comparison of inhibition activity among 
concentrations using ANOVA indicates statistically significant difference with P = 
<0.001. 
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Figure 7.73 : Cytotoxicity effects of cisplatin, in combination with C. zeylanicum 
(branch) ethanolic extract, on HT-29 cells. Each bar represents the mean 
± S.D. calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Cinnamomum zeylanicum (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 0.701) 
 
Group Name N  Missing Mean Std Dev SEM  
10 3 0 45.939 0.209 0.121  
5 3 0 72.503 1.590 0.918  
2.5 3 0 81.272 1.844 1.065  
1.25 3 0 87.604 0.810 0.468  
.626 3 0 92.709 0.908 0.524  
.313 3 0 100.000 0.000 0.000  
.156 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 7311.100 1044.443 1121.029 <0.001  
Residual 16 14.907 0.932    
Total 23 7326.007     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 10 54.061 68.595 <0.001 Yes   
0 vs. 5 27.497 34.890 <0.001 Yes   
0 vs. 2.5 18.728 23.764 <0.001 Yes   
0 vs. 1.25 12.396 15.728 <0.001 Yes   
0 vs. .626 7.291 9.251 <0.001 Yes   
0 vs. .313 0.000 0.000 1.000 No   
0 vs. .156 0.000 0.000 1.000 No   
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Figure 7.74 shows in vitro cytotoxicity effects of cisplatin, in combination with 
Euodia redlevi (fruit&flower) ethanolic extract, on HT-29 cells. The IC50 value of 
cisplatin generated from the dose-response graph is 8.55 ± 0.06 μg/mL. Concentration 
of E. redleri (fruit&flower) ethanolic extract was fixed at 50 μg/mL while concentration 
of cisplatin varied (0-10 μg/mL). Comparison of inhibition activity among 
concentrations using ANOVA indicates statistically significant difference with P = 
<0.001. 
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Figure 7.74 : Cytotoxicity effects of cisplatin, in combination with E. redleri 
(fruit&flower) ethanolic extract, on HT-29 cells. Each bar represents 
the mean ± S.D. calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Euodia redlevi (fruit&flower) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.325) 
 
Equal Variance Test: Passed (P = 0.640) 
 
Group Name N  Missing Mean Std Dev SEM  
10 3 0 41.924 0.420 0.243  
5 3 0 69.704 0.268 0.155  
2.5 3 0 84.551 1.669 0.964  
1.25 3 0 89.347 1.110 0.641  
.626 3 0 92.059 1.628 0.940  
.313 3 0 98.458 0.684 0.395  
.156 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 8362.814 1194.688 1293.814 <0.001  
Residual 16 14.774 0.923    
Total 23 8377.588     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 10 58.076 74.021 <0.001 Yes   
0 vs. 5 30.296 38.613 <0.001 Yes   
0 vs. 2.5 15.449 19.690 <0.001 Yes   
0 vs. 1.25 10.653 13.577 <0.001 Yes   
0 vs. .626 7.941 10.121 <0.001 Yes   
0 vs. .313 1.542 1.965 0.129 No   
0 vs. .156 0.000 0.000 1.000 No   
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Figure 7.75 shows in vitro cytotoxicity effects of cisplatin, in combination with 
Garcinia atroviridis (branch) ethanolic extract, on HT-29 cells. The IC50 value of 
cisplatin generated from the dose-response graph is 8.30 ± 0.12 μg/mL. Concentration 
of G. atroviridis (branch) ethanolic extract was fixed at 50 μg/mL while concentration 
of cisplatin varied (0-10 μg/mL). Comparison of inhibition activity among 
concentrations using ANOVA indicates statistically significant difference with P = 
<0.001. 
 
 
0
10
20
30
40
50
60
70
80
90
100
P
er
ce
n
ta
g
e 
o
f 
ce
ll
 v
ia
b
il
it
y
 (
%
)
Concentration (μg/mL)
 
Figure 7.75 : Cytotoxicity effects of cisplatin, in combination with G. atroviridis 
(branch) ethanolic extract, on HT-29 cells. Each bar represents the 
mean ± S.D. calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Garcinia atroviridis (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 0.471) 
 
Group Name N  Missing Mean Std Dev SEM  
10 3 0 43.920 0.588 0.339  
5 3 0 61.772 0.451 0.260  
2.5 3 0 71.421 1.419 0.820  
1.25 3 0 83.215 1.937 1.118  
.626 3 0 89.231 1.806 1.043  
.313 3 0 100.000 0.000 0.000  
.156 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 8975.235 1282.176 1071.183 <0.001  
Residual 16 19.152 1.197    
Total 23 8994.387     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 10 56.080 62.778 <0.001 Yes   
0 vs. 5 38.228 42.794 <0.001 Yes   
0 vs. 2.5 28.579 31.993 <0.001 Yes   
0 vs. 1.25 16.785 18.790 <0.001 Yes   
0 vs. .626 10.769 12.055 <0.001 Yes   
0 vs. .313 0.000 0.000 1.000 No   
0 vs. .156 0.000 0.000 1.000 No   
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Figure 7.76 shows in vitro cytotoxicity effects of cisplatin, in combination with 
Garcinia mangostana (branch) ethanolic extract, on HT-29 cells. The IC50 value of 
cisplatin generated from the dose-response graph is 9.24 ± 0.55 μg/mL. Concentration 
of G. mangostana (branch) ethanolic extract was fixed at 50 μg/mL while concentration 
of cisplatin varied (0-10 μg/mL). Comparison of inhibition activity among 
concentrations using ANOVA indicates statistically significant difference with P = 
<0.001. 
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Figure 7.76 : Cytotoxicity effects of cisplatin, in combination with G. mangostana 
(branch) ethanolic extract, on HT-29 cells. Each bar represents the mean 
± S.D. calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Garcinia mangostana (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 0.764) 
 
Group Name N  Missing Mean Std Dev SEM  
10 3 0 47.422 1.898 1.096  
5 3 0 64.155 1.773 1.024  
2.5 3 0 77.191 2.131 1.231  
1.25 3 0 80.617 1.401 0.809  
.626 3 0 89.617 2.975 1.718  
.313 3 0 100.000 0.000 0.000  
.156 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 7704.059 1100.580 398.333 <0.001  
Residual 16 44.207 2.763    
Total 23 7748.266     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 10 52.578 38.740 <0.001 Yes   
0 vs. 5 35.845 26.411 <0.001 Yes   
0 vs. 2.5 22.809 16.806 <0.001 Yes   
0 vs. 1.25 19.383 14.281 <0.001 Yes   
0 vs. .626 10.383 7.650 <0.001 Yes   
0 vs. .313 0.000 0.000 1.000 No   
0 vs. .156 0.000 0.000 1.000 No   
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Figure 7.77 shows in vitro cytotoxicity effects of cisplatin, in combination with 
Garcinia mangostana (leaf) ethanolic extract, on HT-29 cells. The IC50 value of 
cisplatin generated from the dose-response graph is 6.74 ± 0.38 μg/mL. Concentration 
of G. mangostana (leaf) ethanolic extract was fixed at 50 μg/mL while concentration of 
cisplatin varied (0-10 μg/mL). Comparison of inhibition activity among concentrations 
using ANOVA indicates statistically significant difference with P = <0.001. 
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Figure 7.77 : Cytotoxicity effects of cisplatin, in combination with G. mangostana (leaf) 
ethanolic extract, on HT-29 cells. Each bar represents the mean ± S.D. 
calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Garcinia mangostana (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Passed (P = 0.368) 
 
Group Name N  Missing Mean Std Dev SEM  
10 3 0 31.176 1.738 1.003  
5 3 0 60.406 4.422 2.553  
2.5 3 0 63.952 0.717 0.414  
1.25 3 0 81.336 0.662 0.382  
.626 3 0 94.412 0.647 0.373  
.313 3 0 100.000 0.000 0.000  
.156 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 13275.755 1896.536 633.627 <0.001  
Residual 16 47.890 2.993    
Total 23 13323.646     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 10 68.824 48.722 <0.001 Yes   
0 vs. 5 39.594 28.030 <0.001 Yes   
0 vs. 2.5 36.048 25.519 <0.001 Yes   
0 vs. 1.25 18.664 13.213 <0.001 Yes   
0 vs. .626 5.588 3.956 0.003 Yes   
0 vs. .313 0.000 0.000 1.000 No   
0 vs. .156 0.000 0.000 1.000 No   
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Figure 7.78 shows in vitro cytotoxicity effects of cisplatin, in combination with 
Hibiscus tiliaceus (leaf) ethanolic extract, on HT-29 cells. The IC50 value of cisplatin 
generated from the dose-response graph is 9.24 ± 0.30 μg/mL. Concentration of H. 
tiliaceus (leaf) ethanolic extract was fixed at 50 μg/mL while concentration of cisplatin 
varied (0-10 μg/mL). Comparison of inhibition activity among concentrations using 
ANOVA indicates statistically significant difference with P = <0.001. 
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Figure 7.78 : Cytotoxicity effects of cisplatin, in combination with H. tiliaceus (leaf) 
ethanolic extract, on HT-29 cells. Each bar represents the mean ± S.D. 
calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Hibiscus tiliaceus (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.165) 
 
Equal Variance Test: Passed (P = 0.817) 
 
Group Name N  Missing Mean Std Dev SEM  
10 3 0 45.809 1.569 0.906  
5 3 0 73.218 2.202 1.271  
2.5 3 0 87.382 0.882 0.509  
1.25 3 0 89.791 1.258 0.726  
.626 3 0 92.067 1.569 0.906  
.313 3 0 100.000 0.000 0.000  
.156 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 7259.192 1037.027 683.955 <0.001  
Residual 16 24.260 1.516    
Total 23 7283.451     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 10 54.191 53.900 <0.001 Yes   
0 vs. 5 26.782 26.638 <0.001 Yes   
0 vs. 2.5 12.618 12.550 <0.001 Yes   
0 vs. 1.25 10.209 10.154 <0.001 Yes   
0 vs. .626 7.933 7.890 <0.001 Yes   
0 vs. .313 0.000 0.000 1.000 No   
0 vs. .156 0.000 0.000 1.000 No   
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Figure 7.79 shows in vitro cytotoxicity effects of cisplatin, in combination with 
Lawsonia inermis (branch) ethanolic extract, on HT-29 cells. The IC50 value of cisplatin 
generated from the dose-response graph is 5.46 ± 0.30 μg/mL. Concentration of L. 
inermis (branch) ethanolic extract was fixed at 50 μg/mL while concentration of 
cisplatin varied (0-10 μg/mL). Comparison of inhibition activity among concentrations 
using ANOVA indicates statistically significant difference with P = <0.001. 
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Figure 7.79 : Cytotoxicity effects of cisplatin, in combination with L. inermis (branch) 
ethanolic extract, on HT-29 cells. Each bar represents the mean ± S.D. 
calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Lawsonia inermis (branch) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.215) 
 
Equal Variance Test: Passed (P = 0.595) 
 
Group Name N  Missing Mean Std Dev SEM  
10 3 0 30.531 0.534 0.308  
5 3 0 51.996 1.413 0.816  
2.5 3 0 58.317 1.515 0.875  
1.25 3 0 67.871 0.447 0.258  
.626 3 0 78.769 1.602 0.925  
.313 3 0 89.728 0.667 0.385  
.156 3 0 99.703 0.424 0.245  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 12706.778 1815.254 1823.107 <0.001  
Residual 16 15.931 0.996    
Total 23 12722.709     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 10 69.469 85.266 <0.001 Yes   
0 vs. 5 48.004 58.920 <0.001 Yes   
0 vs. 2.5 41.683 51.161 <0.001 Yes   
0 vs. 1.25 32.129 39.435 <0.001 Yes   
0 vs. .626 21.231 26.059 <0.001 Yes   
0 vs. .313 10.272 12.607 <0.001 Yes   
0 vs. .156 0.297 0.365 0.720 No   
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Figure 7.80 shows in vitro cytotoxicity effects of cisplatin, in combination with 
Leptospermum flavescens (leaf) ethanolic extract, on HT-29 cells. The IC50 value of 
cisplatin generated from the dose-response graph is 6.33 ± 0.40 μg/mL. Concentration 
of L. flavescens (leaf) ethanolic extract was fixed at 50 μg/mL while concentration of 
cisplatin varied (0-10 μg/mL). Comparison of inhibition activity among concentrations 
using ANOVA indicates statistically significant difference with P = <0.001. 
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Figure 7.80 : Cytotoxicity effects of cisplatin, in combination with L. flavescens (leaf) 
ethanolic extract, on HT-29 cells. Each bar represents the mean ± S.D. 
calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Leptospermum flavescens (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.220) 
 
Equal Variance Test: Passed (P = 0.969) 
 
Group Name N  Missing Mean Std Dev SEM  
10 3 0 35.319 1.553 0.897  
5 3 0 55.336 1.588 0.917  
2.5 3 0 60.191 1.219 0.704  
1.25 3 0 66.320 1.176 0.679  
.626 3 0 75.409 2.284 1.319  
.313 3 0 89.869 1.280 0.739  
.156 3 0 98.212 1.590 0.918  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 10782.455 1540.351 717.027 <0.001  
Residual 16 34.372 2.148    
Total 23 10816.827     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 10 64.681 54.048 <0.001 Yes   
0 vs. 5 44.664 37.322 <0.001 Yes   
0 vs. 2.5 39.809 33.265 <0.001 Yes   
0 vs. 1.25 33.680 28.143 <0.001 Yes   
0 vs. .626 24.591 20.549 <0.001 Yes   
0 vs. .313 10.131 8.466 <0.001 Yes   
0 vs. .156 1.788 1.494 0.155 No   
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Figure 7.81 shows in vitro cytotoxicity effects of cisplatin, in combination with 
Oxalis barrelieri (root) ethanolic extract, on HT-29 cells. The IC50 value of cisplatin 
generated from the dose-response graph is 8.33 ± 0.24 μg/mL. Concentration of O. 
barrelieri (root) ethanolic extract was fixed at 50 μg/mL while concentration of 
cisplatin varied (0-10 μg/mL). Comparison of inhibition activity among concentrations 
using ANOVA indicates statistically significant difference with P = <0.001. 
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Figure 7.81 : Cytotoxicity effects of cisplatin, in combination with O. barrelieri (root) 
ethanolic extract, on HT-29 cells. Each bar represents the mean ± S.D. 
calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Oxalis barrelieri (root) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.086) 
 
Equal Variance Test: Passed (P = 0.886) 
 
Group Name N  Missing Mean Std Dev SEM  
10 3 0 43.059 0.879 0.508  
5 3 0 63.815 1.611 0.930  
2.5 3 0 68.281 2.398 1.385  
1.25 3 0 79.922 2.173 1.254  
.626 3 0 86.006 2.307 1.332  
.313 3 0 98.638 1.719 0.992  
.156 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 8842.094 1263.156 456.996 <0.001  
Residual 16 44.225 2.764    
Total 23 8886.319     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 10 56.941 41.947 <0.001 Yes   
0 vs. 5 36.185 26.656 <0.001 Yes   
0 vs. 2.5 31.719 23.367 <0.001 Yes   
0 vs. 1.25 20.078 14.791 <0.001 Yes   
0 vs. .626 13.994 10.309 <0.001 Yes   
0 vs. .313 1.362 1.004 0.552 No   
0 vs. .156 0.000 0.000 1.000 No   
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Figure 7.82 shows in vitro cytotoxicity effects of cisplatin, in combination with 
Peltophorum pterocarpum (leaf) ethanolic extract, on HT-29 cells. The IC50 value of 
cisplatin generated from the dose-response graph is 7.16 ± 0.19 μg/mL. Concentration 
of P. pterocarpum (leaf) ethanolic extract was fixed at 50 μg/mL while concentration of 
cisplatin varied (0-10 μg/mL). Comparison of inhibition activity among concentrations 
using ANOVA indicates statistically significant difference with P = <0.001. 
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Figure 7.82 : Cytotoxicity effects of cisplatin, in combination with P. pterocarpum (leaf) 
ethanolic extract, on HT-29 cells. Each bar represents the mean ± S.D. 
calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Peltophorum pterocarpum (leaf) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Equal Variance Test: Failed (P < 0.050) 
 
Group Name N  Missing Mean Std Dev SEM  
10 3 0 31.477 1.817 1.049  
5 3 0 64.034 0.713 0.411  
2.5 3 0 77.024 0.0495 0.0286  
1.25 3 0 85.032 0.493 0.285  
.626 3 0 87.679 0.860 0.496  
.313 3 0 93.471 0.750 0.433  
.156 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 11051.394 1578.771 2358.056 <0.001  
Residual 16 10.712 0.670    
Total 23 11062.106     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 10 68.523 102.565 <0.001 Yes   
0 vs. 5 35.966 53.834 <0.001 Yes   
0 vs. 2.5 22.976 34.390 <0.001 Yes   
0 vs. 1.25 14.968 22.404 <0.001 Yes   
0 vs. .626 12.321 18.443 <0.001 Yes   
0 vs. .313 6.529 9.773 <0.001 Yes   
0 vs. .156 0.000 0.000 1.000 No   
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Figure 7.83 shows in vitro cytotoxicity effects of cisplatin, in combination with 
Tetracera indica (fruit) ethanolic extract, on HT-29 cells. The IC50 value of cisplatin 
generated from the dose-response graph is 8.47 ± 0.26 μg/mL. Concentration of T. 
indica (fruit) ethanolic extract was fixed at 50 μg/mL while concentration of cisplatin 
varied (0-10 μg/mL). Comparison of inhibition activity among concentrations using 
ANOVA indicates statistically significant difference with P = <0.001. 
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Figure 7.83 : Cytotoxicity effects of cisplatin, in combination with T. indica (fruit) 
ethanolic extract, on HT-29 cells. Each bar represents the mean ± S.D. 
calculated from three independent determinations. 
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One Way Analysis of Variance  
 
Data source: Tetracera indica (fruit) ethanolic extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.073) 
 
Equal Variance Test: Passed (P = 0.600) 
 
Group Name N  Missing Mean Std Dev SEM  
10 3 0 43.732 1.020 0.589  
5 3 0 64.230 1.872 1.081  
2.5 3 0 73.710 1.584 0.914  
1.25 3 0 79.543 2.294 1.324  
.626 3 0 91.812 3.479 2.009  
.313 3 0 99.915 0.148 0.0853  
.156 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 8756.973 1250.996 409.454 <0.001  
Residual 16 48.884 3.055    
Total 23 8805.857     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 10 56.268 39.426 <0.001 Yes   
0 vs. 5 35.770 25.064 <0.001 Yes   
0 vs. 2.5 26.290 18.421 <0.001 Yes   
0 vs. 1.25 20.457 14.334 <0.001 Yes   
0 vs. .626 8.188 5.738 <0.001 Yes   
0 vs. .313 0.0853 0.0597 0.998 No   
0 vs. .156 0.000 0.000 1.000 No   
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Figure 7.84 shows in vitro cytotoxicity effects of cisplatin, in combination with 
50% MeOH 2% acetic acid fraction of L. flavescens (leaf) ethanolic extract, on HT-29 
cells. The IC50 value of cisplatin generated from the dose-response graph is 8.38 ± 0.36 
μg/mL. Concentration of 50% MeOH 2% acetic acid fraction of L. flavescens (leaf) 
ethanolic extract was fixed at 50 μg/mL while concentration of cisplatin varied (0-10 
μg/mL). Comparison of inhibition activity among concentrations using ANOVA 
indicates statistically significant difference with P = <0.001. 
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Figure 7.84 : Cytotoxicity effects of cisplatin, in combination with 50% MeOH 2% 
acetic acid fraction of L. flavescens (leaf) ethanolic extract, on HT-29 
cells. Each bar represents the mean ± S.D. calculated from three 
independent determinations. 
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One Way Analysis of Variance  
 
Data source: 50% MeOH 2% acetic acid fraction of L. flavescens (leaf) ethanolic 
extract 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.365) 
 
Equal Variance Test: Passed (P = 0.740) 
 
Group Name N  Missing Mean Std Dev SEM  
10 3 0 44.046 0.966 0.558  
5 3 0 62.509 2.219 1.281  
2.5 3 0 68.472 2.683 1.549  
1.25 3 0 76.378 3.514 2.029  
.626 3 0 85.797 4.211 2.431  
.313 3 0 92.504 3.122 1.802  
.156 3 0 100.000 0.000 0.000  
0 3 0 100.000 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 7 8163.980 1166.283 176.455 <0.001  
Residual 16 105.752 6.610    
Total 23 8269.732     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
ComparisonDiff of Means t P P<0.050   
0 vs. 10 55.954 26.656 <0.001 Yes   
0 vs. 5 37.491 17.860 <0.001 Yes   
0 vs. 2.5 31.528 15.019 <0.001 Yes   
0 vs. 1.25 23.622 11.253 <0.001 Yes   
0 vs. .626 14.203 6.766 <0.001 Yes   
0 vs. .313 7.496 3.571 0.005 Yes   
0 vs. .156 0.000 0.000 1.000 No   
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One Way Analysis of Variance  
 
Data source: Overall IC50 for cisplatin combination 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.390) 
 
Equal Variance Test: Passed (P = 0.568) 
 
Group Name  N  Missing Mean Std Dev SEM  
Cisplatin alone 3 0 9.487 0.130 0.0751  
CisP + Ethacrynic acid  3 0 8.783 0.148 0.0857  
CisP + AO (branch) 3 0 8.663 0.126 0.0726  
CisP + AP (leaf) 3 0 4.697 0.180 0.104  
CisP + CZ (branch) 3 0 9.233 0.0702 0.0406  
CisP + ERi (fruit&flower) 3 0 8.547 0.0603 0.0348  
CisP + GA (branch) 3 0 8.300 0.122 0.0702  
CisP + GM (branch) 3 0 9.240 0.555 0.320  
CisP + GM (leaf) 3 0 6.737 0.376 0.217  
CisP + HT (leaf) 3 0 9.237 0.297 0.171  
CisP + LI (branch) 3 0 5.457 0.298 0.172  
CisP + LF (leaf) 3 0 6.333 0.395 0.228  
CisP + OB (root) 3 0 8.327 0.241 0.139  
CisP + PP (leaf) 3 0 7.160 0.185 0.107  
CisP + TI (fruit) 3 0 8.473 0.260 0.150  
CisP + 50% MeOH 2% acetic acid 3 0 8.380 0.361 0.208  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 15 93.359 6.224 84.193 <0.001  
Residual 32 2.366 0.0739    
Total 47 95.725     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050 
  
Cisplatin al vs. CisP + AP (l 4.790 21.577 <0.001 Yes   
Cisplatin al vs. CisP + LI (b 4.030 18.153 <0.001 Yes   
Cisplatin al vs. CisP + LF (l 3.153 14.204 <0.001 Yes   
Cisplatin al vs. CisP + GM (l 2.750 12.387 <0.001 Yes   
Cisplatin al vs. CisP + PP (l 2.327 10.481 <0.001 Yes   
Cisplatin al vs. CisP + GA (b 1.187 5.345 <0.001 Yes   
Cisplatin al vs. CisP + OB (r 1.160 5.225 <0.001 Yes   
Cisplatin al vs. CisP + 50% M 1.107 4.985 <0.001 Yes   
Cisplatin al vs. CisP + TI (f 1.013 4.565 <0.001 Yes   
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Cisplatin al vs. CisP + ERi ( 0.940 4.234 0.001 Yes   
Cisplatin al vs. CisP + AO (b 0.823 3.709 0.004 Yes   
Cisplatin al vs. CisP + Ethac 0.703 3.168 0.013 Yes   
Cisplatin al vs. CisP + CZ (b 0.253 1.141 0.599 No   
Cisplatin al vs. CisP + HT (l 0.250 1.126 0.465 No   
Cisplatin al vs. CisP + GM (b 0.247 1.111 0.275 No   
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050 
  
CisP + Ethac vs. CisP + AP (l 4.087 17.953 <0.001 Yes   
CisP + Ethac vs. CisP + LI (b 3.327 14.614 <0.001 Yes   
CisP + Ethac vs. CisP + LF (l 2.450 10.763 <0.001 Yes   
CisP + Ethac vs. CisP + GM (l 2.047 8.991 <0.001 Yes   
CisP + Ethac vs. CisP + PP (l 1.623 7.131 <0.001 Yes   
CisP + Ethac vs. CisP + GA (b 0.483 2.123 0.321 No   
CisP + Ethac vs. CisP + OB (r 0.457 2.006 0.358 No   
CisP + Ethac vs. CisP + GM (b 0.457 2.006 0.322 No   
CisP + Ethac vs. CisP + HT (l 0.453 1.992 0.291 No   
CisP + Ethac vs. CisP + CZ (b 0.450 1.977 0.256 No   
CisP + Ethac vs. CisP + 50% M 0.403 1.772 0.304 No   
CisP + Ethac vs. CisP + TI (f 0.310 1.362 0.455 No   
CisP + Ethac vs. CisP + ERi ( 0.237 1.040 0.519 No   
CisP + Ethac vs. CisP + AO (b 0.120 0.527 0.602 No   
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APPENDIX V: STANDARD CURVE 
 
Figure 7.85 : Standard curve for SDS-PAGE protein molecular weight determination. 
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